Development of New Breast Cancer Resistance Protein Inhibitors by Juvale, Kapil
Development of New Breast Cancer
Resistance Protein Inhibitors
Dissertation
zur
Erlangung des Doktorgrades (Dr. rer. nat.)
der
Mathematisch-Naturwissenschaftlichen-Fakulta¨t
der
Rheinischen Friedrich-Wilhelms-Universita¨t Bonn
vorgelegt von
Kapil Juvale
aus
Pune, Indien
Bonn 2013
Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakulta¨t
der Rheinischen Friedrich-Wilhelms-Universita¨t Bonn
”
Gedruckt mit Unterstu¨tzung des Deutschen Akademischen Austauschdienstes“
1. Gutachter : Prof. Dr. Michael Wiese
2. Gutachter : Prof. Dr. Gerd Bendas
Tag der Promotion : 10.06.2013
Erscheinungsjahr : 2013
Dedicated to my family and friends
”Without speculation there is no good
and original observation”
Charles Darwin (1809-1882)

Abstract
Chemotherapy is a major form of treatment for cancers. Unfortunately, the majority
of cancers are either resistant to chemotherapy or acquire resistance (MDR) during
treatment. The most common mechanism by which human cancers develop multidrug
resistance is overexpression of certain ATP-binding cassette (ABC) transporters.
Breast Cancer Resistance Protein (BCRP / ABCG2), a member of ATP binding
cassette family ABCG has been found to confer multidrug resistance in cancer
cells. One of the strategies to overcome resistance due to BCRP overexpression
is the investigation of potent and specific BCRP inhibitors. Several inhibitors of
BCRP have been developed in last decade in an attempt to overcome the resistance
mediated by this transporter, but there are only very few potent and selective BCRP
inhibitors such as Ko143. Aim of the current project was to develop new potent
and selective BCRP inhibitors. In this work a total of 131 compounds spanning
different chemical classes such as chalcone, flavonoid and quinazoline were investigated.
Several biological studies were carried out using these compounds to determine their
BCRP inhibitory potential, selectivity, toxicity and efficacy to reverse MDR to certain
anticancer compounds. The study of all three classes of compounds revealed structural
requirements for BCRP inhibition. In this study, chalcones and benzoflavones
showed moderate to good BCRP inhibition with selectivity towards BCRP over other
transporters. Amongst chalcones and flavones, 7,8-benzoflavones were the most potent
BCRP inhibitors. The structural activity relationship of quinazoline compounds
revealed the importance of a 2-phenyl substitution in quinazoline scaffold for BCRP
inhibition. The quinazoline compounds were the most active compounds among
all classes, some of the quinazolines showing even better activity than Ko143. The
results obtained from the study of chalcones, flavonoids and quinazolines as BCRP
inhibitors are promising for the ongoing research to find potent BCRP inhibitors.
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Chapter
Introduction
1.1 Chemotherapy and multidrug resistance (MDR)
Cancer is the main cause of millions of deaths worldwide. In addition to surgery,
chemotherapy is a major form of treatment for different types of cancers. Unfor-
tunately, the majority of cancers are either resistant to chemotherapy or acquire
resistance during treatment [1]. Intrinsic drug resistance relates to the failure of
many tumors to respond to initial chemotherapy, while acquired drug resistance
occurs when tumors initially respond to chemotherapy but later relapses and appears
to be strongly resistant to the original treatment. MDR is a drug resistance by tumor
cells, that consists of simultaneous emergence of cellular resistance to toxic action
of chemotherapeutic drug originally used and to other chemicals having different
chemical structure and mechanism of action. As a result of MDR, chemotherapeutic
agents fail to target the tumor cells and cancer becomes untreatable by chemotherapy
[2]. A common mechanism by which tumors develop multidrug resistance is overex-
pression of efflux transport proteins, especially certain ATP-binding cassette (ABC)
transporters in the plasma membrane of cancer cells [3]. P-glycoprotein (P-gp) and
the multidrug resistance associated protein 1 (MRP1) have been shown to confer
resistance to a broad spectrum of chemotherapeutic agents. More recently BCRP
(breast cancer resistance protein) has been discovered and proved to cause resistance
in tumor cells. [4]
1
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1.2 ATP-binding cassette transporters
Transporters are membrane proteins with multiple membrane-spanning domains,
which facilitate the permeation of low molecular weight compounds and ions across the
biological membranes. ATP-binding cassette (ABC) transporters have been found to
be present in cells of all species, ranging from bacteria to man [5]. ABC transporters
belong to a large family of structurally related transmembrane proteins. In eukaryotic
organisms, ABC transporters are ubiquitously present, especially in human ABC
transporters are widely expressed throughout the body. ABC transporters actively
transport chemically diverse substrates across the membrane and are also involved
in various cellular processes [6, 7]. The transport of substrates is energy dependent
and is driven by ATP hydrolysis.
Till now 49 members of the ABC transporter family have been discovered in humans
[8]. These are divided into seven subfamilies from ABC-A to ABC-G depending on
the similarity in gene structure, sequence homology and order of the domains [9].
The major ABC transporters involved in multidrug resistance are P-glycoprotein
(P-gp / ABCB1 / MDR1), multidrug resistance protein 1 (MRP1 / ABCC1) and
breast cancer resistance protein (BCRP / ABCG2) [10].
The functional unit of ABC transporters consists of two nucleotide binding domains
(NBDs) and two transmembrane domains (TMDs). The transmembrane domains of
ABC transporters consists of six membrane spanning helices. Transported compounds,
xenobiotics in most cases, interact with sites present within the TMDs. A minimum
of 12 membrane-spanning helices are required for transport of a substrate [11]. But,
some transporters like BCRP consists of only one TMD and one NBD, hence are
known as half transporters. Such transporters form homo- or hetero-dimer to function
as full ABC transporters [12]. A schematic representation of typical ABC transporter
is shown in Figure 1.1.
ABC transporters play an important role in tissue defense by removal of toxic
xenobiotics [9, 11, 13]. Hence, ABC transporters are found to be expressed in
biological barriers like the blood-brain barrier (BBB) [14–16], blood-cerebrospinal-
fluid barrier (CSF) [17, 18]. ABC transporters like P-gp and BCRP have also been
shown to be present in the placenta protecting the fetus from xenobiotics [19, 20].
ABC transporter have also been shown to play a role in altering absorption, dis-
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Figure 1.1: Structural features of typical ABC transporters
tribution, metabolism and excretion (ADME) of transported drugs owing to their
presence in several organs like intestine and liver [10, 11, 21–23]. This affects the
oral bioavailability and tissue distribution, making necessary to identify the influence
of transporters on the drug disposition. A list of different ABC transporters and
their presence in several tissues is shown in Table 1.1.
Table 1.1: Major ABC transporters and their localization in tissues [11, 24]
ABC transporter Tissue localization
P-gp / ABCB1
liver, kideny, intestine, placenta,
blood-brain barrier, stem cells
MDR2 /ABCB4 liver
MRP1 / ABCC1
lungs, kidney, testes, cardiac muscle,
placenta, skeletal muscles
MRP2 / ABCC2
lungs, Liver, kidney, placenta,
blood-brain barrier
BCRP / ABCG2
placenta, liver, intestine, breast,
stem cells, blood-brain barrier
Apart from detoxification or affecting an ADME, ABC transporters have been iden-
tified to cause multidrug resistance. ABC transporter have been found to be highly
overexpressed in cancer cells resistant to chemotherapy causing lower accumulation
of cytotoxic anticancer drugs. This mechanism of MDR has been found to be most
relevant to drugs entering cells by passive diffusion such as the chemotherapeutic
agents doxorubicin and paclitaxel [25]. Among all ABC transporters P-gp, the
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MRP family proteins (especially MRP1) and BCRP have been found to be mainly
responsible for MDR [3, 26, 27]. These transporter are discussed in detail in the next
sections.
1.2.1 P-glycoprotein (P-gp) / ABCB1
P-glycoprotien (P-gp) is the first member of the ABC subfamily B (ABCB1) and is
also known as MDR1. It was first discovered and characterized in 1976 by Juliano
and Ling in multidrug resistant Chinese hamster ovary cells [28, 29]. Human ABCB1
was later identified to be overexpressed in cultured cancer cells having MDR against
different anticancer drugs [30]. The active efflux of substrates by P-gp leads to
reduced intracellular concentrations, resulting in resistance to a broad range of
cytotoxic drugs such as Vinca alkaloids, anthracyclines and taxanes.
1.2.1.1 Molecular structure of P-gp
Human ABCB1 consists of 1280 amino acid residues. It has a molecular weight of
about 170 kDa, which may vary from 130-180 kDa depending on the type of cells
and species in which they are expressed [31]. P-gp is composed of 2 homologous
halves of transmembrane doamins (TMDs), each consisting of 6 transmembrane
helices, an N-terminal and a C-terminal. Each half of the protein consists of an
intracellular nucleotide binding domain (NBD) or ATP binding site (see Figure 1.2).
The hydrolysis of ATP provides the energy required for the drug transport [32]. The
two folded halves of the P-gp molecule have approximately 43 % similarity.
Until now several homology models for P-gp have been suggested. The first models
were based on the crystal structures of transporters available from bacteria. Homology
models of the P-gp have been used identify structure of the P-gp as well as detecting
binding sites for substrates and inhibitors [33–36]. Later in 2009 the crystal structure
of mouse P-gp (Abcb1a) was solved. This crystal structure has 87 % identity to that
of human P-gp sequence [37].
Regardless of these models and biochemical data, the molecular mechanism underlying
the substrate transport is still not clear. Two different models have been suggested
to explain the transport of substrates by P-gp. The ‘Flippase’ model was suggested
4
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Figure 1.2: Topological model of ABCB1 / P-gp
by Higgins et al. in 1992, where it was postulated that substrates congregate with
P-gp at the inner side of the plasma membrane. Then, P-gp flips the substrate to the
outer side, from where it can diffuse into the extracellular space (see Figure 1.3) [38].
A second ‘hydrophobic vacuum cleaner’ model was suggested by Gottesman et al. in
1993, where it was also postulated that the substrate diffuses passively into inner side
of the plasma membrane. Here, substrate is detected by the P-gp and ejected directly
outside the membrane. It was also suggested that P-gp forms a single transport
channel by bringing two halves of P-gp together. The transport of substrates occurs
through a single barrel-like structure of transporter (see Figure 1.3) [1].
Figure 1.3: Hydrophobic vacuum cleaner and flippase models for substrate transport
by P-gp, modified from [39].
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1.2.1.2 Substrates and inhibitors of P-gp
Until now many P-gp substrates belonging to different chemical classes have been
identified, which include cytotoxic drugs, antibiotics, antiallergics, HIV protease
inhibitors, calcium channel blockers, central nervous system drugs, cardiacs, steroids
and peptides [39, 40]. Some of these substrates are listed in Table 1.2.
Table 1.2: Substrates and inhibitors of P-gp [39]
Substrates
Anticancer / cytotoxic drugs:
Vinca alkaloids: vinblastine, vincristine
anthracyclines: daunorubicin, doxorubicin
epipodophyllotixins: etoposide, teniposide
taxanes: Paclitaxel, docetaxel
campothecins: irinotecan, SN-38
Antibiotics:
erythromycin, valinomycin
HIV protease inhibitors:
saquinavir, ritonavir, nelfinavir
calcium channel blockers:
diltiazem, felodipine, nifedipine, verapamil,
tiapamil
Fluorescent dyes:
calcein-AM, BCECF-AM, rhodamine 123, Hoechst
33342
Peptides:
gramicidine D, valinomycin
Inhibitors
First generation:
verapamil, cyclosporine A, quinidine, quinine,
nifedipine, dexniguldipine
Second generation:
elacridar (GF120918), biricodar (VX-710),
PSC-833
Third generation:
tariquidar (XR-9576), zosuquidar (LY335979),
laniquidar (R101933), LY475776
Several efforts have been undertaken in the past to develope potent inhibitors of
P-gp. Like substrates, inhibitors of P-gp belong to a broad range of different chemical
classes. The calcium channel blocker verapamil was first investigated by Tsuruo et
6
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al. and was found to be able to reverse the vincristine and vinblastine resistance
in P-gp overexpressing cancer cells [41]. The modulators of P-gp are categorized
into three generations. The first generation of inhibitors consists of compounds that
were already in clinical use for other therapeutic applications. Drug compounds like
verapamil, cyclosporine and quinidine belong to the first generation, but they showed
high toxicity at the required inhibitory concentrations [42]. The second generation
of compounds consists of less toxic inhibitors of P-gp.
Further development of P-gp inhibitors based on structure-activity relationships led
to the third generation of inhibitors which have very low inhibitory concentrations
[43]. When compared to second generation inhibitors, these are not cytochrome P450
3A4 substrates and have no effect on the pharmacokinetic profile of co-administered
drugs [42–44]. A list of selected P-gp inhibitors is given in Table 1.2.
1.2.2 Multidrug Resistance associated Protein 1 (MRP1) /
ABCC1
The multidrug resistance associated protein 1 (MRP1) was first identified by Cole et
al. in 1992 [45]. MRP1 belongs to the C subfamily of ABC transporters and is the
member 1 (ABCC1). It was first discovered in lung cancer cells H69 after continuous
incubation of cells with doxorubicin. In normal tissues, similar to P-gp, MRP1 also
plays an important role in protection from toxic xenobiotics [17, 46]. It has been
found to be present in almost all tissues and organs, being highly expressed in testes,
kidneys, lungs, gastrointestinal track and BBB [45, 47]. MRP1 has been found to
be overexpressed in a wide variety of solid tumors such as those of lung, breast and
prostate and also has been shown to cause MDR against several cytotoxic drugs in
different cancers [48].
1.2.2.1 Molecular structure of MRP1
Although MRP1 shows a partly similar resistance profile to that of P-gp, the amino
acid sequence identity is only to the extent of 15 % [49]. MRP1 consists of 1531
amino acid residues and has a molecular weight of about 190 kDa. The MRP1
consists of a core structure that is common to many ABC proteins like P-gp, having
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two hydrophobic transmembrane domains (TMDs) each followed by a NBD. In
addition to the central core, it contains a third TMD0, which has five transmembrane
α−helices and an extracellular N-terminus [50]. The TMD1 and TMD2 in the central
core play a role in substrate transport while, TMD0 has no transport ability. The
structure of MRP1 is depicted in Figure 1.4.
Figure 1.4: Topological model of MRP1
1.2.2.2 Substrates and inhibitors of MRP1
Several substrates of MRP1 have been identified until now. These include a vast
variety of hydrophobic compounds, organic anion conjugates and nonconjugated
compounds. MRP1 plays major role in transport of glucuronoide, sulfate and
glutathion conjugates, protecting the tissues from toxic metabolites. A detailed list
of MRP1 substrates is given in Table 1.3.
Until now very few specific MRP1 inhibitors such as MK571 (a leukotriene receptor
antagonist) [51] and ONO-1078 (a peptide leukotriene receptor antagonist) [52] have
been found. The glutathion transport by MRP1 has been shown to be inhibited
by the tricyclic isoxazole compounds LY402913 [53] and LY475776 [54]. Recently
Koley et al. showed that MK571 was able to inhibit the MRP1 mediated transport
of thiodione [55]. The nonspecific organic anion transport inhibitors like probenicid
and indomethacin have also been found to inhibit MRP1 [56].
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Table 1.3: Substrates of MRP1 [57, 58]
Conjugates GSH conjugates:
leukotriene C4, leukotriene D4, leukotriene E4,
hydroxynonenal-SG, melphalan, chlorambucil
glucuronide conjugates:
glucuronosylbilirubin,
estradiol-17-β-D-glucuronide, etoposide
glucoronoide
sulfate conjugates:
dehydroepiandrosterone 3-sulfate,
sulfatolithocholyl taurine, estrone 3-sulfate
Anticancer /
cytotoxic
drugs
Vinca alkaloids:
vincristine and vinblastine
anthracyclines:
doxorubucin and daunorubicin
others:
etoposide, SN-38, methotrexate
Peptides: N -acetyl-Leu-Leu-norleucinal (ALLN), GSH,
GSSG
Fluorescent
dyes
calcein-AM, BCECF
1.2.3 Breast cancer resistance protein (BCRP) / ABCG2
Breast cancer resistance protein (BCRP) belongs to subfamily G, member 2 of ABC
transporters. It was first cloned by Doyle et al. in 1998 from a doxorubicin resistant
MCF-7 breast cancer cell line (MCF-7/AdrVp) and from which it derived its name
‘breast cancer resistance protein’ [59]. These cells were sensitive to vinca alkaloids,
cisplatin and paclitexal, which are either P-gp or MRP1 substrates, suggesting
the presence of an other ABC transporter. But, unlike the name suggest BCRP
is not limited to expression in breast tissue and caner cells. It was later found
in mitoxantrone resistant cancer cells and in placenta. Hence it is also known as
mitoxantrone resistant protein (MXR) or placental ABC protein (ABCP). Because of
its structural and sequence homology to Drosophila white, brown and scarlet protein
genes and the human white homologue (ABCG1), it was named ABCG2 by the
Human Genome Nomenclature Committee [60].
9
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1.2.3.1 Molecular structure of BCRP
BCRP is a 655 amino acid protein having a molecular weight of about 72 kDa. In
comparison to other ABC transporters, BCRP is a half transporter with reversed
NBD-TMD configuration. Although the exact structure of the BCRP is not clear,
it has been suggested to have an N-terminal nucleotide binding domain (NBD)
and a C-terminal transmembrane domain (TMD) consisting of six transmembrane
α−helices [61]. A topology model of the BCRP is shown in Figure 1.5. Owing to
its half transporter nature, BCRP is believed to homodimerize or oligomerize to
function as an efflux protein [62]. It has been suggested by Xu et al. that, BCRP
functions as a tetramer bridged by disulphide bonds [63].
Figure 1.5: Topology model of BCRP
1.2.3.2 Localization of BCRP in human tissues
BCRP has been shown to be present in many normal tissues and it plays an important
physiological role. Doyle et al. reported the presence of high levels of BCRP in
placenta and lower levels in the brain, small intestine, testes, liver, spleen, ovaries
and prostate gland [59]. Fetsch et al. have shown the presence of BCRP in the
adrenal gland, central nervous system, small and large intestine, lungs, stomach and
pancreas [64]. The tissue distribution of BCRP shows overlap with P-gp, suggesting
its role in tissue protection from xenobiotics.
BCRP has also been found to be expressed in stem cells, especially in the hematopoi-
etic cells [65]. BCRP has been identified to transport the Hoechst 33342 dye from
10
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cells within the ‘side-population’ (SP) region. Despite the exact role of BCRP in stem
cells is not known, it has been postulated that BCRP may play role in protection of
stem cells [66]. Localization of BCRP and its physiological role is listed in Table 1.4.
Table 1.4: Tissue distribution and physiological role of BCRP [60, 67]
Tissue Physiological role
Placenta protection of the fetus from toxins
Liver and biliary
tract
hepato-biliary excretion, biliary excretion of
drugs, xenobiotics or endogenous compound
conjugates
Stem cells SP-phenotype and protection against hypoxia
Intestine reduction of drug absorption
Brain protection against xenobiotics
Breast secretion of B vitamin required for fat
metabolism
Kidney renal excretion
1.2.3.3 Role of BCRP in MDR
Multidrug resistance caused by overexpression of BCRP was first observed in MCF-
7/AdrVp after a long term selection of MCF-7 human breast cancer cell line with
doxorubicin [59]. Later an identical transporter (MXR) was identified in a mitox-
antrone resistant cell line derived from the S1 human colon carcinoma cells [68].
Several cell lines including MCF-7, S1, gastric carcinoma EPG85-257 and fibrosar-
coma EPF86-079, showed resistance to mitoxantrone due to overexpression of BCRP
[59, 68, 69]. Several studies showed that the overexpression BCRP leads to resistance
to topotecan [70, 71]. Several transfection studies were performed to prove the role
of BCRP in the MDR to drugs like mitoxantrone and topotecan. The expression of
the BCRP protein and/or mRNA has been detected in numerous types of human
cancers, such as solid tumors and hematological malignancies. Immunohistochemical
studies of several tumors have shown overexpression of BCRP in more than 40 %
of solid tumors [72]. BCRP expression in premature stem cells of different tissues
was confirmed, suggesting its role in protection of cancer stem cell subpopulation
particularly under hypoxic conditions [8, 73].
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Table 1.5: BCRP substrates
Class of drugs /
compounds
Drugs / compounds
Anthracenes
mitoxantrone [74, 75]
aza-anthrapyrazole [76, 77]
bisantrene [78]
Campothecins
topotecan [78]
irinotecan [79, 80]
SN-38 [81]
9-amino-campothecin [82]
diflomotecan [83]
Anthracyclines
doxorubicin* [84, 85]
daunorubicin* [86]
Antifolate methotrexate** [87, 88]
Nucleoside analogs
azidothymidine (AZT) [89, 90]
lamivudine [89, 90]
Other drug
flavopiridol [91, 92]
prazosin [78]
imatinib mesylate (STI571) [93]
pantoprazole [94]
indocarbazole [95]
ciprofloxacin [96]
erythromycin [97]
Fluorescent dyes
Hoechst 33342 [65]
BODIPY-prazosin [75, 78]
BCECF-AM [98]
6-carboxy-2’,7’-dichlorofluorescein[99]
Conjugates of
glucuronoide and
sulfate
benzo[a]pyrene-3-glucuronide [100]
estrone-3-sulfate [101, 102]
dehydroepiandrosterone sulfate [103]
17β-estradiol sulfate [101]
Porphyrines
pheophorbide A [104, 105]
protoporphyrin IX [105]
phytoporphyrin [106]
pyropheophorbide A methylester [107]
* Transported only by BCRP mutants R482T or R482G
** Transported only by wild-type BCRP (R482).
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1.2.3.4 Substrates of BCRP
Mitoxantrone was the first substrate reported for BCRP. It has been shown to
confer resistance to different anticancer drugs which include, campothecins such as
topotecan, irinotecan (CPT-11) and SN-38 (an active metabolite of irinotecan). The
anthracycline class of compounds has also been shown to be transported in BCRP
overexpressing MCF-7/AdrVp3000 and S1-M1–80 cells [85]. But these compounds
were not transported in wild type cells expressing BCRP with an amino acid residue
arginine at position 482. Anthracyclines were identified to be transported only by the
BCRP mutant R482G (glycine at position 482) or R482T (threonine at position 482)
found in the S1-M1-80 and MCF-7/AdrVp3000 cell lines respectively [108]. Also, the
antifolate drug methotrexate was found to be transported only by wild type BCRP
[88, 109].
In addition to its role to confer MDR against chemotherapeutic agents, BCRP
has been identified to actively transport structurally different organic molecules,
conjugated or unconjugated compounds, such as flavopiridol, estrone-3-sulfate,
benzo[a]pyrene-3-glucuronide and prazosin. Several fluorescent dyes like BODIPY-
prazosin, Hoechst 33342, pheophorbide A have also been found to be substrates of
BCRP. A list of BCRP substrates is given in Table 1.5.
1.2.3.5 Inhibitors of BCRP
BCRP has been shown to play a vital role in the development of MDR in different
carcinomas. Hence it was of a great interest to identify modulators of BCRP
mediated MDR. Since the discovery of the transporter protein, several efforts have
been undertaken to find inhibitors.
The second generation P-gp inhibitor elacridar (GF120918), an acridone carboxamide
derivative was found to be a potent inhibitor of BCRP [110]. The structurally related
P-gp inhibitor tariquidar (XR9576) was also shown to inhibit BCRP [107]. Later
Rabindran et al. discovered that fumitremorgin C (FTC), a tremorgenic mycotoxin
produced by the fungus Aspargillus fumigatus, was able to effectively reverse the
multidrug resistance and increase cellular drug accumulation in BCRP overexpressing
cells. FTC efficiently inhibits BCRP in vitro at concentrations in the micromolar
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range and has little effect on P-gp or MRP1 mediated drug resistance, suggesting
its specificity for BCRP [76, 80]. But its in vivo study was precluded owing to its
neurotoxicity. Novobiocin, a coumermycin antibiotic has been shown to be a specific
BCRP inhibitor, however with high IC50 values in the range of 20 to 80 µM only
[111].
Recently, Allen et al. studied various tetracyclic indolyl diketopiperazine analogues
of FTC as inhibitors of murine and human BCRP. The most potent analogues Ko132
and Ko134 showed comparable or greater activity than FTC. These compounds
showed very low in vivo toxicity [112]. The desmethoxy analog of the FTC showed
decreased BCRP inhibitory activity, suggesting the importance of the methoxy group
at the aromatic indole ring. Hence, the methoxylated analog of Ko134 was synthesized
(Ko143, see Figure 1.6), which was found to be the most potent analogue [113].
Figure 1.6: Selected inhibitors of BCRP
Specific
inhibitors
Fumitremorgin C (FTC) Ko143
Broad
spectrum
inhibitors
Imatinib Gefitinib
Elacridar (GF120918)
Flavonoids
Techtochrysin 6-Prenylchrysin
Various tyrosin kinase inhibitors (TKIs) like gefitinib, imatinib, EKI-785 and C11033
were analyzed for their interaction with BCRP. Some of these compounds inhibited
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BCRP at submicromolar concentrations [114–116]. Very recently Pick et al. were
able to show the effect of TKIs gefitinib and PD158780 on BCRP expression [117].
Both compounds were found to reduce the total and surface BCRP expression in
EGFR-positive MDCK BCRP cells by interacting with the PI3K/Akt signaling
pathway.
Several naturally occurring flavonoids have been investigated for their ability to
reverse the BCRP mediated MDR. Initially, some flavonoids like chrysin and biochanin
A were found to be effective at micomolar concentrations [118]. Later it was shown
that tectochrysin and the synthetic analog 6-prenylchrysin were potent inhibitors
of BCRP [119]. These compounds are different from GF120918, FTC and Ko143
in a way that they bind to distinct sites on BCRP or induce differential effect on
coupling between ATP hydrolysis and drug transport [119].
Whether any of these compounds will be clinically useful in reversing BCRP-mediated
multidrug resistance has yet to be determined. Also the molecular mechanism
by which these compounds interfere with drug transport by BCRP is still poorly
understood. Until now, only a few clinical studies have been performed on BCRP
inhibitors. Elacridar (GF120918), a dual P-gp/BCRP inhibitor has been investigated
extensively in preclinical and clinical studies [120]. Clinical trials conducted by
Furman et al. using gefitinib for the inhibition of intestinal P-gp and BCRP showed
increased oral bioavailability of irinotecan [121].
In the current study several chalcones, benzochalcones, flavones, benzoflavones and
quinazolines have been investigated to find new selective and potent inhibitors of
BCRP. Synthesis and biological investigation of these compounds is discussed in the
next chapters.
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Chapter
Objectives of the work
In the last decade, several BCRP inhibitors have been developed in the pursuit of
overcoming the multidrug resistance due to overexpression of BCRP in variety of
cancers. These include naturally occurring as well as synthetic compounds having a
wide range of chemical structures. BCRP being the latest identified ABC transporter
[59], there is very little knowledge about its functional structure and substrate /
inhibitor binding sites. Hence there is a need of developing and identifying potent and
selective inhibitors of BCRP, which could help in discovering structural requirements
as well as possible binding sites. Currently only very few potent and selective
inhibitors like ko143 are known, which encourage to synthesize and identify new
BCRP inhibitors.
The aim of the dissertation was:
1. To design and synthesize library of compounds of different chemical classes
based on the results of previous studies aiming to find new potent and selective
BCRP inhibitors.
2. Biological studies of these compounds to determine their inhibitory potencies
against BCRP. Based on the results obtained, structural features required for
the BCRP inhibition will be elucidated.
3. Checking the selectivity of synthesized compounds towards BCRP inhibition
over the other major ABC transporters P-gp and MRP1.
4. To check the effectiveness and toxicity of the lead compounds, to identify their
potential for preclinical studies.
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In the current work three different classes of compounds were synthesized and
investigated for their BCRP inhibition and selectivity and are discussed below.
2.1 Synthesis and evaluation of chalcones and
benzochalcones as BCRP inhibitors
Chalcone, precursor of naturally occurring flavonoids, have been extensively studied
for their biological activities. Liu et al. investigated several chalcones with basic
functionality as P-gp inhibitors [122]. These compounds showed very less BCRP
inhibition. Later Han et al. identified halogenated chalcones as selective BCRP
inhibitors [123]. Despite these studies, no structure activity relationship is available.
In this work, synthesis of several chalcones with varying substituents on ring A
and ring B of the chalcone scaffold, as well as several 3’,4’-benzochalcones and
5’,6’-benzochalcones was planned. The aim of these modifications was to find out
the importance of different substituents and to study the effect of replacing ring A
of the chalcone with a naphthyl ring (see Figure 2.1).
Figure 2.1: General structures of investigated chalcones and benzochalcones
2.2 Synthesis and evaluation of flavones and
benzoflavones as BCRP inhibitors
Naturally occurring flavonoids have been extensively studied for their ability to
modulate ABC transporters like P-gp and BCRP [118, 124–127]. Zhang et al. [128]
and Pick et al. [125] have suggested several structural requirements for BCRP
inhibition. It was suggested that presence of a 3-methoxy substituent in flavone leads
to an increase in activity. Recently 7,8-benzoflavone was reported to be a potent
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inhibitor of BCRP [128, 129]. Based on these studies, several modifications in the
flavone moiety were planned to study the effect of different substituents. As only the
unsubstituted 7,8-benzoflavone has been investigated till now, different substituted
7,8-benzoflavones were planned to be synthesized to identify more potent derivatives.
Also, for comparison purposes several 5,6-benzoflavones will be investigated. These
compounds could be synthesized from the chalcones investigated in the chalcone
project (see section 2.1). General structures of the synthesized and tested flavone
derivatives are given in Figure 2.2.
Figure 2.2: General structures of investigated flavones and benzoflavones
2.3 Synthesis and evaluation of substituted
quinazolines as BCRP inhibitors
Very recently several Tyrosine kinase inhibitors (TKIs) have been investigated for
their BCRP inhibition [117, 130–132]. TKIs having a quinazoline scaffold have been
shown to inhibit BCRP in the micromolar range. Some of these compounds were
additionally shown to decrease the BCRP expression in cells [117]. In these studies
only very few quinazoline compounds have been investigated and hence no structure
activity relationship (SAR) is available. Also all compounds investigated earlier lack
variation in the substitution at position 2 of the quinazoline nucleus. In the current
study it will be attempted to develop a SAR by varying the quinazoline structure at
positions 2, 4, 6 and 7 (see Figure 2.3).
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Figure 2.3: General structure of quinazoline type BCRP inhibitors and possible
modifications
All synthesized compounds will be checked for BCRP, P-gp and MRP1 inhibition.
Also their efficacy and intrinsic toxicity will be checked in the MTT assay.
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Project 1: Investigation of
chalcones and benzochalcones
as BCRP inhibitors
Chalcones are naturally occurring compounds with a scaffold of ‘trans-1,3-diaryl-2-
propen-1-one’ (see Figure 3.1). Chalcones belong to the flavonoid family and are
precursors of flavoinoids and isoflavonoids. These compounds are found abundantly
in various plant species like Glycyrrhiza, Scutellaria, Angelica and Piper and are
used as traditional medicines [133]. They are also important intermediates in
the synthesis of biologically important heterocycles such as flavones, pyrazolines,
oxazolines, benzothiapines, etc.
Figure 3.1: Structure of the chalcone scaffold
Until now, the chalcone class of compounds have been extensively investigated for
varying biological activities. A wide range of pharmacological activities such as
antimicrobial [134], anti-inflammatory [135, 136], antioxidant [137, 138], antituber-
cular [139], antimalarial [140, 141], antileishmanial [141], anticancer [142–146] and
antifungal [147, 148], etc. have been identified.
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3.1 Chalcones as modulators of ABC transporters: an
overview
Chalcones, being precursors of flavonoids have been investigated as ABC transporter
inhibitors. First in 1998 Bois et al. investigated several halogenated chalcones for
their binding affinity to P-gp [149]. Later, they found a few 4-alkoxy chalcones as
potential modulators of P-gp mediated MDR [150]. In 2008, Liu et al. reported
several chalcones with basic functionalities to be potent inhibitors of P-gp, but these
compounds showed no effect on the uptake of mitoxantrone in BCRP overexpressing
MCF-7 cells [122].
Han et al. investigated a series of non-basic chalcones with halogenated substitutions
on ring B of the chalcone. These compounds were found to be good inhibitors of
BCRP, showing little or no inhibition of P-gp [151]. Also in 2009 Boumendjel et al.
showed the ability of JAI-51 (a chalcone derivative with indole ring in place of ring
B) to inhibit P-gp and BCRP [152]. Structures of lead compounds found in these
studies are depicted in Figure 3.2.
2’,4’,6’-trihydroxy-4-iodochalcone
(high P-gp binding affinity) [149]
4-alkoxychalcone
(very high P-gp binding affinity) [150]
chalcone with basic functionality
(P-gp inhibitor) [122]
non-basic halogenated chalcone
(BCRP inhibitor) [151]
Figure 3.2: Structures of lead chalcones as P-gp and BCRP inhibitors
Despite these studies, structure-activity relationship analyses of chalcones as BCRP
inhibitors are not available. In earlier works, only BCRP inhibition of compounds
with halogenated ring B was studied. Therefore, it was of great interest to study
various chalcone derivatives with varying substituents (especially methoxy) on both
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rings A and B. Also, several benzochalcones (naphthyl ring instead of ring A) have
been investigated in the current study.
3.2 Synthesis of chalcones and benzochalcones
In the current study, three different types of chalcones were synthesized, namely
chalcones, 3’,4’-benzochalcones and 5’,6’-benzochalcones. All chalcones and ben-
zochalcones were synthesized by Claisen-Schmidt condensation (a modified Aldol
condensation reaction) with minor modifications [153, 154]. The classical method
for synthesis of chalcones involves reaction of equimolar amounts of acetophenones
and aldehydes at room temperature in presence of sodium hydroxide or potassium
hydroxide as base catalyst. The general mechanism of the Claisen-Schmidt conden-
sation is given in Figure 3.3. All the investigated chalcones were synthesized by the
classical method, while benzochalcones were synthesized using an ultrasound bath
with lithium hydroxide as catalyst instead of sodium hydroxide.
3.2.1 Synthesis of chalcones
Chalcones with varying substitutions on ring A and B of the scaffold were synthesized
by the classical method for synthesis of chalcones. For the variation of ring A sub-
stituents, various multisubstituted acetophenones were used as starting material. For
this purpose acetophenone, 2’-hydroxyacetophenone, 2’-4’-dihydroxyacetophenone
and 3’,4’-dimethoxyacetophenone were obtained from commercial sources. 2’,4’-
Dihydroxyacetophenone was further converted into 2’-hydroxy-4’-methoxyacetophenone
(1) by O-methylation reaction using dimethyl sulfate and potassium carbonate (see
section 7.1.2.1). 4’,6’-dimethoxy-2’hydroxyacetophenone (2) was synthesized by the
same procedure from 2’,4’,6’-trihydroxyaccetophenone and excess of dimethyl sulfate
(see section 7.1.2.2). The 2’,4’-dimethoxyacetophenone (3) was synthesized from
2’,4’-dihydroxy acetophenone using methyl iodide as methylating agent and potassium
carbonate as base (see section 7.1.2.3).
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Figure 3.3: Mechanism involved in synthesis of the chalcone by Claisen-Schmidt
condensation
Scheme 3.1 General reaction for synthesis of chalcones
The investigated chalcones (4-33) were synthesized using the above mentioned ace-
tophenones. A general procedure for the synthesis is given in section 7.1.2.4 and
the general reaction is given in Algorithm 3.1. In short, the selected acetophenone
and benzaldehyde were dissolved in ethanol, to the resulting solution 20 % sodium
hydroxide was added drop-wise under constant stirring. After addition of sodium
hydroxide, the color of the solution changed suddenly to dark yellow / dark orange.
The reaction mixture was stirred for 24 to 72 hours until the reaction was complete.
The reaction time for chalcones synthesized from unsubstituted acetophenone (4,
5), 2’,4’-dimethoxyacetophenone (22-26) and 3’,4’-dimethoxyacetophenone (30-33)
was shorter as compared to that for chalcones synthesized from hydroxylated ace-
tophenones. After completion of the reaction, the reaction mixture was poured
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onto crushed ice and neutralized with dilute hydrochloric acid, which resulted in
precipitation of solid product.
3.2.2 Synthesis of 3’,4’- and 5’,6’-benzochalcones
In case of benzochalcones, the phenyl ring A of the chalcone scaffold was replaced
by a naphthyl ring. In the current study several 3’,4’-benzochalcones and 5’,6’-
benzochalcones were synthesized. During the synthesis of benzochalcones it was
observed that, when the reaction was carried out using the classical method (NaOH
as base and at RT) the reaction was almost always incomplete even after 72 h of
stirring. Hence the reaction was carried out using lithium hydroxide, which is a
stronger base and by using ultrasound bath instead of stirring. This led to complete
conversion of starting materials into product and a shorter reaction time.
Scheme 3.2 General reaction involved in synthesis of benzochalcones
A general procedure for the synthesis of benzochalcones is given in section 7.1.2.5
and a scheme of the general reaction is depicted in Algorithm 3.2. In short, 2-acetyl-
1-hydroxynaphthalene (for synthesis of 3’,4’-benzochalcones, 34-40) or 1-acetyl-2-
hydroxynaphthalene (for synthesis of 5’,6’-benzochalcones, 41-47) were dissolved in
methanol, lithium hydroxide was added to the solution and the reaction flask was
kept in an ultrasound bath for 1-5 hours until completion. Reaction under ultrasound
condition reduced the reaction time and also gave almost always pure products. After
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completion of the reaction, the reaction mixture was poured onto crushed ice and
neutralized using dilute hydrochloric acid, which resulted in formation of a lot of
precipitate. The precipitate was filtered and washed with plenty of water to yield
the required benzochalcone.
3.3 Biological investigation of chalcones and
benzochalcones
In the current study a total of 30 chalcones and 14 benzochalcones bearing varying
substituents were synthesized to evaluate their BCRP inhibition potential. For
this purpose the Hoechst 33342 accumulation assay, which is a functional assay was
applied. In this assay the ability of the synthesized compounds to inhibit the substrate
extrusion by BCRP was measured. These compounds were further investigated for
their P-gp and MRP1 inhibition in the calcein AM assay. The results obtained
from these assays allowed to test the selectivity of the compounds towards BCRP
inhibition. A few compounds were found to be potent inhibitors of BCRP, which were
further investigated for their ability to reverse resistance to cytotoxic compounds in
the MTT assay. These compounds were also tested for their intrinsic cytotoxicity.
3.3.1 Investigation of BCRP inhibition in the Hoechst 33342
accumulation assay
Hoechst 33342 is a benzimidazole derivative and a substrate of BCRP (Figure 3.4).
It shows fluorescence when bound to DNA in the cells, especially adenine and
thymine rich sequences and also when bound to the cell membrane. It shows very
low fluorescence in aqueous solutions in the absence of cells. Hence, the intracellular
concentration of Hoechst 3342 can be determined by measuring its fluorescence. Being
a substrate of BCRP it is transported outside the cells overexpressing BCRP, leading
to decreased fluorescence. Inhibition of the BCRP leads to decreased extrusion of
Hoechst 33342 and increased fluorescence. A detailed procedure of the assay is given
in section 7.2.3.1.
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Figure 3.4: Structural formula of Hoechst 33342 (hydrochloride salt)
In general, Hoechst 33342 (final concentration 1 µM) was added to the cell suspension
with or without inhibitor. Fluorescence in KHB in the absence of cells was used
for background correction. The fluorescence of Hoechst 33342 was then measured
using microplate reader for 120 minutes at a constant interval of 60 seconds. The
intracellular concentration of Hoechst 33342 slowly increases and reaches a maximum
plateau after certain time. In case of BCRP overexpressing cells without inhibitor, no
increase in fluorescence is seen, while in presence of the inhibitor a gradual increase in
fluorescence (dependent on the amount of BCRP inhibition) is seen. A representative
kinetic diagram for Hoechst 33342 in presence of the standard inhibitor Ko143
in BCRP overexpressing cells is shown in Figure 3.5. Plateau fluorescence values
obtained from minutes 100 to 109 were used to generate concentration-response
curves with nonlinear regression using a four-parameter logistic equation.
Figure 3.5: Left: Representative fluorescence–time curves of Hoechst 33342 in BCRP
overexpressing cells in presence of Ko143. Only a few concentrations and time points
are shown for clarity. Right: Concentration-response curve generated from plateau
values of fluorescence-time curves.
In these experiments the response obtained in wild type cells not expressing BCRP
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was used as control. For comparison purposes in most of the cases XR9577
(WK-X-24) (BCRP and P-gp inhibitor [155, 156]) was used as standard. XR9577
(WK-X-24) was used as a standard for day to day experiments owing to its easy
availability and low cost over Ko143. The most potent BCRP inhibitor Ko143 was
used as external standard for correlation with inhibitory potencies of synthesized
chalcones. All the compounds were investigated for their BCRP inhibition in two
different BCRP overexpressing cells viz., MCF-7 MX and MDCK BCRP cells. The
activity data obtained for the chalcones and benzochalcones in the Hoechst 3342
accumulation assay is given in Table 3.1 and Table 3.2.
Figure 3.6: Scatterplot of the pIC50values determined in the Hoechst 33342 assay
using MCF-7 MX and MDCK BCRP cells. Each point is an average of at least three
independent experiments. The squared correlation coefficient r2 = 0.89, n = 35.
To determine the correlation between IC50values obtained using MCF-7 MX and
MDCK BCRP cells, a scatter plot (see Figure 3.6 ) was generated for all the
investigated compounds. The scatter plot was analyzed by linear regression, which
gave a good correlation factor (r2) of 0.89, suggesting equivalent inhibitory effect in
selected MCF-7 MX cells and transfected MDCK BCRP cells.
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Table 3.1: Synthesized chalcones and their inhibitory potencies against MCF-7 MX
and MDCK BCRP cells in the Hoechst 33342 accumulation assay
Chalcones (4-33)
Compd Substituents
on ring A
Substituents
on ring B
MCF-7 MX
IC50 ± SD
(µM)*
MDCK BCRP
IC50 ± SD
(µM)*
4 H 3,4-OCH3 n.a. n.a.
5 H 2-Cl n.a. n.a.
6 2’-OH H n.a. n.a.
7 2’-OH 4-OCH3 n.a. n.a.
8 2’-OH 3,4-OCH3 5.07 ± 0.27 4.97 ± 0.31
9 2’,4’-OH H n.a. n.a.
10 2’,4’-OH 4-OCH3 33.3 ± 7.09 12.0 ± 1.69
11 2’,4’-OH 3,4-OCH3 0.93 ± 0.03 0.85 ± 0.13
12 2’,4’-OH 3-OCH3 2.80 ± 0.17 1.94 ± 0.17
13 2’,4’-OH 2-Cl 3.21 ± 0.69 3.28 ± 0.50
14 2’,4’-OH 4-Cl 6.07 ± 2.37 6.37 ± 0.70
15 2’-OH,4’-OCH3 H 31.0 ± 6.39 30.9 ± 1.34
16 2’-OH,4’-OCH3 4-OCH3 4.20 ± 0.76 2.20 ± 0.75
17 2’-OH,4’-OCH3 3,4-OCH3 2.17 ± 0.41 1.06 ± 0.17
18 2’-OH,4’-OCH3 3-OCH3 3.15 ± 0.59 1.47 ± 0.31
19 2’-OH,4’-OCH3 2-Cl 6.85 ± 0.76 3.32 ± 0.57
20 2’-OH,4’-OCH3 4-Cl 13.5 ± 1.02 10.7 ± 2.82
21 2’-OH,4’-OCH3 3,4-Cl n.a. n.a.
22 2’,4’-OCH3 4-OCH3 2.34 ± 0.62 1.91 ± 0.78
23 2’,4’-OCH3 3,4-OCH3 2.20 ± 0.40 1.03 ± 0.29
24 2’,4’-OCH3 2-Cl 3.13 ± 0.57 2.63 ± 0.29
25 2’,4’-OCH3 4-Cl 3.09 ± 0.44 1.13 ± 0.21
26 2’,4’-OCH3 3,4-Cl n.a. n.a.
27 2’-OH,4’,6’-OCH3 4-OCH3 5.83 ± 0.32 3.00 ± 0.50
28 2’-OH,4’,6’-OCH3 3,4-OCH3 0.75 ± 0.03 0.53 ± 0.22
29 2’-OH,4’,6’-OCH3 2-Cl 5.27 ± 0.35 2.82 ± 0.26
30 3’,4’-OCH3 4-OCH3 2.19 ± 0.43 1.16 ± 0.34
31 3’,4’-OCH3 3,4-OCH3 3.28 ± 0.64 3.80 ± 0.13
32 3’,4’-OCH3 2-Cl 3.04 ± 0.21 2.89± 0.11
33 3’,4’-OCH3 4-Cl 2.72 ± 0.42 1.73 ± 0.13
* Data are expressed as mean ± SD (n = 3), n.a. = not active
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Table 3.2: Synthesized benzochalcones and their inhibitory potencies against MCF-7
MX and MDCK BCRP cells in the Hoechst 33342 accumulation assay
3’,4’-Benzochalcones (34-40) 5’,6’-Benzochalcones (41-47)
Compd Substituents
on the ring B
MCF-7 MX
IC50± SD
(µM)*
MDCK BCRP
IC50± SD
(µM)*
34 H 24.3 ± 3.11 9.23 ±1.00
35 4-OCH3 16.9 ± 1.02 9.83 ± 0.72
36 3,4-OCH3 2.50 ± 0.45 1.95 ± 0.39
37 3-OCH3 11.8 ± 1.97 5.68 ± 0.50
38 2-Cl n.a. n.a.
39 4-Cl n.a. n.a.
40 3,4-Cl 26.1 ± 3.77 22.4 ± 6.88
41 H 2.77 ± 0.41 2.58 ± 0.94
42 4-OCH3 3.81 ± 0.62 2.89 ± 0.73
43 3,4-OCH3 1.84 ± 0.87 0.72 ± 0.14
44 3-OCH3 1.93 ± 0.15 1.93 ± 0.15
45 2-Cl 5.21 ± 0.75 5.58 ± 0.60
46 4-Cl n.a. n.a.
47 3,4-Cl 8.78 ± 1.66 7.26 ± 1.10
XR9577 - 0.99 ±0.15 0.82 ± 0.18
Ko143 - 0.33 ± 0.05 0.25 ± 0.04
* Data are expressed as mean ± SD (n = 3), n.a. = not active
3.3.1.1 Structure-activity relationship
Several substituent requirements on the chalcone scaffold for BCRP inhibition could
be suggested.
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a) Effect of substituents present on ring A of chalcones:
It was observed that compounds with no substituents on ring A of the chalcone (4,
5) showed no BCRP inhibition. Also presence of a single substituent (hydroxy) at
position 2’ of the chalcone scaffold (6-8) did not improve the inhibition ability of
these compounds. Although, compounds bearing multiple substituents at positions 2’,
3’, 4’ and 6’ of the ring A showed substantial BCRP inhibition. In case of chalcones
with 3,4-dimethoxy substituents on ring B (11, 17, 23, 28), it was observed that
compounds with hydroxyl group at position 2’ (ring A) have slightly increased
activity as compared to compounds bearing methoxy substituents. However, no
substantial difference was noted for substitution at position 4’ of the ring A. Presence
of a methoxy group at position 6’ had only a very slight effect on the activity.
Compounds bearing 3’,4’-dimethoxy substituent (30-33) showed comparable activity
to those having 2’,4’-dimethoxy substituents (22-26).
b) Effect of substituents present on ring B of chalcones:
In the study by Han et al., effects of chloro substituents present at different positions
of ring B of the chalcone scaffold were investigated [123]. It was observed that
presence of 2-chloro and 4-chloro substituents led to increased BCRP inhibition. In
the current study several compounds with methoxy and chloro substituents on ring B
were compared for their BCRP inhibition. It was clearly observed that substitution
was needed on ring B of the chalcone, as unsubstituted chalcones (6, 9, 15) were
found to be inactive. Chalcones with 3,4-dimethoxy substitution on ring B showed
maximum efficacy of BCRP inhibition, with the chalcones 11, 17, 23, 28 being
most potent. A 3-methoxy substituent in case of compounds (12, 18) showed better
potencies compared to a 4-methoxy substituent on ring B (10, 16), both having
the same substituents at ring A. Chalcones with 2-chloro and 4-chloro substituents
were found to be active, while presence of a 3,4-dichloro substituent (21, 26) led to
inactivity.
The effect of different substituents on BCRP inhibitory potency of chalcones is
summarized in Figure 3.7.
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Figure 3.7: Effect of different substituents on the BCRP inhibition by chalcones
(4-33). ⊕: leads to increase in BCRP inhibition, 	: leads to decrease in BCRP
inhibition.
c) Effect of substituting ring A with a naphthyl ring:
Several benzochalcones bearing a naphthyl ring instead of ring A of the chalcone scaf-
fold were investigated. For this purpose 3’,4’-benzochalcones and 5’,6’-benzochalcones
were synthesized and tested in the Hoechst 33342 assay for their BCRP inhibition.
It was observed that 5’,6’-benzochalcones (41-47) were more potent as compared
to 3’,4’-benzochalcones (34-40). The effect of variations in substituents on ring B
in benzoflavones was similar to the case of chalcones. The 3,4-dimethoxy substi-
tuted benzoflavones (36, 43) were more potent compared to those bearing other
substituents. Compounds bearing 3,4-dichloro substituents (40, 47) were the least
active ones.
When activities of all three types of investigated chalcones are compared, 3’,4’-
benzochalcones were found to be the least active followed by 5’,6’-benzochalcones,
while chalcones with retained phenyl ring A structure were the most active. A
schematic comparison of activity of chalcones with benzochalcones is depicted in
Figure 3.8.
Figure 3.8: Comparison of activities of chalcones and benzochalcones
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3.3.2 Screening of chalcones and benzochalcones for P-gp and
MRP1 inhibition in the calcein AM accumulation assay
To test the selectivity of the chalcones towards BCRP inhibition, their effect on
the other major ABC transporters P-gp and MRP1 was investigated. Calcein
acetoxymethyl ester (calcein AM) is a non-fluorescent hydrophobic compound which
on hydrolysis by intracellular unspecific esterases converts into fluorescent calcein.
Calcein shows fluorescence with an excitation maximum of 496 nm and an emmision
maximum of 520 nm. Calcein AM has been shown to be a substrate for both P-gp
and MRP1, but it is not transported by BCRP [157, 158]. Owing to its high lipid
solubility, it can rapidly penetrate the plasma membrane of cells, while calcein being
hydrophilic and negatively charged can leave the cells only by active transport. When
P-gp or MRP1 is inhibited, this leads to an increase in calcein accumulation, resulting
in increased fluorescence. This increase in fluorescence can be used as a parameter
of P-gp or MRP1 inhibition. A detailed procedure for the calcein AM accumulation
assay is given in section 7.2.3.3.
Figure 3.9: Conversion of non-fluorescent calcein AM to fluorescent calcein by intra-
cellular esterases
For the purpose of screening all chalcones were investigated at 10 µM final concen-
tration using calcein AM accumulation assay. For checking P-gp inhibition, P-gp
overexpressing A2780 adr cells were used, while for MRP1 inhibition 2008 MRP1
cells were used. Cyclosporine A, which is a well known inhibitor of both P-gp
and MRP1 was used as a standard at 10 µM concentration [159]. For comparing
the inhibitory activity of tested compounds, percentage response was calculated
considering standard (cyclosporine A) response as 100 %. Response obtained from
the cells without any inhibitor was used as a negative control. From the Figure 3.10,
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it can be seen that all chalcones showed only very weak inhibitory effect on P-gp,
while none of them showed substantial inhibition of MRP1. Only compounds 13 and
31 gave P-gp inhibition response greater than 25 % when compared to cyclosporine
A. This indicates that the investigated chalcones are selective BCRP inhibitors.
A) P-gp Inhibition
B) MRP1 inhibition
Figure 3.10: Effect of chalcones and benzochalcones (4-47) on the accumulation of
calcein AM in P-gp (A) and MRP1 (B) overexpresssing cells. All chalcones were
investigated at 10 µM concentration (n=3). Cyclosporine A (Cs A), 10 µM , was
used as a positive control leading to total inhibition. Data is expressed as response
in percentage of standard Cs A, vehicle (KHB) was used as negative control.
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3.3.3 MTT cytotoxicity assay
One of the methods to determine the cell viability is a MTT cytotoxicity assay.
MTT (Methylthiazolyldiphenyl-tetrazolium bromide or 3-(4,5-dimethythiazol-2-yl)-
2,5-diphenyl tetrazolium bromide) a yellow tetrazole is reduced by mitochondrial
succinate dehydrogenase to formazan. Formazan is an insoluble, dark purple colored
compound which forms crystals due to its insolubility. The formazan crystals can be
dissolved in DMSO and then measured colorometrically. The reduction of MTT is
possible only in metabolically active (living) cells and hence only these produce dark
purple colored formazan crystals. The reaction involved in the process is shown in
Figure 7.7.
The procedure for performing the MTT assay is described in detail in section 7.2.3.4.
In short, cells were seeded into 96 well plate and incubated for 6 hours at 5 %
CO2 and 37 ºC. Test compound dilutions prepared in PBS were added to cells and
incubated again for 72 hours. Then MTT solution was added and plates were further
incubated for 1 hour. The formation of formazan crystals was confirmed under
microscpe. The supernatant was removed and DMSO was added to dissolve the
formazan crystals. The color intensity was measured using a microplate reader at
544 nm with background correction at 710 nm.
3.3.3.1 Investigation of selected chalcones to reverse MDR by MTT assay
To investigate the influence of chalcones on the antiproliferative effect of cytotoxic
agents in presence of the BCRP transporter, cytotoxicity of mitoxantrone and SN-38
was evaluated in both MDCK BCRP and MCF-7 MX cells. For this purpose, cell
viability was determined using MTT assay for the most potent chalcone (28) and
benzochalcone (43). GI50 values of the two anticancer agents were determined in the
absence and presence of selected compounds at three different concentrations. Both
compounds were able to reverse the resistance of the BCRP expressing cell lines,
proving their functional efficacy.
The effect of chalcone 28 on the GI50 of mitoxantrone in MCF-7 / MX cells is shown
in Figure 3.11. The compound was investigated at concentrations of 1µM , 3 µM
and 5 µM . It can be clearly seen that, even the lowest concentration of compound
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28 (1µM) was able to reverse the resistance and the higher concentrations led to
complete reversal of the resistance.
Figure 3.11: Effect of chalcone 28 on the GI50 of mitoxantrone in MCF-7 MX cells.
The compound was investigated at 1, 3, and 5 µM concentrations. Untreated cells
were used as control. The figure shows average and standard deviation obtained
from three independent experiments, n = 3.
Figure 3.12: Representative dose–response curve of SN-38 in presence of compound
43. Arrows indicate dose dependent effect of the benzochalcone on sensitisation
of MDCK BCRP cells towards SN-38. Open circle: MDCK sensitive cells, closed
square: MDCK BCRP cells, triangle: MDCK BCRP cells + 1 µM 43, closed circle:
MDCK BCRP cells + 3 µM 43, diamond: MDCK BCRP cells + 5 µM 43.
Compound 43 was investigated for its ability to reverse the SN-38 resistance in
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MDCK BCRP cells. For this purpose, three different concentrations (1 µM , 3 µM
and 5 µM) of benzochalcone 43 were selected. Representative dose–response curves
of SN-38 in presence of benzochalcone 43 are shown in Figure 3.12. From the shift
in the dose-response curve of MDCK BCRP cells towards lower concentrations, it
can be clearly seen that compound 43 was able to sensitize BCRP overexpressing
cells towards SN-38 toxicity.
3.3.3.2 Cytotoxicity of selected chalcones and benzochalcones
In the current study several potent and selective inhibitors of BCRP were found, but,
to make them potential candidates for future in vivo studies it was important that
the compounds possessed no or very low intrinsic cytotoxicity. To determine the cyto-
toxicity of selected potent chalcones and benzochalcone, MTT cytotoxicity assay was
applied using MDCK BCRP and MDCK sensitive cells. The concentration-response
curves obtained for compounds 11, 28 and 43 are shown in Figure 3.13. Because
of the limited solubility of these compounds in PBS, the highest concentration was
prepared by using a methanol in an amount that the final concentration of methanol
was not more than 2 %. Blank dilutions containing the same amount of methanol
were used to confirm that any cytotoxicity shown at the highest concentration was
not due the compound.
Chalcone 11 and benzochalcone 43 showed no cytotoxicity even at a concentration
of 100 µM . From Figure 3.13 it can be seen that a slight reduction in cell viability
at the highest concentrations of these compounds was due to the presence of the
small amount of methanol. However, chalcone 28 bearing multiple methoxy groups
on both rings of the chalcone moiety, showed cytotoxicity with estimated GI50 values
of 20.8 µM in MDCK BCRP cells and 23.8 µM in MDCK sensitive cells. Chalcones
11 and 28 differ in structure only at ring A, where the additional methoxy groups on
ring A of compound 28 could be responsible for the observed cytotoxicity. Though
the GI50 value for this compound is approximately 40 times higher than the IC50
values for BCRP inhibition, it could limit its usability in in vivo studies. Since,
compounds 11 and 43 showed no cytotoxicity along with high BCRP inhibitory
ability, these compounds are promising for future preclinical studies.
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11 28
43
Figure 3.13: Cytotoxicity of chalcones 11, 28 and benzochalcone 43 in MDCK BCRP
and sensitive cells. Open circle: MDCK BCRP cells, closed circle: MDCK sensitive
cells and closed triangle: dilution solvent (PBS) containing 2 % methanol at the
highest concentration.
In summary, several chalcones, 3’,4’-benzochalcones and 5’,6’-benzochalcones were
investigated for their inhibitory effects and selectivity towards BCRP. In the current
work the effect of different substituents on both A and B rings of the chalcone scaffold
was investigated. It was clearly observed that among all chalcones, compounds with
3,4-dimethoxy substituents at ring B were most active. The inhibitory effect of the
most active compounds was confirmed by MTT cytotoxicity assay. Compounds 11
and 28 were found to be the most potent and selective BCRP inhibitors, being only
little less active as compared to the most active BCRP inhibitor Ko143.
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Flavonoids are a group of naturally occurring low molecular weight polyphenolic
compounds. Flavonoids are found in a wide variety of plants and are present in fruits,
roots, stems and flowers. Flavonoids are well known for their beneficial effects on
health and are consumed in daily diets in form of tea and wine [160–167]. Different
flavonoids have been found to be useful as anti-inflammatory [168], anticancer [169],
antidepressant [170, 171], antiallergic [168, 172] and hepatoprotective [173, 174], etc.
Figure 4.1: Basic structure of flavonoids (benzo[α]pyrane with a phenyl ring at
position 2 or 3)
Flavonoids are structurally related compounds with a chroman type of skeleton
bearing a phenyl ring at position 2 or 3 of benzo[α]pyrane (see Figure 4.1). These
compounds are sub-classified into flavones, isoflavones, flavanones, flavanols, flavonols
and anthocyanins depending on the variation in the benzo[α]pyrane structure (see
Figure 4.2).
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Flavone Isoflavone Flavanone
Flavonol Flavanol Anthocyanin
Figure 4.2: Subclasses of flavonoids
4.1 Overview of flavonoids as ABC transporter
modulators
In the last decades a variety of flavonoids have been investigated for their modulation
of major ABC transporters like P-gp, MRP and BCRP. In 1994 Scambia et al.
showed the inhibitory effect of the polyhydroxy flavonoid quercetin on the efflux of
rhodamine 123 in doxorubicin resistant cells and proposed P-gp as possible target
[175]. Subsequently in 1997, Shapiro et al. reported a similar inhibitory effect of
quercetin on P-gp mediated transport of Hoechst 33342 [176]. Later Ferte et al.
studied several synthetic flavones and flavanones containing a N -benzylpiperazine side
chain and found that these compounds were able to modulate the P-gp mediated MDR
[177]. Several other groups have reported inhibitory effects of naturally occurring
flavonoids like sinensetin, kaempferol, biochanin A, myricetin, morin, baicalein and
fisetin among others, on the substrate transport by P-gp [178–180]. Chan et al. have
reported synthetic apigenin homodimers linked with defined-length poly(ethylene
glycol) spacers to be inhibitors of P-gp [181]. Also Wong et al. showed MRP1
inhibition by several bivalent apigenin homodimers [182].
Flavonoids as BCRP inhibitors: Flavonoids (especially naturally occurring)
have been studied for their BCRP inhibition by several working groups. Imai et al.
investigated several flavones, isoflavones, flavanones, flavanols and flavonols for their
ability to reverse the resistance in BCRP overexpressing K562 (human leukemic)
cells. It was shown that all flavones such as acaetin, apigenin, chrysin, etc. were able
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to reverse the BCRP mediated resistance, while flavanols and isoflavones were the
least active classes [183]. Zhang et al. and Ahmed-Belkacem et al. have extensively
studied several flavonoids and reported SAR (structure-activity relationship) for
BCRP inhibition [119, 128]. The latter have also reported 6-prenylchrysin and
techtochrysin to be potent inhibitors of BCRP. Recently in our group Anne Pick
performed QSAR (quantitative structure-activity relationship) studies on flavonoids
extracted from several plant sources [125]. A summary of the results obtained in
all three SAR studies performed is depicted in Figure 4.3. In 2005, Zhang et al.
also reported 7,8-benzoflavone (see Figure 4.3) to be a potent inhibitor of BCRP
[128, 129].
Figure 4.3: Left: Structure-activity relationship of flavonoids for BCRP inhibition
based on studies by Zhang et al., Ahmed-Belkacem et al. and Pick et al. ⊕: leads
to increase in BCRP inhibition, 	: leads to decrease in BCRP inhibition. Right:
Structure of a reported potent BCRP inhibitor 7,8-benzoflavone.
Based on all these studied synthesis of new flavones and benzoflavones was planned
with the aim of finding more potent and selective BCRP inhibitors. As only the
unsubstituted 7,8-benzoflavone has been reported till now, it was interesting to
investigate the effect of substitution on phenyl ring at position 2 of the flavone
scaffold. Also several substituted 5,6-benzoflavones were synthesized to check the
effect of variation in the position of benzo- substituent in the ring A of the flavone
scaffold. Synthesis and biological investigation of these compounds are discussed
below.
4.2 Synthesis of benzoflavones
In this work, different substituted 7,8-benzoflavones and 5,6-benzoflavones were
synthesized to study their ability to inhibit BCRP. The 7,8-benzoflavones were
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synthesized from 3’,4’-benzochalcones while 5’,6’-benzochalcones were used for the
synthesis of 5,6-benzoflavones.
Benzochalcones were converted to benzoflavones by cyclisation using iodine as catalyst.
The detailed procedure for the synthesis of these compounds is given in section 7.1.2.6.
In short, the corresponding 3’,4’-benzochalcone or 5’,6’-benzochalcone was dissolved
in dimethyl sulfoxide (DMSO) and catalytic amount of iodine granules was added.
The reaction mixture was refluxed for 7-8 hours until the reaction was complete.
Afterwards, the reaction mixture was poured onto crushed ice and extracted with ethyl
acetate. The organic phase was evaporated yielding a dark brown solid. The impure
benzoflavone was then purified by column chromatography using dichloromethane
: methanol (9.5 : 0.5) as eluent. The general reaction involved in the synthesis of
benzoflavones is given in Algorithm 4.1.
Scheme 4.1 Synthesis of benzoflavones
4.3 Synthesis of 3-hydroxyflavones and
3-hydroxybenzoflavones
To confirm the negative effect of the presence of a hydroxy substituent at position 3
of the flavone scaffold, several 3-hydroxy flavones and benzoflavones were synthesized.
These compounds were further converted to 3-methoxy flavones and benzoflavones
(see section 4.4) to compare their activities. The 3-hydroxylated compounds were
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synthesized by cyclization of the corresponding chalcones or benzochalcones via
Algar-Flynn-Oyamada (AFO) reaction [184]. This reaction involves oxidation of
2’-hydroxy chalcones to 2-aryl-3-hydroxy-4H -l-benzopyran-4-ones (flavone-3-ols) in
presence of alkaline hydrogen peroxide. Along with formation of 3-hydroxy flavones
there is the possibility of formation of aurones as side products. This is dependent on
the type of attack by the phenolate on the carbons bearing the oxirane oxygen (see
Figure 4.4). It was suggested by Cummins et al. that when the reaction was carried
out using 6’-methoxychalcones it led to formation of aurones as major products [185].
This was a major obstacle in the synthesis of 3-hydroxy derivatives of flavones and
hence only certain chalcones were successfully converted to 3-hydroxy flavones or
benzoflavones.
Figure 4.4: Mechanism involved in the synthesis of 3-hydroxyflavones and possible
formation of aurones as side products. The mechanism depicted here is adapted
from the work of Gormley et al. [186] and Cummins et al. [185] .
A general procedure for the synthesis of 3-hydroxy flavones and benzoflavones is given
in section 7.1.2.7. In short, the selected chalcone or benzochalcone was dissolved in
ethanol. To the solution, 25 % sodium hydroxide solution was added in small portions,
followed by drop wise addition of 25 % hydrogen peroxide. The reaction mixture was
stirred at room temperature overnight. After completion of the reaction, the resulting
reaction mixture was poured onto crushed ice and neutralized by addition of dilute
hydrochloric acid with constant stirring yielding a yellow colored precipitate. All
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compounds were recrystallized from ethanol. The general reaction scheme involved
in the synthesis of 3-hydroxy flavones and benzoflavones is given in Algorithm 4.2.
Scheme 4.2 Synthesis of 3-hydroxy flavones or benzoflavones from corresponding
chalcones or benzochalcones
4.4 Synthesis of 3-methoxy-flavones and
3-methoxybenzoflavones
The work done in our group by Anne Pick suggested that, presence of a 3-methoxy
substituent in the flavone scaffold leads to increased BCRP inhibition. Hence, 3-
hydroxyflavones and benzoflavones were further converted into 3-methoxy flavones
and benzoflavones. Two goals were achieved through these compounds, first to
confirm the positive effect of a 3-methoxy substiuent seen in naturally occurring
flavonoids and second to check the similar effect in benzoflavones.
Most of the 3-methoxy compounds were synthesized by O-methylation using methyl
iodide, from the corresponding 3-hydroxy flavones (see section 4.3). The naturally
occurring pentahydroxy flavonoids quercetin and morin were converted into pen-
tamethyl analogs using methyl iodide while, for tetramethyl analogs dimethyl sulfate
was used. The reactions involved in the synthesis of these compounds are given in
Algorithm 4.3.
The synthesis procedure for 3-methoxy flavones and benzoflavones is given in
section 7.1.2.8. In short, the selected 3-hydroxyflavone or 3-hydroxybenzoflavone was
dissolved in acetone and potassium carbonate was added. To the reaction mixture
methyl iodide was added drop wise in excess quantity and the mixture was refluxed
for 24 h. After completion of the reaction acetone and unreacted methyl iodide
was removed under reduced pressure. To the residue, water was added and the
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precipitated product was filtered and washed with plenty of water to remove traces
of potassium carbonate. The product was recrystallized from ethanol.
Scheme 4.3 Synthesis of 3-methoxy flavones and benzoflavones (A). Synthesis of
pentamethyl and tetramethyl derivatives of quercetin and morin (B).
For synthesis of pentamethylquercetin (3,3’,4’,5,7-pentamethoxy flavone) or pen-
tamethylmorin (2’,3,4’,5,7-pentamethoxy flavone) from quercetin (3,3’,4’,5,7-pentahydroxy
flavone) or morin (2’,3,4’,5,7-pentahydroxy flavone), a similar approach like the above
described was used. Here, the amount of methyl iodide was 5 fold excess to that of
starting material to assure that all hydroxy groups are methylated.
Initially, a similar approach was also used for the synthesis of tetramethylquercetin (5-
hydroxy-3,3’,4’,7-tetramethoxy flavone) and tetramethylmorine (5-hydroxy-2’,3,4’,7-
tetramethoxy flavone). However, it always resulted in complete methylation of the
starting compounds even after controlling the quantity of methyl iodide used. Hence
the reaction conditions were modified, where a mixture of acetone / water (2:1) was
used as solvent. Dimethyl sulfate was used as methylating agent and potassium
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hydroxide was used as base. Small portions of dimethyl sulfate and potassium
hydroxide were added to the refluxing reaction mixture in intervals of 10-20 minutes.
After completion of the reaction, it was found that a small amount of pentamethyl
product was formed along with the desired tetramethyl product. The resulted crude
product was eluted on silica (40-63 µm) using hexan:ethylacetate (1:3) as mobile
phase to get the pure tetramethyl compounds.
4.5 Biological evaluation of flavones and
benzoflavones
The synthesized compounds were investigated for their BCRP inhibition ability by
measuring accumulation of Hoechst 33342 and pheophorbide A in MDCK BCRP
cells. All compounds were additionally tested for their P-gp and MRP1 inhibition
in the calcein AM assay. Cytotoxicity of the representative most active compounds
was assessed by MTT-cytotoxicity assay. Also, MDR reversal effectiveness of the
most potent compounds was confirmed by checking the chemsensitisation in BCRP
overexpressing cells. The assays performed and results obtained are described below.
4.5.1 Investigation of BCRP inhibition
For the estimation of BCRP inhibition of the synthesized flavones and benzoflavones
Hoechst 33342 and pheophorbide A assays were utilized. The use of two different sub-
strates for determining the BCRP inhibition allows to check for substrate specificity
of the inhibitor. For performing these experiments the more stable MDCK BCRP
cells were selected over MC-7 MX cells. It was shown in section 3.3.1 that the results
obtained with MDCK BCRP cells are comparable to those obtained using BCRP
overexpressing MCF-7 MX cells. The functioning and the principle involved in the
Hoechst 33342 assay are already discussed (section 3.3.1 and section 7.2.3.1). The
IC50 values of the investigated flavones and benzoflavones obtained in the Hoechst
33343 assay using MDCK BCRP cells are given in Table 4.1 and Table 4.2.
In these studies Ko143 was used as standard. Figure 4.5 depicts representative
concentration-response curves obtained in the Hoechst 33342 assay for the most
active compound 74 compared to the standard Ko143.
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Figure 4.5: Representative concentration-response curves of compound 74 (open
circles, IC50 = 0.43 ± 0.02 µM) and Ko143 (closed squares, IC50 = 0.25 ± 0.04
µM) obtained in the Hoechst 33342 assay (see Table 4.2). Each data point shown
represents the average of 3 independent experiments and error bars indicate the
standard deviation.
Pheophorbide A assay: Pheophorbide A is a porphyrine type compound and a
substrate of BCRP [104]. An advantage of pheophorbide A is that, it has been shown
to be transported only by BCRP and not by P-gp or MRP1 making it a specific
substrate of BCRP. It shows fluorescence with excitation maximum of 395 nm and
emission maximum at 670 nm. Inhibition of BCRP leads to concentration dependent
increase in pheophorbide A accumulation and effectively in its fluorescence. For
determination of the intracellular fluorescence of pheophorbide A, flow cytometry
technique was applied. A detailed procedure for performing the assay is given in
section 7.2.3.2.
Figure 4.6: Structure of pheophorbide A
In short, different concentrations of selected compounds and cells were seeded in
U-shaped microplates and incubated for 30 minutes. After this, pheophorbide A with
a final concentration of 0.5 µM was added and microplates were further incubated
for 120 minutes. After incubation the cells were re-suspended. The intracellular
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fluorescence of pheophorbide A was measured using FACScalibur flow-cytometer in
the FL3 channel.
A. B.
C.
Figure 4.7: (A): A dot plot of cell population (MDCK BCRP) obtained from FSC
height against SSC height, the red circle indicates gating of the healthy cell population.
(B): Fluorescence intensity of pheophorbide A at FL3 after gating (in presence of 10
µM Ko143 in MDCK BCRP cells). (C): A representative concentration-response
curve obtained from the fluorescence data for Ko143 using MDCK BCRP cells in
the pheophorbide A assay.
The analysis of the data generated by flow cytometry was performed using BD
CellQuest Pro software. A prepared analysis sheet was used, where it was possible
to check the plot of FSC count against SSC count, which enables gating of the cell
population from debris. Figure 4.7 shows a dot plot of cell population (FSC against
SSC) and a histogram obtained by plotting fluorescence (FL-3 height) against the
number of gated events. From this fluorescence data a concentration-response curve
was generated with the help of a four-parameter logistic equation in GraphPad Prism
software. In Figure 4.7 a concentration-response curve for Ko143 (IC50 = 0.33 µM)
using MDCK BCRP cells is depicted.
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Table 4.1: Synthesized flavones and their inhibitory potencies against MDCK BCRP cells in Hoechst 33342 and pheophorbide A
accumulation assays.
Compd R3 R5 R7 R2’ R3’ R4’
Hoechst
33342 assay
Pheophorbide
A assay
IC50 ± SD
(µM)*
IC50 ± SD
(µM)*
3-Hydroxyflavones
56 OH H H H H H n.a. n.a.
57 OH H H H H OCH3 n.a. n.a.
58 OH H H H OCH3 OCH3 n.a. n.a.
59 OH H OCH3 H OCH3 OCH3 1.01 ± 0.10 1.77 ± 0.14
60 OH OCH3 OCH3 H H OCH3 12.4 ± 0.47 8.95 ± 0.65
3-Methoxyflavones
68 OCH3 H H H H H 1.21 ± 0.12 1.28 ± 0.17
69 OCH3 H H H H OCH3 7.74 ± 0.35 6.50 ± 0.58
70 OCH3 H H H OCH3 OCH3 1.18 ± 0.29 1.34 ±0.19
71 OCH3 H OCH3 H OCH3 OCH3 1.18 ± 0.18 2.14 ± 0.31
79 OCH3 OCH3 OCH3 H OCH3 OCH3 0.822 ± 0.169 1.88 ± 0.24
80 OCH3 OCH3 OCH3 OCH3 H OCH3 5.98 ± 0.45 5.94 ± 0.74
81 OCH3 OH OCH3 H OCH3 OCH3 0.540 ± 0.079 0.570 ± 0.093
82 OCH3 OH OCH3 OCH3 H OCH3 3.27 ± 0.15 3.89 ± 0.16
* Data are expressed as mean ± SD (n = 3), n.a. = not active
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Table 4.2: Synthesized benzoflavones and their inhibitory potencies against MDCK
BCRP cells in Hoechst 33342 and pheophorbide A accumulation assays.
Compd R3 R3’ R4’
Hoechst 33342
assay
Pheophorbide A
assay
IC50 ± SD
(µM)*
IC50 ± SD
(µM)*
Benzoflavones
49 H H H 1.31 ± 0.12 1.40 ± 0.18
50 H H OCH3 1.28 ± 0.07 1.29 ± 0.09
51 H OCH3 OCH3 1.23 ± 0.08 1.13 ± 0.19
52 H OCH3 F 0.522 ± 0.083 0.457 ± 0.124
53 H H H 8.32 ± 0.61 6.05 ± 1.62
54 H H OCH3 2.46 ± 0.15 1.69 ± 0.07
55 H OCH3 OCH3 0.590 ± 0.064 0.458 ± 0.053
3-Hydroxybenzoflavones
61 OH H H 2.89 ± 0.73 1.59 ± 0.14
62 OH H OCH3 6.93 ± 1.58 4.97 ± 0.88
63 OH OCH3 OCH3 0.724 ± 0.049 1.52 ± 0.08
64 OH OCH3 F 22.5 ± 4.90 17.9 ±± 0.29
65 OH H H 11.0 ± 2.98 13.6 ± 2.40
66 OH H OCH3 8.93 ±2.37 6.12 ± 1.54
67 OH OCH3 OCH3 6.12 ± 0.35 4.84 ± 0.99
3-Methoxybenzoflavones
72 OCH3 H H 2.71 ± 0.41 2.31 ±± 0.04
73 OCH3 H OCH3 1.06 ± 0 .26 3.07 ± 0.38
74 OCH3 OCH3 OCH3 0.426 ± 0.019 0.468 ± 0.034
75 OCH3 OCH3 F 2.44± 0.25 4.01 ± 0.77
76 OCH3 H H 11.1 ± 1.37 12.5 ± 0.65
77 OCH3 H OCH3 3.07 ±0.04 8.02 ± 1.39
78 OCH3 OCH3 OCH3 4.27 ± 0.64 5.25 ± 0.67
Ko143 – 0.25 ± 0.04 0.33 ± 0.05
* Data are expressed as mean ± SD (n = 3)
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The IC50 values obtained in the pheophorbide A assay for the investigated compounds
in MDCK BCRP cells are given in Table 4.1 and Table 4.2. Pheophorbide A assays
for flavones 56-60, 68-71 and 79-82 were performed by Katja Stefan and the results
were taken from her master thesis for comparison purposes [187].
4.5.1.1 Structural features of flavones and benzoflavones for BCRP inhibition
In case of flavones, two types of compounds were investigated 1) those having
hydroxy substituents at position 3 of the flavone nucleus (56-60) and 2) those
having methoxy substituents at the same position (68-71 and 79-82). Generally,
compounds possessing a 3-OH substitutent were found to be very less active or
even inactive when compared to compounds bearing a 3-OCH3 substituent, as it
can be seen in Table 4.1. The results obtained from the functional assays described
in this study are in accordance with the structure-activity relationship proposed
earlier by several investigators [125, 128, 188]. It was also observed that presence of
methoxy groups on the side ring (at position 2) of flavone led to an increase in activity.
Presence of 3’,4’-OCH3 substitution was found to be optimum for BCRP inhibition.
The comparison of IC50 values for compounds 79-82 shows the importance of the
presence of a 5-OH substituent (in compounds 81 and 82) for BCRP inhibition.
Replacement of 5-OH with 5-OCH3 leads to a decrease in activity (compare with
compounds 79 and 80). In case of these compounds it was also observed that
presence of 2’,4’-dimethoxy substituent (80, 82) led to strong decrease in activity
when compared to 3’,4’-dimethoxy substituted compounds (79, 81). Compound 81,
bearing 3-OCH3 and 5-OH substituents on the flavone scaffold was found to be the
most potent in the flavone series with an IC50 value of 0.54 µM in Hoechst 33342
assay.
The second series includes 7,8-benzoflavones and 5,6-benzoflavones. Compound 49,
the unsubstituted benzoflavone was shown to be a potent inhibitor of BCRP by
Zhang et al. [128] and was included in the current study for comparison purposes.
As it can be seen from Table 4.2, also in case of 7,8- and 5,6-benzoflavones the
presence of a 3-OH substituent (in compounds 61-67) led to a decrease in activity.
While, particularly in case of 7,8-benzoflavones the presence of a 3-OCH3 group
(compounds 72-74) led to a strong increase in BCRP inhibition. As in the case of
flavones, 3’,4’-OCH3 substituted benzoflavones were more potent BCRP inhibitors
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when compared to unsubstituted compounds and those bearing a 4’-OCH3 substituent
only. Compound 52 having a 3’-OCH3, 4-F substitution was found to be the most
active (IC50= 0.52 ± 0.08 µM in the Hoechst 33342 assay) amongst the benzoflavones
having no substitution at position 3. However, other derivatives of this compound (64
and 75) showed less activity. From Table 4.2, it can be seen that 5,6-benzoflavones
are less potent as compared to 7,8-benzoflavones with exception of compound 55
which showed strong BCRP inhibition (IC50= 0.59 ± 0.06 µM in the Hoechst 33342
assay).
The BCRP inhibition analysis done by two different assays gave comparable results
with good correlation (r2 = 0.89) between both assays as shown in Figure 4.8. Also
the Hill slopes of the dose response curves were similar and not significantly different
from one, except for a few experiments. This indicates that the inhibitory activity of
these compounds is not substrate specific.
Figure 4.8: Scatterplot of pIC50 values for BCRP inhibition obtained in the Hoechst
33342 assay and the pheophorbide A assay. Each point indicates mean of IC50
values obtained in three independent experiments and error bars indicate standard
deviation. The squared correlation coefficient is r2 = 0.89, n = 32.
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7,8-benzoflavones > flavones > 5,6-benzoflavones
Figure 4.9: Effect of different substituents on BCRP inhibitory activity of flavonoids.
Dotted lines indicate 7,8- or 5,6-benzo substitution for benzoflavones. ⊕: leads to
increase in BCRP inhibition, 	: leads to decrease in BCRP inhibition.
From the activity data of all compounds, it was found that 7,8-benzoflavones are
more active as compared to flavones, while 5,6-benzoflavones are the least active
class with exception of compound 55. The effect of different substituents on BCRP
activity is summarized in Figure 4.9.
4.5.2 Determination of P-gp and MRP1 inhibition in the calcein
AM assay
All compounds were first screened for their P-gp and MRP1 inhibition to investigate
selectivity towards BCRP. Screening was performed at 10 µM final inhibitor concen-
tration using calcein AM assay. Functionality and principle involved in the calcein
AM assay are described in section 3.3.2 and section 7.2.3.3.
In the screening, cyclosporine A, a P-gp and MRP1 inhibitor, was used as a standard.
Most compounds showed no or very weak inhibition of P-gp and MRP1. The effect
of the compounds on calcein accumulation in P-gp overexpressing A2780 adr cells
is illustrated in Figure 4.10. Figure 4.11 shows the effect of the compounds on
accumulation of calcein in MRP1 overexpressing 2008 MRP1 cells. In case of flavones
only compound 79 was found to show substantial effect on both P-gp and MRP1.
While in case of benzoflavones, only 7,8-benzoflavones showed considerable effect.
Compounds showing more than 25 % of response when compared to control (response
in non P-gp or MRP1 expressing sensitive cells) were further investigated with a
range of different concentrations to calculate their IC50 values.
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Figure 4.10: Effect of flavones and benzoflavones on accumulation of calcein in
P-gp overexpressing A2780 adr cells. The compounds were investigated at 10
µM final concentration. Cyclosporine A (CsA, 10 µM) was used as a standard.
Response in absence of any compound was used as negative control. Data are
expressed as response in percentage of control (accumulation of calcein in non
P-gp expressing sensitive A2780 cells) and presented as the mean ± SD of three
independent experiments.
Figure 4.11: Effect of flavones and benzoflavones on accumulation of calcein in
MRP1 overexpressing 2008 MRP1 cells. The compounds were investigated at 10
µM final concentration. Cyclosporine A (CsA, 10 µM) was used as a standard.
Response in absence of any compound was used as negative control. Data are
expressed as response in percentage of control (accumulation of calcein in non MRP1
expressing sensitive 2008 cells) and presented as the mean ± SD of three independent
experiments.
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Table 4.3: Inhibitory potencies of selected flavonoids using A2780 adr and 2008 MRP1
cells in calcein AM assay. Data are expressed as mean ± SD (n=3). Cyclosporine A
was used as standard.
Compd
A2780 adr
IC50 ± SD (µM)
2008 MRP1
IC50 ± SD (µM)
49 24.6 ± 3.98 11.3 ± 2.49
50 19.7 ± 2.82 9.86 ± 1.05
51 4.00 ± 0.22 1.76 ± 0.04
52 n.a.* 15.1 ± 3.83
63 4.27 ± 0.59 n.a.
72 n.a 27.5 ± 4.44
73 n.a 19.0 ± 2.48
74 21.9 ± 2.33 21.8 ± 2.74
79 23.4 ± 2.78 26.35 ± 2.65
80 27.1 ± 3.53 n.a.
Cyclosporine A 0.99 ± 0.08 2.81 ± 0.62
* n.a. = not active, showing a response of less than 25 % of
control in screening at 10 µM concentration (see Figure 4.10
and Figure 4.11).
P-gp and MRP1 inhibition data of selected compounds are given in Table 4.3.
Compound 51, a 7,8-benzoflavone bearing 3’,4’-OCH3 substituents was found to be
the most potent and active for both P-gp and MRP1 inhibition. It was even more
potent than cyclosporine A in MRP1 inhibition. Compound 74, the most active
flavonoid in the current study showed very weak P-gp and MRP1 inhibition with
almost 50 times less activity compared to BCRP inhibition.
4.5.3 Intrinsic cytotoxicity of selected flavones and
benzoflavones in the MTT assay
In the current study of flavonoids, few flavones and benzoflavones were found to
be potent inhibitors of BCRP. To make further investigation of these compounds
possible, the intrinsic cytotoxicity was checked in the MTT cytotoxicity assay. For
this purpose, from flavones and benzoflavones, the most potent compounds (59, 81,
55 and 74) from each class were selected. The toxicity studies of these compounds
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were performed using MDCK BCRP and sensitive MDCK cells. Owing to low aqueous
solubility of these compounds at higher concentrations, the highest concentration
(100 µM) was prepared using methanol (not more than 2 % end concentration). To
check the effect of this small amount of methanol on cell toxicity, blank experiments
were performed using dilution solvents (PBS) containing same amount of methanol.
59 81
55 74
Figure 4.12: Cytotoxicity of selected compounds was determined in the MTT assay
using MDCK BCRP and sensitive MDCK cells. Flavones 59 and 81 and ben-
zoflavones 55 and 74 were investigated up to 100 µM concentration, for 72 h. Open
circle: MDCK BCRP cells, closed circle: MDCK sensitive cells and closed triangle:
dilution solvent (PBS) containing 2 % methanol in highest concentration.
For all compounds, very little toxicity could be observed at 100 µM and none of the
compounds showed cytotoxicity at lower concentrations. For most of the compounds
GI50 could be estimated to be more than 100 µM and only for compound 81 GI50
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was estimated to be around 85 µM. These concentrations are much higher than that
required for the BCRP inhibition.
4.5.4 Re-sensitization of BCRP overexpressing cells towards
SN-38 and Hoechst 33342 cytotoxicity
MTT assay was also used to investigate the effect of flavone (81) and benzoflavone
(74) on the antiproliferative effect of cytotoxic agents in presence of the BCRP
transporter. Cytotoxicity of SN-38 (the active metabolite of irinotecan) and Hoechst
33342 was evaluated in MDCK BCRP cells. The cytotoxic effect of both drugs
was determined in absence and presence of 5 µM and 10 µM concentrations of the
selected compounds. Both compounds were found to be able to reverse the resistance
of the BCRP expressing cell lines, proving their functional efficacy. Figure 4.13
shows representative dose–response curves of SN-38 in presence of compound 81 and
of Hoechst 33342 in presence of compound 74.
Figure 4.13: Representative shift in dose–response curves of SN-38 and Hoechst 33342
cytotoxicity. Left: effect of compound 81 on SN-38 cytotoxicity in BCRP cells.
Right: effect of compound 74 on cytotoxicity of Hoechst 33342. Both compounds
were investigated at 5 µM (open circles) and 10 µM (closed circles) concentrations.
BCRP cells without inhibitor (open triangles) are more resistant than sensitive cells
(closed squares).
The shift in the dose–response curves of MDCK BCRP cells in presence of these
compounds towards lower concentrations indicates sensitization to cytotoxicity of SN-
57
Chapter 4 Project 2: Flavones and benzoflavones as BCRP inhibitors
38 and Hoechst 33342. The GI50 values of SN-38 in absence of BCRP inhibitor were
8.5 µM for MDCK BCRP cells and 0.81 µM for MDCK sensitive cells, indicating
resistance to SN-38 in MDCK BCRP cells. In presence of compound 81 (10µM),
the GI50 value for MDCK BCRP cells was reduced to 0.78 µM indicating complete
reversal of resistance. Similar results were observed for Hoechst 33342 cytotoxicity
in presence compound 74, where the GI50 of Hoechst 33342 in MDCK BCRP cells
was reduced to 2.2 µM (in presence of inhibitor 74) from 12.7 µM (in absence
of inhibitor). This outcome, proves their ability to overcome the MDR in BCRP
overexpressing cells.
In summary, in the current study several 7,8-benzoflavones, 5,6-benzoflavones were
synthesized and investigated for their BCRP inhibition potential along with compar-
ison to multisubstituted flavones. From the activity data obtained in the Hoechst
33342 and pheophorbide A assays it was possible to propose the effect of different
substituents as well as the effect of attachment of a benzo-ring at position 7,8 or
5,6 of the flavone moiety. 7,8-benzoflavones were found to be more potent than
flavones and 5,6-benzoflavones. The inhibitory effect of these compounds was further
confirmed by evaluating the influence of selected compounds on the cytotoxicity of
SN-38 and Hoechst 33342 in BCRP overexpressing cells. Most of the synthesized
compounds were found to be selective towards BCRP. Cytotoxicity of the most
active compounds was determined in the MTT cytotoxicity assay. Compound 74
was found to be a non-toxic potent BCRP inhibitor having 50 times more selectivity
towards BCRP. Compound 51, a substituted 7,8-benzoflavone could be a good broad
spectrum MDR modulator as it produced low IC50 values for all BCRP, P-gp and
MRP1.
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Quinazoline (Figure 5.1) is a heterocyclic compound consisting of two fused six
membered aromatic rings, a benzene and a pyrimidine ring and is also known as
benzo-1,3-diazine. Quinazoline was first prepared by Gabriel in 1903 [189].
Figure 5.1: General structure of quinazoline
Compounds containing the quinazoline heterocycle have been shown to posses a vast
variety of biological activities such as, sedative [190], analgesic [191, 192], anti-diabetic
[193], anticonvulsant [194, 195], antiallergic [196, 197], antimalerial [198, 199] and
antihypertensive [200, 201], etc. Quinazoline derivatives have been shown to have
anticancer activity [202–206]. There are several marketed drugs bearing a quinazoline
nucleus, for example prazosin, gefitinib, erlotinib, alfuzosin, trimetrexate, bunazosin,
vandetanib, etc. Quinazoline compounds have also been shown to modulate ABC
transporters as described below.
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5.1 Quinazolines as modulators of ABC transporters
Until now, a few quinazoline derivatives have been shown to be substrates as well
as inhibitors of ABC transporters. Prazosin, a quinazoline compound and an α-
adrenergic blocker has been shown to be transported by BCRP in several studies
[207, 208]. It was also shown to be transported by P-gp to lesser extent by Zhou
et al [92]. BODIPY-prazosin a fluorescent derivative is used widely for transport
activity studies on BCRP [75]. Polli et al. found that P-gp and BCRP play a role
in transporting lapatinib, a tyrosin kinase inhibitor (TKI) [209]. Similar results
were shown by Kodaira et al. for another TKI quinazoline, erlotinib [210]. Recently,
tandutinib also a TKI quinazoline was identified to be a substrate of BCRP by Deng
et al [211].
BCRP substrates BCRP inhibitors
Prazosin Gefitinib
Lapatinib PD153035
Tandutinib Erlotinib
Figure 5.2: Substrates and inhibitors of BCRP containing the quinazoline scaffold
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Along with being transported by P-gp and BCRP, recently a few TKI quinazolines
were identified to be good inhibitors of BCRP. In 2004 Yanase et al. showed the
inhibitory effect of gefitinib (marketed as Iressa) on BCRP [212], while later in
2006 Leggas et al. showed the inhibitory effect of this compound on both P-gp and
BCRP [213]. Contradictory results were recently published by Agarwal et al. where
distribution of gefitinib was found to be limted by P-gp and BCRP through its
transport [214]. The BCRP inhibitory effect of gefitinib was recently confirmed in
our group by Anne Pick, where it was also shown that gefitinib was able to decrease
the overall and surface expression of BCRP in EGFR-positive MDCK BCRP cells
by interacting with the PI3K/Akt signaling pathway [117]. Few other quinazoline
nucleus bearing compounds such as PD153035 and erlotinib have been shown to
inhibit BCRP. Structures of selected quinazoline BCRP substrates and inhibitors
are given in Figure 5.2.
In the study done by Anne Pick, a few quinazoline compounds were found to be
potent inhibitors of BCRP with IC50 values in the sub-micromolar range. But these
compounds lack variation in the substituents present on the quinazoline moiety.
Hence, with the aim of finding more potent quinazoline compounds and possibly
identification of structural requirements for BCRP inhibition, several quinazoline
derivatives were synthesized. Synthesis and biological evaluation of these compounds
are discussed in the following sections.
5.2 Synthesis of quinazoline derivatives
Figure 5.3: Modifications of the quinazoline scaffold
In the current study, several modifications of the quinazoline scaffold were planned
with the primary aim of finding more potent BCRP inhibitors showing less toxic-
ity when compared to already available TKI quinazolines. The quinazoline TKIs
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investigated until now for BCRP inhibition possess substituents only at positions
4, 6 and 7 of the quinazoline moiety. Hence, in this work compounds with different
substitution, starting with 2-phenyl substituted derivatives were investigated for
their activity against BCRP. Different combinations of modifications at position 2, 4,
6, 7 of quinazoline were made and are summarized in Figure 5.3.
5.2.1 Synthesis of 2-phenyl-4-anilinoquinazolines
The first variation of the quinazoline scaffold involved synthesis of several quinazoline
compounds bearing a phenyl ring at position 2 and a substituted anilino group
at position 4 of the quinazoline. In these compounds positions 6 and 7 were kept
unsubstituted.
The synthesis of 2-phenyl-4-anilino compounds involved the following steps:
1. Synthesis of 2-phenylquinazoline-4(3H )-one (83): This compound was synthesized
by using method A described in section 7.1.2.11. The quinazolinone compound was
synthesized by fusion of anthranilamide with benzaldehyde in presence of iodine and
potassium carbonate. Dimethylformamide (DMF) was used as solvent. The reaction
mixture was heated for 4-5 hours at 70-90 °C. After completion of the reaction the
solution was poured onto crushed ice to get a crude product precipitate. Traces of
iodine were removed by washing the product with sodium thiosulfate and later with
plenty of water. The product was recrystallized from ethanol to yield pale yellow
crystals with 79 % yield. This compound was used further for the synthesis of the
4-chloro derivative.
2. Conversion of 4-quinazolinone to 4-chloro-2-phenylquinazoline (87): The quina-
zolinone (83) was converted to 4-chloro-2-phenylquinazoline by chlorination using
phosphorus oxychloride (POCl3) as described in section 7.1.2.12. Compound 83 was
refluxed in excess quantity of POCl3 for 9 hours. After completion of the reaction,
excess of POCl3 was removed under reduced pressure. The residue was added to
ice-water and neutralized with ammonium hydroxide. The solution was extracted
with dichloromethane and the solvent was removed under reduced pressure to yield
pale yellow solid with 87 % yield.
3. Synthesis of 4-anilinoquinazolines (98-115) from 87 and substituted anilines:
Using the 4-choloro-2-phenylquinazoline (87) several 4-anilino derivatives were syn-
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thesized as described in section 7.1.2.14. In short, 4-chloro-2-phenylquinazoline was
dissolved in refluxing isopropanol and the selected aniline was added drop wise. The
reaction mixture was refluxed for 3-4 hours. After completion of the reaction in most
cases the product precipitated, which was filtered and washed with cold isopropanol
to remove traces of the aniline. For compounds bearing methoxy or hydroxy sub-
stituents on aniline there was no formation of precipitate. In such cases, the solvent
was removed under reduced pressure. Compounds were purified by recrystallization
from ethanol.
A synthesis scheme involving these 3 steps is given in Algorithm 5.1 and a list of
compounds synthesized is given in Table 5.1.
Scheme 5.1 Synthesis of 2-phenyl-4-anilinoquinazolines (98-115)
5.2.2 Synthesis of 2-(3,4-dimethoxyphenyl)-4-anilinoquinazolines
The second modification of the quinazolines was the replacement of the 2-phenyl ring
by a 2-(3,4-dimethoxyphenyl) substituent. These compounds were synthesized in
similar way as described above. The 2-(3,4-dimethoxyphenyl)quinazolin-4(3H )-one
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(84) was synthesized from anthranilamide and 3,4-dimethoxybenzaldehyde in presence
of iodine and potassium carbonate using DMF as solvent. This compound was further
converted to 4-Chloro-2-(3,4-dimethoxyphenyl)quinazoline (88) by chlorination using
POCl3. Finally compound 88 was reacted with substituted anilines in isopropanol
as solvent to get 2-(3,4-dimethoxyphenyl)-4-anilinoquinazolines (116-126). A list of
synthesized compounds is given in Table 5.2, while a reaction involved in synthesis
is shown in Algorithm 5.2
Scheme 5.2 Synthesis of 2-(3,4-dimethoxyphenyl)-4-anilinoquinazolines (116-126)
5.2.3 Synthesis of 4-anilinoquinazolines
In the third modification of the quinazoline scaffold a few derivatives bearing no
substitution at position 2, 6 and 7 were synthesized to check the importance of the
2-phenyl ring on the BCRP inhibitory activity. The synthesis route was almost
the same as described in section 5.2.1 with modification in the synthesis of the
quinazolinone. For the synthesis of quinazolin-4(3H )-one (85), method B described
in section 7.1.2.11 was used, where the reactant was used as solvent and no catalyst
was used. Compound 85 was synthesized by fusion of anthranilic acid and formamide.
The mixture of these two components was heated at 150 ºC for approximately 15
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hours. After completion of the reaction, water was added to the reaction mixture
and further stirred at room temperature for 30 minutes. The precipitate was filtered
and washed with plenty of water. The quinazolinone (85) obtained was further
converted to 4-chloroquinazoline (89) by refluxing with POCl3. This compound was
further used to synthesize the final 4-anilinoquinazolines (127-131) by reacting it
with substituted anilines. The reactions involved in synthesis of 4-anilinoquinazolines
are given in Algorithm 5.3. All the synthesized compounds are listed in Table 5.3.
Scheme 5.3 Synthesis of 4-anilinoquinazolines (127-131)
5.2.4 Synthesis of 6,7-dimethoxy-4-anilinoquinazolines
To check if there is any positive effect of substitution at position 6 and 7 of the quina-
zoline scaffold on BCRP inhibition, several 6,7-dimethoxy-4-anilinoquinazolines (132-
138) were synthesized. The synthesis was performed as described in section 5.2.3,
where 6,7-Dimethoxyquinazolin-4(3H )-one (86) was synthesized from 4,5-dimethoxy-
anthranilic acid (2-amino-4,5-dimethoxybenzoic acid) and formamide without using
any catalyst. Compound 86 was converted to 4-Chloro-6,7-dimethoxyquinazoline
(90) by reacting it with POCl3 at refluxing temperature. The 4-chloro deriva-
tive was reacted with substituted anilines in isopropanol to yield 6,7-dimethoxy-4-
anilinoquinazolines (132-138). The reactions involved in the synthesis are given in
Algorithm 5.4 and a list of compounds is given in Table 5.4.
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Scheme 5.4 Synthesis of 6,7-dimethoxy-4-anilinoquinazolines (132-138)
5.2.5 Synthesis of 4-N-piperazinylquinazolines
Several quinazoline derivatives bearing a N -phenyl-piperazine substituent at position
4 were synthesized to compare their activity with the anilinoquinazolines. For the
synthesis of 4-N -piperazinylquinazolines (139-145), 4-choloro-2-phenylquinazoline
(87) was reacted with several substituted N -phenylpiperazines (91-97) in presence
of potassium carbonate, using isopropanol as solvent. As the compounds did not
precipitate after completion of reaction, the solvent was removed under reduced
pressure. To the residue water was added, the precipitated product was filtered and
washed with water to remove traces of potassium carbonate.
The synthesis of N -phenylpiperazines used here is described in section 7.1.2.13.
These compounds were synthesized from bis(2-chloroethyl)amine hydrochloride and
substituted anilines using diethylene glycol monomethylether as solvent. It gave the
hydrochloride salt of the N -phenylpiperazine which was converted to the free N -
phenylpiperazine by treatment with sodium carbonate. Compounds were directly used
for synthesis of 4-N -piperazinylquinazolines (139-145) without further purification.
The general reactions involved in synthesis of 4-N -piperazinylquinazolines are given
in Algorithm 5.5. All synthesized compounds are listed in Table 5.5.
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Scheme 5.5 Synthesis of 4-N -piperazinylquinazolines (139-145)
5.2.6 Synthesis of 2,4-bis-anilinoquinazolines
The last series of quinazoline compounds contained anilino substituents at position
2 and 4 of the quinazoline scaffold. The anilino substitution at position 2 and 4
was kept the same. A general procedure for synthesis of 2,4-bisanilinoquinazolines
(146-150) is given in section 7.1.2.16. These compounds were synthesized from
2,4-dichloro-6,7-dimethoxyquinazoline (procured from Acros Organics, Belgium) by
reacting with two moles of substituted anilines in isopropanol as solvent. The reaction
mixture was refluxed until the reaction was complete, which resulted in precipitation
of the product. Precipitated product was filtered and washed with cold isopropanol
and ether. The dried product was recrystallized from ethanol. The general reactions
involved in synthesis of compounds 146-150 are given in Algorithm 5.6.
Scheme 5.6 Synthesis of 2,4-bis-anilinoquinazolines (146-150)
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5.3 Biological evaluation of quinazolines
All synthesized compounds were tested for BCRP inhibition in Hoechst 33342
(compounds 98-150) and pheophorbide A assays (compounds 116-150). Most
potent and promising BCRP inhibitor compounds were further checked for selectivity
by testing their ability to inhibit P-gp and MRP1 in the calcein AM assay. Intrinsic
cytotoxicity and efficacy of selected compounds were checked in MTT cytotoxicity
assay.
5.3.1 Hoechst 33342 and Pheophorbide A assays for
determining BCRP inhibition
Functioning and the procedure for performing the Hoechst 33342 accumulation assay
are given in section 3.3.1 and section 7.2.3.1, while the pheophorbide A assay is
discussed in section 4.5.1 and section 7.2.3.2. Both assays were performed using
MDCK BCRP cells and the results obtained are discussed below.
In the first series of quinazolines several 2-phenyl-4-anilinoquinazolines (98-115)
were synthesized. The IC50 values obtained for these compounds in the Hoechst
33342 are given Table 5.1. All compounds in this class of quinazolines were found to
be active. From Table 5.1 it is apparent that, from the anilinoquinazolines 98–115,
those bearing a meta-substituent on the aniline are more potent than ortho- or para-
substituted analogs (see compounds 100, 109, 112, 113 and 115). Compounds
bearing substituents at ortho position of aniline were the least active compounds
followed by para substituted compounds. Compound 109 was the most potent in the
set, with an IC50 of 0.13 µM , which is even lower than that of the standard Ko143
(0.25 µM , see Table 5.6). A comparison of the concentration-response curves for
these two compounds is shown in Figure 5.4. It was interesting to see that compound
115 bearing a more polar substitutent (OH) was also very active BCRP inhibitor
with an IC50 value of 0.15 µM .
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Table 5.1: Synthesized 2-phenyl-4-anilinoquinazolines and their inhibitory potencies
against MDCK BCRP cells in Hoechst 33342 accumulation assays.
2-Phenyl-4-anilinoquinazolines (98-115)
Compd R
Hoechst 33342
assay
IC50 ± SD (µM)*
98 H 2.57 ± 0.28
99 2-Br 3.75 ± 0.53
100 3-Br 0.57 ± 0.04
101 4-Br 6.83 ± 0.97
102 3-Cl 1.93 ± 0.28
103 3-Cl, 4-F 1.66 ± 0.11
104 2-OCH3 2.25 ± 0.07
105 3-OCH3 1.32 ± 0.10
106 4-OCH3 1.93 ± 0.11
107 3,4- OCH3 0.19 ± 0.01
108 2-NO2 5.93 ± 0.10
109 3-NO2 0.13 ± 0.03
110 4-NO2 0.97 ± 0.24
111 3-NO2, 4-F 2.46 ± 0.14
112 3-CN 0.14 ± 0.04
113 3-CF3 0.25 ± 0.10
114 4-CF3 1.53 ± 0.13
115 3-OH 0.15 ± 0.03
* Data are expressed as mean ± SD (n = 3).
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Figure 5.4: Representative concentration-response curves of compound 109 (closed
circles, IC50 = 0.13 ± 0.03 µM) and Ko143 (open circles, IC50 = 0.25 ± 0.04 µM)
obtained in the Hoechst 33342 assay. Each data point shown represents average of 3
independent experiments with error bars indicating standard deviation.
The second series of quinazolines consists of 2-(3,4-dimethoxyphenyl)-4-anilinoquinazolines
(116-126), where the influence of methoxy groups at the 2-phenyl ring was in-
vestigated. It can be seen from Table 5.2 that in most cases presence of 3,4-
dimethoxyphenyl substitution led to a slight increase in the activity, although it
was very marginal when compared to 2-phenyl-4-anilinoquinazolines. As in case of
compounds 98-115, similar effect of substituents present on the 4-anilino ring was
observed for compounds 116-126. Meta substituted compounds (see 117, 120, 122,
123 and 125) were highly active when compared to ortho (see 119 and 124) or para
(see 121 and 126) substituted compounds. In this series compound 120 was the
most potent compound with an IC50 value of 0.076 µM in Hoechst 33342 assay and
0.092 µM in the pheophorbide A assay. This compound was found to be the most
potent amongst all investigated quinazolines in the current work.
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Table 5.2: Synthesized 2-(3,4-dimethoxyphenyl)-4-anilinoquinazolines and their in-
hibitory potencies against MDCK BCRP cells in Hoechst 33342 and pheophorbide
A accumulation assays.
2-(3,4-Dimethoxyphenyl)-4-anilinoquinazolines (116-126)
Compd R
Hoechst 33342
assay
Pheophorbide A
assay
IC50 ± SD (µM)* IC50 ± SD (µM)*
116 H 1.99 ± 0.20 4.09 ± 1.60
117 3-Br 0.29 ± 0.03 0.40 ± 0.09
118 3,4-OCH3 0.42 ± 0.05 0.61 ± 0.04
119 2-NO2 0.64 ± 0.08 1.55 ± 0.29
120 3-NO2 0.076 ± 0.019 0.092 ± 0.024
121 4-NO2 0.30 ± 0.04 0.32 ± 0.09
122 3-CF3 0.30 ± 0.04 0.24 ± 0.05
123 3-CN 0.19 ± 0.01 0.30 ± 0.06
124 2-OH 0.26 ± 0.07 0.29 ± 0.03
125 3-OH 0.14 ± 0.03 0.11 ± 0.01
126 4-OH 0.47 ± 0.05 0.68 ± 0.12
* Data are expressed as mean ± SD (n = 3).
The next modification undertaken was to synthesize compounds without any sub-
stituents at position 2 of the quinazoline moiety. As it can be seen from Figure 5.2,
all published TKI quinazolines lack substituents at position 2. Hence two different
types of 4-anilino quinazolines were synthesized, first without any substitution at
positions 2, 6 and 7 of the quinazoline (compounds 127-131) and second bearing no
substitution at position 2, but methoxy substitution at position 6 and 7 (132-138).
The IC50 values obtained in Hoechst 33342 and pheophorbide A assays are give in
Table 5.3 (for compounds 127-131) and Table 5.4 (for compounds 132-138).
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It was clearly observed that removal of the phenyl substituent at position 2 of the
quinazoline led to a drastic decrease in the activity. In these two series of quinazolines,
mostly compounds bearing meta substituted anilines were chosen based on earlier
results. There was no substantial difference in the activities of the compounds with
or without 6,7-dimethoxy substituent. This suggests that, the presence of methoxy
substituents at position 6 and 7 of the quinazoline sccaffold was not important for
the BCRP inhibition. For comparison purposes the TKI quinazoline PD153035
(compound 132) was included in the current study and gave the same results as
reported by Pick et al. [117].
Table 5.3: Synthesized 4-anilinoquinazolines and their inhibitory potencies against
MDCK BCRP cells in Hoechst 33342 and Pheophorbide A accumulation assays.
4-Anilinoquinazolines (127-131)
Compd R
Hoechst 33342
assay
Pheophorbide A
assay
IC50 ± SD (µM)* IC50 ± SD (µM)*
127 3-Br 1.08 ± 0.25 1.48 ± 0.19
128 3-CN 1.18 ± 0.24 2.03 ± 0.55
129 3-NO2 1.13 ± 0.37 0.89 ± 0.14
130 3-CF3 0.94 ± 0.19 1.55 ± 0.33
131 3,4-OCH3 4.79 ± 0.87 3.38 ± 0.76
* Data are expressed as mean ± SD (n = 3).
The fifth modification consisted of a piperazine ring instead of an amine linker
at position 4 of the quinazoline. The IC50 values for 4-N -piperazinylquinazolines
(139-145) are given in Table 5.5. It was observed that, all compounds with N -
phenyl-piperazinyl substitution at position 4 showed highly reduced inhibitory activity
when compared to compounds 98-115 having the same 2-phenylquinazoline scaffold.
This reduction in activity might result from the change in the length and type of
the linker at position 4 of quinazoline scaffold, leading to differences in the spacial
arrangement of the substituted phenyl ring.
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Table 5.4: Synthesized 6,7-dimethoxy-4-anilinoquinazolines and their inhibitory poten-
cies against MDCK BCRP cells in Hoechst 33342 and pheophorbide A accumulation
assays.
6,7-Dimethoxy-4-anilinoquinazolines (132-138)
Compd R
Hoechst 33342
assay
Pheophorbide A
assay
IC50 ± SD (µM)* IC50 ± SD (µM)*
132 3-Br 1.73 ± 0.15 2.32 ± 0.70
133 3-CF3 2.40 ± 0.79 1.98 ± 0.42
134 3-CN 1.06 ± 0.12 0.93 ± 0.06
135 2-NO2 3.80 ± 0.53 3.97 ± 0.61
136 3-NO2 0.81 ± 0.06 0.91 ± 0.36
137 4-NO2 2.92 ± 0.39 2.46 ± 0.50
138 3,4-OCH3 7.38 ± 2.19 3.79 ± 0.27
* Data are expressed as mean ± SD (n = 3).
Table 5.5: Synthesized 4-N -piperazinylquinazolines and their inhibitory potencies
against MDCK BCRP cells in Hoechst 33342 and pheophorbide A accumulation
assays.
4-N -Piperazinylquinazolines (139-145)
Compd R
Hoechst 33342
assay
Pheophorbide A
assay
IC50 ± SD (µM)* IC50 ± SD (µM)*
139 H 8.92 ± 1.82 9.05 ± 1.32
140 3-Br 5.12 ± 0.57 4.98 ± 0.32
141 3-Cl 5.91 ± 1.73 4.87 0.56
142 3-Cl,4-F 8.22 ± 1.36 10.12 ± 1.58
143 3-OCH3 8.90 ± 2.35 9.23 ± 1.97
144 3-NO2 7.95 ± 0.35 6.99 ± 1.02
145 4-NO2 9.35 ± 2.79 8.05 ± 1.78
* Data are expressed as mean ± SD (n = 3).
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The last modification carried out included compounds bearing 2,4-bis-anilino sub-
stituents at the quinazoline scaffold. Compounds 146-150 bear the same substituent
at position 2 and 4 of the quinazoline. The IC50 values obtained for these compounds
in Hoechst 33342 and pheophorbide A assays are given in Table 5.6. The major
problem occurring while testing these compound was their poor aqueous solubility.
For testing these compounds, a slightly higher amount of methanol (not more than
5 % in highest concentration) was used. These compounds were also found to be
good inhibitors of BCRP with submicromolar IC50 values. As it can be seen from
Table 5.6, the compound with 3-nitro substiutent on the aniline (149) yielded lower
IC50 values over other substituents. Despite of good inhibitory activity of these
compounds, low solubility limits their further use.
Table 5.6: Synthesized N 2,N 4-disubsubstituted quinazolines and their inhibitory
potencies against MDCK BCRP cells in Hoechst 33342 and pheophorbide A accu-
mulation assays.
N 2,N 4-Disubsubstituted quinazoline (146-150)
Compd R
Hoechst 33342
assay
Pheophorbide A
assay
IC50 ± SD (µM)* IC50 ± SD (µM)*
146 3-Br 0.67 ± 0.10 0.86 ± 0.14
147 3-CF3 0.80 ± 0.02 0.61 ± 0.15
148 3-CN 0.48 ± 0.04 0.47 ± 0.03
149 3-NO2 0.33 ± 0.08 0.32 ± 0.06
150 3,4-OCH3 1.74 ± 0.26 1.52 ± 0.30
Ko143 - 0.25 ± 0.02 0.33 ± 0.05
* Data are expressed as mean ± SD (n = 3).
After comparing all the modifications it can be concluded that the presence of
2-phenyl substitution led to strong increase in BCRP inhibition. In all types of
quinazolines synthesized, compounds bearing meta substitution on the 4-anilino ring
of anilinoquinazoline were the most active. When the activity data of compounds
74
5.3 Biological evaluation of quinazolines
127-131 and 132-138 were compared, it was observed that, substitution at position
6 and 7 of the quinazoline scaffold did not lead to an increase in the activity. This
suggests that substitution at position 6 and 7 of the quinazoline is not needed
for BCRP inhibition, although substitution at position 2 is desirable. A summary
of structural features of the quinazoline scaffold for BCRP inhibition is given in
Figure 5.5
Figure 5.5: Structural features of quinazolines as BCRP inhibitors. ⊕ : showed good
activity, ⊕⊕ : showed very high activity, 	 : led to decrease in activity.
Compounds 116-150 were investigated in both Hoechst 33342 and Pheophorbide
A assays. The comparison of the pIC50 values obtained using these two different
substrates gave a good correlation with squared correlation coefficient (r2) of 0.94.
The scatterplot obtained by plotting pIC50 values in the Hoechst3342 assay against
the pheophorbide A assay is shown in Figure 5.6.
Figure 5.6: Scatterplot of pIC50 values for BCRP inhibition obtained in the Hoechst
33342 assay and the pheophorbide A assay. Each point indicates mean of IC50
values obtained in three independent experiments and error bars indicate standard
deviation. The squared correlation coefficient is r2 = 0.94, n = 36.
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5.3.2 P-gp and MRP1 inhibition by quinazolines
In the current study, all investigated compounds were found to be active against
BCRP. In order to check the selectivity of quinazolines towards BCRP inhibition,
selected most potent compounds from each class were investigated for P-gp and
MRP1 inhibition in the calcein AM assay. The principle of the calcein AM assay
is described in section 3.3.2 and section 7.2.3.3. Screening of selected compounds
(see Figure 5.7 for compound numbers) was done at a concentration of 10 µM , in
the calcein AM assay using A2780 adr (for P-gp) and 2008 MRP1 (for MRP1) cell
lines. Cyclosporine A (10 µM) was used as a standard for both P-gp and MRP1
inhibition. The data of the investigated compounds are expressed as % response
obtained in sensitive cells (positive control), while the response obtained in absence
of any compound was used as negative control.
A)
B)
Figure 5.7: Influence of quinazolines at 10 µM concentration on accumulation of
calcein AM in P-gp (A) and MRP1 (B) overexpressing cells. Cyclosporine A
(CsA, 10 µM) was used as a standard. Response in absence of any compound was
used as negative control. Data are expressed as response in percentage of control
(accumulation of calcein AM in non P-gp or MRP1 expressing sensitive cells) and
presented as the mean ± SD of three independent experiments.
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As seen from Figure 5.7 most of the compounds showed very low inhibitory activity
against P-gp and MRP1. Only compounds bearing a 3,4-dimethoxy substitution
on the anilino ring of anilinoquinazolines showed more than 50 % inhibition when
compared to control. Amongst the most potent BCRP inhibitors, compounds 109
and 115 showed no effect on both P-gp and MRP1, while compounds 120 and 125
showed little effect on P-gp and even less on MRP1. The effect of compounds 120
and 125 on P-gp could due to the presence of 3,4-dimethoxy substitution on the
2-phenyl ring of these quinazolines. Compounds showing response of more than 25
% of the control were further investigated to determine their IC50 values and these
are given in Table 5.7.
Table 5.7: Inhibitory potencies of selected quinazolines using A2780 adr and 2008
MRP1 cells in the calcein AM assay. Data are expressed as mean ± SD (n=3).
Cyclosporine A was used as standard.
Compd
A2780 adr
IC50 ± SD (µM)
2008 MRP1
IC50 ± SD (µM)
100 12.38 ± 1.72 n.a.*
107 5.85 ± 0.79 11.18 ± 0.58
117 11.76 ± 1.03 14.09 ± 1.65
118 3.49 ± 0.23 7.82 ± 0.62
120 9.56 ± 0.81 n.a.
125 18.21 ± 2.10 n.a.
Cyclosporine A 0.92 ± 0.12 2.70 ± 0.58
* n.a. = not active, showing a response of less than 25 % of
control in screening at 10 µM concentration (see Figure 5.7).
5.3.3 Intrinsic cytotoxicity of selected quinazolines
Quinazoline compounds have been shown to be inhibitors of tyrosine kinases [215–219].
Tyrosine kinases play an important role in a variety of normal cellular regulatory
processes and tyrosine kinase inhibitors are typically used as anticancer agents.
Quinazolines like gefitinib and erlotinib are the inhibitors of epidermal growth factor
receptor (EGFR) tyrosine kinase, and are marketed for the treatment of cancers with
mutated and overactive EGFR (especially for nonsmall cell lung cancer) [220].
Interestingly, from the literature survey it was found that, quinazolines reported as
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potent TKIs were lacking a 2-phenyl substitution and most of them posses substitution
at position 6 and 7 [218, 221–224]. These findings were more interesting, as the most
potent BCRP inhibitors found in the current study (109, 112, 115, 120 and 125)
lack substitution at position 6 and 7 and bear a phenyl ring at position 2 of the
quinazoline scaffold. Despite these findings, it was important to check the possible
intrinsic cytotoxicity of the synthesized compounds, as the aim of current study
was to find potent and nontoxic inhibitors of BCRP. The cytotoxicty of compounds
109, 115, 120 and 125 was checked in MTT cytotoxicity assay. MTT assay was
performed as described in section 3.3.3 and section 7.2.3.4. The toxicity studies of
these compounds were performed using MDCK BCRP and sensitive MDCK cells.
The concentration-response curves obtained are given in Figure 5.8.
109 115
120 125
Figure 5.8: Cytotoxicity of selected compounds was determined in the MTT assay
using MDCK BCRP and sensitive MDCK cells. Quinazolines 109, 115, 120 and
125 were investigated up to 100 µM concentration, for 72 h. Open circle: MDCK
BCRP cells, closed circle: MDCK sensitive cells and closed triangle: dilution solvent
(PBS) containing 2 % methanol in highest concentration.
From Figure 5.8 it can be seen that all four quinazolines tested showed a varying
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amount of cytotoxicity. Especially compound 125 bearing 3-hydroxy-anilino sub-
stition at position 4 of the 2-(3,4-dimethoxyphenyl)-4-anilinoquinazolines, showed
high intrinsic cytotoxicity which could ultimately limiting from further in vivo inves-
tigations. In order to check usability of these compounds, therapeutic ratios were
calculated from the IC50 values obtained in Hoechst assay and GI50 values from MTT
assay using the following formula,
Therapeutic ratio = GI50IC50
Table 5.8: Inhibitory activity and cytotoxicity of the most potent quinazolines
Compd IC50 in Hoechst
33342 assay
(µM)
GI50 in MTT
assay (µM)*
Therapeutic
ratio
109 0.13 67.8 521.5
115 0.15 51.11 340.7
120 0.076 20.8 273.7
125 0.14 4.61 32.9
* GI50 values obtained using MDCK BCRP cells in MTT cytotoxicity assay
From the Table 5.8, it is clear that 2-phenyl-4-anilinoquinazolines 109 and 115
are promising BCRP inhibitors owing to their high therapeutic ratio. Compound
125 has the lowest therapeutic ratio, which limits its further use. Increase in the
cytotoxicity of compounds 120 and 125 could be the result of extra 3,4-dimethoxy
substituents on 2-phenyl ring of anilinoquinazolines.
5.3.4 MDR reversal ability of quinazolines
In all the tests described above, it was revealed that compounds 109 and 115
(belonging to the first series 2-phenyl-4-anilinoquinazolines) were selective inhibitors
of BCRP with high therapeutic ratios. To determine the efficacy of these compounds
to reverse MDR in BCRP overexpressing cells, MTT assays were performed. Here
the ability of these two quinazolines (at 1 µM and 5 µM final concentrations) to
reverse resistance to Hoechst 33342 and SN-38 was investigated.
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Figure 5.9 shows the shift in the dose–response curves of SN-38 and Hoechst 33342
in MDCK BCRP cells in presence of compounds 109 and 115. This shift in dose-
response curves towards lower concentrations indicates sensitization of MDCK BCRP
cells to cytotoxicity of SN-38 and Hoechst 33342. Both compounds were able to
significantly reverse the resistance even at concentration as low as 1 µM and a
complete reversal of resistance was observed at 5 µM concentration.
Figure 5.9: Representative dose–response curves of SN-38 and Hoechst 33342 cyto-
toxicity. Left: effect of compound 109 on SN-38 cytotoxicity in BCRP cells. Right:
effect of compound 115 on cytotoxicity of Hoechst 33342. Both compounds were
investigated at 1 µM (open circles) and 5 µM (closed circles) concentrations. BCRP
cells without inhibitor (open triangles) showed less sensitivity towards SN-38 or
Hoechst 33342, than sensitive cells (closed squares).
In summary, a total of 53 quinazoline derivatives spanning six different modifications
were synthesized and investigated for BCRP, P-gp and MRP1 inhibition. Compounds
bearing a 2-phenyl substitutent in 4-anilinoquinazolines (98-126) were the most
active amongst all variations. It was revealed that a meta substituted anilino group
present at position 4 of the quinazoline nucleus resulted in increased activity. Nitro,
cyano and hydroxy substituted compounds were found to be the most potent BCRP
inhibitors. The 2-phenyl-4-anilinoquinazolines 109 and 115 were the most promising
selective BCRP inhibitors with high therapeutic ratio. The inhibitory effect of these
compounds was confirmed by testing their influence on the cytotoxicity of SN-38 and
Hoechst 33342 in BCRP overexpressing cells.
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The main aim of the current study was to synthesize a library of structurally different
classes of compounds to find new potent, selective and nontoxic BCRP inhibitors. In
this work a total of 131 compounds spanning three different structural classes viz.
chalcones, flavonoids and quinazolines were synthesized. Several biological studies
were carried out using these compounds to determine their BCRP inhibitory potential,
selectivity, toxicity and efficacy to reverse MDR to certain cytotoxic compounds.
In the first project a series of substituted chalcones, 3’,4’-benzochalcones and 5’,6’-
benzochalcones were synthesized by the Claisen-Schmidt condensation reaction
(see chapter 3). As depicted in Algorithm 6.1 the synthesis of various chalcones and
benzochalcones was carried out from the corresponding substituted acetophenone and
substituted benzaldehyde. Most of these compounds were synthesized in one step with
varying degree of difficulty of formation of product. A classical method of synthesis
of chalcones which involves stirring the reaction mixture at room temperature and
use of NaOH as base, was modified for the synthesis of benzochalcones. The classical
method was successfully replaced with ultrasonication and with the use of the strong
base LiOH, which resulted in shorter reaction times. These substances were evaluated
for their ability to inhibit BCRP in the Hoechst 33342 accumulation assay using MCF-
7 MX and MDCK BCRP cells. Most of the compounds bearing multi-substitutions
on ring A of the chalcone were found to be BCRP inhibitors. Chalcones were found
to be more potent than 5’,6’-benzochalcones followed by 3’,4’-benzochalcones. The
current study revealed the positive effect of methoxy groups on the inhibitory activity
of these compounds. All active compounds were found to be selective towards BCRP
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inhibition. Also, it was seen that most active compounds have very low cytotoxicity
and these compounds are able to reverse the resistance to mitoxantrone and SN-38
in BCRP overexpressing MDCK cells. In this study the lead chalcones 11 (IC50 =
0.85 µM) and 28 (IC50 = 0.53 µM) bearing methoxy substitution on ring B were
found to be both selective and potent inhibitors of BCRP.
Scheme 6.1 Synthesis of chalcones, benzochalcones , flavones and benzoflavones
The second project in this work involved synthesis and investigation of substituted
flavones, 7,8-benzoflavones and 5,6-benzoflavones (see chapter 4). To study the effect
of substitution at position 3 of flavonoid scaffold, 3-hydroxyflavones, 3-methoxy
flavones, benzoflavones, 3-hydroxybenzoflavones and 3-methoxybenzoflavones were
synthesized. The synthesis of these compounds was accomplished from the corre-
sponding chalcones (Algorithm 6.1). Selected chalcones and benzochalcones were
converted to 3-hydroxyflavones and 3-hydroxybenzoflavones which were subsequently
converted to 3-methoxyflavones and 3-methoxybenzoflavones. The naturally occurring
flavonoids quercetin and morin were converted to pentamethoxy and tetramethoxy
derivatives to study the effect of hydroxy and methoxy substitution at position 5
of the flavonoid scaffold. Benzochalcones were also converted to benzoflavones with
unsubstituted position 3. Out of all compounds 7,8-benzoflavones were found to be
the most active BCRP inhibitors in the Hoechst 33342 and pheophorbide A assays. In
contrast, 5,6-benzoflavones were the least active, which could be a result of blocking
the position 5 of the flavonoid scaffold. The substitution at position 5 in flavones was
shown to affect the activity, where hydroxy substitution was found to be better than
methoxy substitution (see Figure 6.1). The positive effect of methoxy substitution
and decremental effect of hydroxy substitution at position 3 of the flavonoid scaffold
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was seen in both flavone and benzoflavone classes of investigated flavonoids. Some
of the investigated compounds were found to inhibit P-gp and MRP1, although to
a lesser extent. Compound 51, a substituted 7,8-benzoflavone produced low IC50
values for all three transporters BCRP, P-gp and MRP1, suggesting its usability
as a good broad spectrum MDR modulator. Compound 74 (IC50 = 0.47 µM), a
7,8-benzoflavone bearing methoxy susbtitution at positions 3, 3’ and 4’ was found to
be the most potent and nontoxic flavonoid with 50 fold selectivity for BCRP. This
compound was shown to be able to reverse the resistance to Hoechst 33342 in BCRP
overexpressing cells.
Figure 6.1: Overview of activity of flavonoids as BCRP inhibitors
The last series of compounds investigated in search for potent BCRP inhibitors
consisted of quinazoline compounds (see chapter 5). Several substituted quinazolines
spanning 6 different modifications at position 2, 4, 6 and 7 of the quinazoline scaffold
were synthesized. Most of the synthesized compounds bear anilino substitution at
position 4 of the quinazoline nucleus. All the compounds were synthesized using
different synthesis routes as depicted in Algorithm 6.2. The first step was the synthesis
of substituted 4-quinazolinones which were further converted to 4-chloroquinazolines
using POCl3. Four different types of 4-chloroquinazolines were synthesized which
were later reacted with a variety of anilines or N -phenylpiperazines to obtain six
different classes of final quinazoline compounds.
From all types of compounds studied in this work, quinazolines were found to be the
most potent inhibitors of BCRP. From the biological studies it could be suggested that
6,7-methoxy groups in quinazoline are not essential for the activity, however presence
of a phenyl ring at position 2 is important. It was also found that meta substituted
anilinoquinazolines were the most potent BCRP inhibitors. From a study of published
and marketed tyrosine kinase inhibitors, it was found that they lack the 2-phenyl ring
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Scheme 6.2 Summary of synthetic routes used to prepare quinazolines 98-150.
All the reactions were carried out under heating or refluxing conditions, where
a: substituted aniline, b: isopropanol, c: substituted N -phenylpiperazine and d:
potassium carbonate.
and that substitution at position 6 and 7 was essential for tyrosine kinase inhibition,
which is in contrast to the structural requirements for BCRP inhibition. Although
tyrosine kinase inhibition studies on synthesized compounds was not performed, it
could be expected that these compounds will have lower inhibitory potential for
tyrosine kinase. In this study compounds 109 (IC50 = 0.13 µM), and 115 (IC50 =
0.15 µM), both belonging to the 2-phenyl-4-anilinoquinazoline series, were found to
be selective and highly potent inhibitors of BCRP with very high therapeutic ratios.
These compounds had much lower IC50 values than Ko143 (the most potent inhibitor
known until now, IC50 = 0.25 µM).
The results obtained from the study of chalcones, flavonoids and quinazolines as
BCRP inhibitors are promising for the ongoing research to find potent BCRP
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inhibitors. Especially, quinazoline lead compounds can be further investigated for
their cytotoxicity in different cell lines and for the effect on tyrosine kinase, which
could make in vivo studies possible.
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7.1 Chemistry
7.1.1 General materials and methods
Chemicals: All chemicals were procured from Acros Organics (Geel, Belgium),
Alfa Aesar (Karlsruhe, Germany), Sigma-Aldrich (Steinheim, Germany) or Merck
(Darmstadt, Germany).
Chromatography:
Thin layer chromatography: During the synthesis, reaction progress was moni-
tored using analytical thin layer chromatography (TLC) on silica gel plates (Silica Gel
60 F254 from Merck). TLC plates were coated with silica gel containing fluorescent
indicator, which on presence of compounds that absorb UV at 254 nm showed dark,
quenched spots on a bright background. For detection, a UV cabinet with short-wave
UV light source (254 nm) was used.
Column chromatography: For the purification of certain compounds column
chromatography was performed. For this purpose chromatography columns of
different size were selected depending on the yield of the compound. Silica gel 60
(40-63 µm) obtained from Merk, was used as stationary phase. For the preparation
of the column, a slurry of silica gel was prepared in the selected mobile phase and
was filled in a glass column with due care not to form any bubbles. After packing
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the stationary phase, a thin layer of sea sand was applied, which was helpful to
keep the stationary phase constant after loading a sample. Compound samples were
first dissolved in a small amount of mobile phase before loading on to the column.
Slight pressure was applied to column to increase the flow of mobile phase with aid
of a hand pump. Collected fractions were checked by TLC and pure fractions were
evaporated under reduced pressure to yield the solid compounds.
NMR-Spectroscopy and elemental analysis: Structures and purity of all com-
pounds were confirmed by NMR and elemental analysis. NMR spectra were recorded
in DMSO-d6 or CDCl3.
1H NMR spectra were obtained on a Bruker Advance 500
(500 MHz); 13C NMR, Bruker Advance 500 (126 MHz); chemical shifts are expressed
in δ values (ppm) using the solvent peak as an internal standard (DMSO-d6 2.49/39.7
ppm or CDCl3 7.26/77.0 ppm); multiplicity of resonance peaks is indicated as singlet
(s), doublet (d), triplet (t), quartet (q) and multiplet (m). The 13C signals were
assigned with the aid of distortion less enhancement by polarization transfer (DEPT)
and attached proton test (APT), the J values are in Hertz. Elemental analyses were
performed on a Vario EL of Elementar (Hanau, Germany). The values for carbon,
nitrogen and hydrogen are given in percentage. Found values were all within ± 0.4
% of the theoretical values except when indicated.
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7.1.2 General synthesis procedures
7.1.2.1 Synthesis of 2-hydroxy-4-methoxyacetophenone (1)
A mixture of 2,4-dihydroxyacetophenone (6 g, 39.5 mmol), dimethyl sulfate (4.1
ml, 43.4 mmol) and potassium carbonate (8.2 g, 59.2 mmol) in 100 ml acetone was
stirred at room temperature for 6 h. After completion of the reaction as indicated
by TLC, the solid was filtered off and the solvent was evaporated. The residue was
chromatographed over silica gel column using petroleum ether/ethylacetate (9:1) as
mobile phase to yield 2-hydroxy,4-methoxyacetophenone (5.2 g, 80 %) as white solid.
Molecular weight: 166.17 g/mol
1H NMR (DMSO-d6) δ: 12.62 (s, 1H), 7.82 (d, J = 8.9 Hz, 1H), 6.51 (dd, J = 8.9,
2.5 Hz, 1H), 6.33 (d, J = 2.5 Hz, 1H), 3.80 (s, 3H), 2.55 (s, 3H).
13C NMR (DMSO-d6) δ: 203.09, 165.79, 164.28, 133.33, 113.97, 107.24, 100.87, 55.78,
26.77.
7.1.2.2 Synthesis of 4,6-dimethoxy-2-hydroxyacetophenone (2)
To a refluxing mixture of 2,4,6-trihydroxyacetophenone-monohydrate (5 g, 26.8 mmol)
and potassium carbonate (7.5 g, 54.3 mmol) in 50 ml acetone, dimethyl sulfate was
added at 3 h intervals (3 x 1.75 ml, 20 mmol). The reaction was refluxed for 15 h
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until it was complete. The solid was filtered off and the solvent was evaporated to
yield 4,6-dimethoxy-2-hydroxyacetophenone (4.2 g, 80 %) as yellow solid.
Molecular weight: 196.20 g/mol
1H NMR (DMSO-d6) δ: 13.74 (s, 1H), 6.10 (d, J = 2.4 Hz, 1H), 6.06 (d, J = 2.4
Hz, 1H), 3.80 (s, 3H), 3.73 (s, 3H), 2.53 (s, 3H).
13C NMR (DMSO-d6) δ: 202.91, 166.28, 162.93, 162.02, 157.58, 93.81, 91.15, 56.17,
55.96, 28.81.
7.1.2.3 Synthesis of 2,4-dimethoxyacteophenone (3)
To a mixture of 2,4-dihydroxyacetophenone (6 g, 39.5 mmol) and potassium carbonate
(8.2 g, 59.2 mmol) in 100 ml acetone, methyl iodide (6.2 ml, 100 mmol) was added.
The resulting reaction mixture was refluxed for 24 h. After completion of the reaction
as indicated by TLC, the solid was filtered off and the solvent was evaporated
under reduced pressure. The resulting solid was recrystallized from ethanol to yield
2,4-dimethoxyacteophenone (5.95 g, 84 %) as yellow solid.
Molecular weight: 180.20 g/mol
1H NMR (DMSO-d6) δ: 7.80 (d, J = 7.6 Hz, 1H), 6.82 – 6.73 (m, 2H), 3.59 (d, J =
7.2 Hz, 6H), 2.35 (s, 3H).
13C NMR (DMSO-d6) δ: 202.91, 166.28, 162.93, 162.02, 157.58, 93.81, 91.15, 56.17,
55.96, 28.81.
7.1.2.4 General procedure for synthesis of chalcones
To a previously cooled mixture of 5 mmol of the selected acetophenone and 5 mmol
of a selected benzaldehyde in 25 ml ethanol, 20 % NaOH (5 ml) was added drop-wise
90
7.1 Chemistry
under vigorous stirring. The mixture was stirred at room temperature for 24–72
h. After completion of the reaction as indicated by TLC, the mixture was poured
onto crushed ice and acidified with dilute HCl. Precipitated product was filtered by
suction and washed to neutral. The solid was recrystallized from dilute ethanol to
yield the chalcone
(E)-3-(3,4-Dimethoxyphenyl)-1-phenylprop-2-en-1-one (4)
Synthesized from acetophenone and 3,4-dimethoxybenzaldehyde, yield 61 %.
Molecular weight: 268.31 g/mol
1H NMR (CDCl3) δ: 7.90 (d, J = 15.1 Hz, 1H), 7.80 (dd, J = 7.4, 1.4 Hz, 2H), 7.54
(dd, J = 13.6, 11.3 Hz, 2H), 7.46 (t, J = 7.4 Hz, 2H), 7.21–7.16 (m, 2H), 6.99 (d, J =
7.4 Hz, 1H), 3.82 (d, J = 21.9 Hz, 6H).
13C NMR (CDCl3) δ: 191.02, 150.98, 150.02, 144.78, 139.01, 133.69, 130.20, 129.13,
128.52, 123.94, 123.01, 112.69, 111.32, 55.94, 56.15.
Anal. Calcd for C17H16O3*0.2 H2O: C, 65.03; H, 9.30. Found: C, 65.21; H, 9.16.
(E)-3-(2-Chlorophenyl)-1-phenylprop-2-en-1-one (5)
Synthesized from acetophenone and 2-chlorobenzaldehyde, yield 64 %.
Molecular weight: 242,70 g/mol
91
Chapter 7 Experimental work
1H NMR (CDCl3) δ: d 7.97 (d, J = 14.9 Hz, 1H), 7.69 (dd, J = 7.3, 1.5 Hz, 2H),
7.52–7.49 (m, 1H), 7.48–7.39 (m, 4H), 7.37 (d, J = 14.8 Hz, 1H), 7.34–7.25 (m, 2H).
13C NMR (CDCl3) δ 191.56, 140.83, 138.01, 132.95, 132.04, 131.48, 130.91, 129.14,
128.18, 127.85, 128.15, 127.08, 125.72.
Anal. Calcd for C15H11ClO: C, 74.23; H, 4.57. Found: C, 74.08; H, 4.62.
(E)-1-(2-Hydroxyphenyl)-3-phenylprop-2-en-1-one (6)
Synthesized from 2-hydroxyacetophenone and benzaldehyde, yield 69 %.
Molecular weight: 224.25 g/mol
1H NMR (DMSO-d6) δ: 12.45 (s, 1H), 8.24 (dd, 1H), 8.02 (d, J = 15.6 Hz, 1H),
7.92–7.88 (m, 2H), 7.84 (d, J = 15.6 Hz, 1H), 7.56 (ddd, J = 8.4, 7.2, 1.7 Hz, 1H),
7.48–7.45 (m, 3H), 7.03– 6.98 (m, 2H).
13C NMR (DMSO-d6) δ: 193.75, 161.94, 144.87, 136.42, 134.58, 131.07, 131.00,
129.26, 129.08, 121.99, 120.93, 119.29, 117.85.
Anal. Calcd for C15H12O2: C, 80.34; H, 5.39. Found: C, 80.51; H, 5.28.
(E)-1-(2-Hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (7)
Synthesized from 2-hydroxyacetophenone and 4-methoxybenzaldehyde, yield 78 %.
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Molecular weight: 254.28 g/mol
1H NMR (CDCl3) δ: 12.92 (s, 1H), 7.92–7.88 (m, 2H), 7.61 (d, J = 8.7 Hz, 2H), 7.52
(d, J = 15.4 Hz, 1H), 7.47 (ddd, J = 8.6, 7.2, 1.6 Hz, 1H), 7.01 (dd, J = 8.4, 1.1 Hz,
1H), 6.94 (d, J = 8.8 Hz, 2H), 6.93–6.90 (m, 1H), 3.85 (s, 3H).
13C NMR (CDCl3) δ: 193.64, 163.52, 162.00, 145.32, 136.11, 130.52, 129.50, 127.33,
120.10, 118.72, 118.56, 117.58, 114.50, 55.43.
Anal. Calcd for C16H14O3: C, 75.57; H, 5.55. Found: C, 75.24; H, 5.72.
(E)-3-(3,4-Dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (8)
Synthesized from 2-hydroxyacetophenone and 3,4-dimethoxybenzaldehyde, yield 75
%.
Molecular weight: 284.31 g/mol
1H NMR (CDCl3) δ: 12.89 (s, 1H), 7.91 (dd, J = 8.1, 1.6 Hz, 1H), 7.87 (d, J = 15.4
Hz, 1H), 7.50–7.46 (m, 1H), 7.27–7.23 (m, 1H), 7.15 (d, J = 2.0 Hz, 1H), 7.02 (d, J =
1.1 Hz, 1H), 7.00 (d, J = 1.1 Hz, 1H), 6.95–6.88 (m, 2H), 3.94 (d, J = 12.6 Hz, 6H).
13C NMR (CDCl3) δ: 193.54, 163.51, 151.79, 149.29, 145.62, 136.13, 129.49, 127.57,
123.56, 120.06, 118.69, 118.58, 117.77, 111.14, 110.26, 56.00, 55.98.
Anal. Calcd for C17H16O4: C, 71.82; H, 5.67. Found: C, 71.79; H, 5.48.
(E)-1-(2,4-Dihydroxyphenyl)-3-phenylprop-2-en-1-one (9)
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Synthesized from 2,4-dihydroxyacetophenone and benzaldehyde, yield 64 %.
Molecular weight: 240.25 g/mol
1H NMR (DMSO-d6) δ: 13.35 (s, 1H), 8.19 (d, J = 9.0 Hz, 1H), 7.96 (d, J = 15.4 Hz,
1H), 7.85 (dd, J = 6.7, 3.2 Hz, 2H), 7.70 (d, J = 15.5 Hz, 1H), 7.46 (dd, J = 5.0, 1.9
Hz, 3H), 6.42 (dd, J = 8.9, 2.4 Hz, 1H), 6.30 (d, J = 2.4 Hz, 1H).
13C NMR (DMSO-d6) δ: 191.61, 165.93, 165.41, 143.75, 134.75, 133.28, 130.78,
129.36, 129.11, 129.03, 128.65, 121.46, 113.18, 108.41, 102.73.
Anal. Calcd for C15H12O3: C, 74.99; H, 5.03. Found: C, 75.06; H, 5.16.
(E)-1-(2,4-Dihydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (10)
Synthesized from 2,4-dihydroxyacetophenone and 4-methoxybenzaldehyde, yield 79
%.
Molecular weight: 270.28 g/mol
1H NMR (DMSO-d6) δ: 13.51 (s, 1H), 10.64 (s, 1H), 8.17 (d, J = 9.0 Hz, 1H), 7.85
(d, J = 8.8 Hz, 2H), 7.79 (d, J = 14.4 Hz, 1H), 7.12 (d, J = 8.7 Hz, 1H), 7.02 (d, J =
8.8 Hz, 2H), 6.41 (dd, J = 8.9, 2.4 Hz, 1H), 6.28 (d, J = 2.4 Hz, 1H), 3.82 (s, 3H).
13C NMR (DMSO-d6) δ: 191.66, 165.93, 165.17, 161.62, 143.86, 133.09, 131.97,
131.09, 127.43, 118.74, 114.66, 114.58, 113.17, 108.27, 102.73, 55.56.
Anal. Calcd for C16H14O4: C, 71.10; H, 5.22. Found: C, 71.50; H, 4.96.
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(E)-1-(2,4-Dihydroxyphenyl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one (11)
Synthesized from 2,4-dihydroxyacetophenone and 3,4-dimethoxybenzaldehyde, yield
72 %.
Molecular weight: 300.31 g/mol
1H NMR (DMSO-d6) δ: 13.55 (s, 1H), 8.20 (d, J = 9.0 Hz, 1H), 7.79 (dd, J = 40.4,
15.4 Hz, 2H), 7.54 (d, J = 2.0 Hz, 1H), 7.38 (dd, J = 8.4, 1.9 Hz, 1H), 7.02 (d, J =
8.4 Hz, 1H), 6.42 (dd, J = 8.9, 2.4 Hz, 1H), 6.28 (d, J = 2.4 Hz, 1H), 3.84 (d, J =
22.4 Hz, 6H).
13C NMR (DMSO-d6) δ: 191.68, 165.97, 165.18, 151.59, 149.22, 144.41, 133.12,
127.59, 124.40, 118.73, 113.15, 111.74, 111.02, 108.22, 102.74, 55.93, 55.77.
Anal. Calcd for C17H16O5: C, 67.99; H, 5.37. Found: C, 67.73; H, 5.51.
(E)-1-(2,4-Dihydroxyphenyl)-3-(3-methoxyphenyl)prop-2-en-1-one (12)
Synthesized from 2,4-dihydroxyacetophenone and 3-methoxybenzaldehyde, yield 67
%.
Molecular weight: 270.28 g/mol
1H NMR (DMSO-d6) δ: 13.11 (s, 1H), 8.08 (d, J = 8.2 Hz, 1H), 7.84 (d, J = 15.3
Hz, 1H), 7.61 (d, J = 15.3 Hz, 1H,), 7.54–6.58 (m, 6H), 3.89 (s, 3H).
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13C NMR (DMSO-d6) δ: 191.66, 165.93, 165.17, 161.62, 143.86, 133.09, 131.97,
131.09, 127.43, 118.74, 114.66, 114.58, 113.17, 108.27, 102.73, 55.56.
Anal. Calcd for C16H14O4: C, 71.10; H, 5.22. Found: C, 70.89; H, 5.37.
(E)-3-(2-Chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (13)
Synthesized from 2,4-dihydroxyacetophenone and 2-chlorobenzaldehyde, yield 81%.
Molecular weight: 274.70 g/mol
1H NMR (DMSO-d6) δ: 13.17 (s, 1H), 10.79 (s, 1H), 8.21 (dd, J = 7.3, 2.2 Hz, 1H),
8.18 (d, J = 9.0 Hz, 1H), 8.09 (d, J = 15.5 Hz, 1H), 8.01 (d, J = 15.5 Hz, 1H), 7.56
(dd, J = 7.7, 1.6 Hz, 1H), 7.46 (ddd, J = 6.2, 4.4, 1.2 Hz, 2H), 6.43 (dd, J = 8.9, 2.4
Hz, 1H), 6.31 (d, J= 2.4 Hz, 1H).
13C NMR (DMSO-d6) δ: 191.15, 165.99, 165.70, 138.16, 134.53, 133.49, 132.41,
132.18, 130.21, 128.88, 127.84, 124.40, 113.24, 108.61, 102.80.
Anal. Calcd for C15H11ClO3: C, 65.58; H, 4.04. Found: C, 65.39; H, 4.19.
(E)-3-(4-Chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (14)
Synthesized from 2,4-dihydroxyacetophenone and 4-chlorobenzaldehyde, yield 84 %.
Molecular weight: 274.70 g/mol
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1H NMR (DMSO-d6) δ: 12.58 (s, 1H), 10.58 (s, 1H), 7.95–7.90 (m, 2H), 7.73 (dd,
J = 8.9, 5.2 Hz, 1H), 7.55 (d, J = 8.7 Hz, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.39–7.29 (m,
2H), 6.36 (dd, J = 8.8, 2.4 Hz, 1H), 6.23 (d, J = 2.3 Hz, 1H).
13CNMR (DMSO-d6) δ: 202.78, 165.00, 164.33, 142.26, 137.90, 133.80, 131.25, 129.81,
128.85, 122.28, 113.01, 108.23, 102.43.
Anal. Calcd for C15H11ClO3: C, 65.58; H, 4.0. Found: C, 65.52; H, 4.21.
(E)-1-(2-Hydroxy-4-methoxyphenyl)-3-phenylprop-2-en-1-one (15)
Synthesized from 2-hydroxy-4-methoxyacetophenone and benzaldehyde, yield 62 %.
Molecular weight: 254.28 g/mol
1H NMR (DMSO-d6) δ: 13.49 (s, 1H), 7.95 (d, J = 15.1 Hz, 1H), 7.63 (d, J = 1.7 Hz,
1H), 7.61 (d, J = 9.3 Hz, 1H), 7.56–7.53 (m, 2H), 7.43–7.35 (m, 3H), 6.65 (dd, J =
7.6, 1.4 Hz, 1H), 6.61 (d, J = 1.6 Hz, 1H), 3.87 (s, 3H).
13C NMR (DMSO-d6) δ: 192.78, 165.22, 164.48, 144.23, 135.03, 130.98, 129.17,
128.88, 129.87, 128.07, 128.07, 122.22, 114.91, 106.23, 101.47, 56.04.
Anal. Calcd for C16H14O3: C, 75.57; H, 5.55. Found: C, 75.62; H, 5.39.
(E)-1-(2-Hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
(16)
97
Chapter 7 Experimental work
Synthesized from 2-hydroxy-4-methoxyacetophenone and 4-methoxybenzaldehyde,
yield 71 %.
Molecular weight: 284.31 g/mol
1H NMR (DMSO-d6) δ: 13.56 (s, 1H), 8.26 (d, J = 9.1 Hz, 1H), 7.87 (d, J = 8.8 Hz,
2H), 7.85 (s, 1H), 7.81 (s, 1H), 7.02 (d, J = 8.8 Hz, 2H), 6.55 (dd, J = 9.0, 2.5 Hz,
1H), 6.50 (d, J = 2.5 Hz, 1H), 3.83 (d, J = 8.1 Hz, 6H).
13C NMR (DMSO-d6) δ: 192.04, 165.99, 165.85, 161.72, 144.38, 132.67, 131.22,
127.36, 118.65, 114.59, 114.01, 107.43, 101.08, 55.87, 55.55.
Anal. Calcd for C17H16O4 * 0.2 H2O: C, 71.20; H, 5.91. Found: C, 71.14; H, 5.69.
(E)-3-(3,4-Dimethoxyphenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-
one (17)
Synthesized from 2-hydroxy-4-methoxyacetophenone and 3,4-dimethoxybenzaldehyde,
yield 89 %.
Molecular weight: 314.33 g/mol
1H NMR (DMSO-d6) δ: 13.61 (s, 1H), 8.28 (d, J = 9.1 Hz, 1H), 7.87 (d, J = 15.3 Hz,
1H), 7.79 (d, J = 15.3 Hz, 1H), 7.56 (d, J = 2.0 Hz, 1H), 7.41 (dd, J = 8.4, 1.9 Hz,
1H), 7.03 (d, J = 8.4 Hz, 1H), 6.56 (dd, J = 9.0, 2.5 Hz, 1H), 6.51 (d, J = 2.5 Hz,
1H), 3.87–3.81 (m, 9H).
13C NMR (DMSO-d6) δ: 192.07, 166.00, 165.94, 151.72, 149.23, 144.93, 132.69,
127.54, 124.55, 118.66, 113.98, 111.75, 111.14, 107.46, 101.04, 55.95, 55.88, 55.78.
Anal. Calcd for C18H18O5 * 0.25 H2O: C, 67.81; H, 5.81. Found: C, 67.71; H, 5.77.
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(E)-1-(2-Hydroxy-4-methoxyphenyl)-3-(3-methoxyphenyl)prop-2-en-1-one
(18)
Synthesized from 2-hydroxy-4-methoxyacetophenone and 3-methoxybenzaldehyde,
yield 68 %.
Molecular weight: 284.31 g/mol
1H NMR (DMSO-d6) δ: 13.40 (s, 1H), 8.29 (d, J = 9.1 Hz, 1H), 8.00 (d, J = 15.5 Hz,
1H), 7.79 (d, J = 15.5 Hz, 1H), 7.51–7.48 (m, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.37 (t,
J = 7.9 Hz, 1H), 7.03 (ddd, J = 8.2, 2.6, 0.9 Hz, 1H), 6.56 (dd, J = 9.0, 2.5 Hz, 1H),
6.51 (d, J = 2.5 Hz, 1H), 3.84 (d, J = 8.2 Hz, 6H).
13C NMR (DMSO-d6) δ: 192.04, 166.19, 165.88, 159.80, 144.24, 136.06, 132.90,
130.05, 122.06, 121.64, 117.01, 114.01, 113.67, 107.55, 101.06, 55.89, 55.45.
Anal. Calcd for C17H16O4: C, 71.82; H, 5.67. Found: C, 71.66; H, 5.486.
(E)-3-(2-Chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one (19)
Synthesized from 2-hydroxy-4-methoxyacetophenone and 2-chlorobenzaldehyde, yield
74 %.
Molecular weight: 288.73 g/mol
1H NMR (DMSO-d6) δ: 13.19 (s, 1H), 8.26 (d, J = 9.1 Hz, 1H), 8.22 (dd, J = 7.4, 2.1
Hz, 1H), 8.11 (d, J = 15.5 Hz, 1H), 8.04 (d, J = 15.4 Hz, 1H), 7.57 (dd, J = 7.7, 1.6
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Hz, 1H), 7.47 (ddd, J = 14.5, 7.1, 1.8 Hz, 2H), 6.57 (dd, J = 9.0, 2.5 Hz, 1H), 6.52 (d,
J = 2.5 Hz, 1H), 3.85 (s, 3H).
13C NMR (DMSO-d6) δ: 191.55, 166.38, 165.83, 138.54, 134.58, 133.01, 132.30,
132.26, 130.18, 128.92, 127.82, 124.31, 114.08, 107.72, 101.13, 55.96.
Anal. Calcd for C16H13ClO3 / 0.2 H2O: C, 65.74; H, 4.62. Found: C, 65.71; H, 4.39.
(E)-3-(4-Chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one (20)
Synthesized from 2-hydroxy-4-methoxyacetophenone and 4-chlorobenzaldehyde, yield
79 %.
Molecular weight: 288.73 g/mol
1H NMR (DMSO-d6) δ: 13.34 (s, 1H), 8.27 (d, J = 9.1 Hz, 1H), 8.02 (d, J = 15.5 Hz,
1H), 7.94 (d, J = 8.4 Hz, 2H), 7.79 (d, J = 15.5 Hz, 1H), 7.52 (d, J = 8.5 Hz, 2H),
6.56 (dd, J = 9.0, 2.5 Hz, 1H), 6.51 (d, J = 2.5 Hz, 1H), 3.84 (s, 3H).
13C NMR (DMSO-d6) δ: 191.87, 166.24, 165.85, 142.72, 135.40, 133.66, 132.90,
130.88, 129.07, 122.19, 114.01, 107.59, 101.08, 55.91.
Anal. Calcd for C16H13ClO3: C, 66.56; H, 4.54. Found: C, 66.31; H, 4.54.
(E)-3-(3,4-Dichlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
(21)
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Synthesized from 2-hydroxy-4-methoxyacetophenone and 3,4-dichlorobenzaldehyde,
yield 67 %.
Molecular weight: 323.17 g/mol
1H NMR (DMSO-d6) δ: 13.29 (s, 1H), 8.31–8.28 (m, 2H), 8.09 (d, J = 15.5 Hz, 1H),
7.87 (dd, J = 8.4, 2.0 Hz, 1H), 7.76 (d, J = 15.5 Hz, 1H), 7.71 (d, J = 8.3 Hz, 1H),
6.57 (dd, J = 9.0, 2.5 Hz, 1H), 6.51 (d, J = 2.5 Hz, 1H), 3.85 (s, 3H).
13C NMR (DMSO-d6) δ: 191.75, 166.39, 165.96, 141.37, 135.58, 133.05, 133.02,
131.99, 131.13, 130.40, 129.48, 123.59, 114.03, 107.66, 101.08, 55.96.
Anal. Calcd for C16H12Cl2O3: C, 59.46; H, 3.74. Found: C, 59.41; H, 3.79.
(E)-1-(2,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (22)
Synthesized from 2,4-dimethoxyacetophenone and 4-methoxybenzaldehyde, yield 85
%.
Molecular weight: 298.33 g/mol
1H NMR (DMSO-d6) δ: 7.68–7.64 (m, 2H), 7.58 (d, J = 8.6 Hz, 1H), 7.50 (d, J =
15.8 Hz, 1H), 7.39 (dd, J = 15.8, 0.7 Hz, 1H), 7.01–6.96 (m, 2H), 6.67 (d, J = 2.2 Hz,
1H), 6.65–6.61 (m, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.79 (d, J = 3.7 Hz, 3H).
13C NMR (DMSO-d6) δ: 189.51, 163.84, 161.15, 160.16, 141.45, 131.97, 130.23,
127.58, 124.92, 121.82, 114.59, 106.03, 98.80, 56.05, 55.69, 55.44.
Anal. Calcd for C18H18O4: C, 72.47; H, 6.08. Found: C, 72.58; H, 5.95.
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(E)-1-(2,4-Dimethoxyphenyl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one (23)
Synthesized from 2,4-dimethoxyacetophenone and 3,4-dimethoxybenzaldehyde, yield
76 %.
Molecular weight: 328.36 g/mol
1H NMR (DMSO-d6) δ: 7.56 (d, J = 8.5 Hz, 1H), 7.47 (d, J = 15.8 Hz, 1H), 7.39
(d, J = 15.7 Hz, 1H), 7.30 (d, J = 1.9 Hz, 1H), 7.26 (dd, J = 8.3, 2.0 Hz, 1H), 6.99
(d, J = 8.3 Hz, 1H), 6.68 (d, J = 2.2 Hz, 1H), 6.63 (dd, J = 8.6, 2.2 Hz, 1H), 3.88 (s,
3H), 3.84 (s, 3H), 3.80 (d, J = 7.4 Hz, 6H).
13C NMR (DMSO-d6) δ: 189.79, 163.74, 160.08, 151.03, 149.12, 142.03, 131.85,
127.81, 125.21, 122.70, 121.93, 111.91, 110.95, 105.99, 98.85, 56.03, 55.73, 55.70,55.70.
Anal. Calcd for C19H20O5: C, 69.50; H, 6.14. Found: C, 69.29; H, 6.01.
(E)-3-(2-Chlorophenyl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one (24)
Synthesized from 2,4-dimethoxyacetophenone and 2-chlorobenzaldehyde, yield 69 %.
Molecular weight: 302.75 g/mol
1H NMR (DMSO-d6) δ: 7.92 (dd, J = 7.2, 2.3 Hz, 1H), 7.82 (d, J = 15.8 Hz, 1H),
7.64 (d, J = 8.6 Hz, 1H), 7.59 (d, J = 15.8 Hz, 1H), 7.56–7.53 (m, 1H), 7.43 (ddd,
J = 6.7, 5.7, 1.8 Hz, 2H), 6.69 (d, J = 2.3 Hz, 1H), 6.65 (dd, J = 8.6, 2.3 Hz, 1H),
3.90 (s, 3H), 3.85 (s, 3H).
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13C NMR (DMSO-d6) δ: 189.06, 164.39, 160.57, 135.96, 134.07, 132.74, 132.30,
131.61, 130.13, 129.92, 128.23, 127.93, 121.14, 106.31, 98.75, 56.13, 55.76.
Anal. Calcd for C17H15ClO3: C, 67.44; H, 4.99. Found: C, 67.73; H, 5.183.
(E)-3-(4-Chlorophenyl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one (25)
Synthesized from 2,4-dimethoxyacetophenone and 4-chlorobenzaldehyde, yield 72 %.
Molecular weight: 302.75 g/mol
1H NMR (DMSO-d6) δ: 7.95 (dd, J = 7.1, 2.3 Hz, 1H), 7.79 (d, J = 15.6 Hz, 1H),
7.69 (d, J = 8.4 Hz, 1H), (d, J = 7.4 Hz, 2H), 7.43 (dd, J = 11.2, 7.7 Hz, 3H), 6.69 (d,
J = 2.3 Hz, 1H), 6.65 (dd, J = 8.6, 2.3 Hz, 1H), 3.91 (s, 3H), 3.89 (s, 3H).
13C NMR (DMSO-d6) δ: 189.08, 164.42, 161.22, 135.76, 133.99, 132.84, 132.26,
131.57, 130.78, 130.03, 128.74, 128.02, 121.12, 106.45, 98.64, 56.23, 55.68.
Anal. Calcd for C17H15ClO3: C, 67.44; H, 4.99. Found: C, 67.25; H, 5.02.
(E)-3-(3,4-Dichlorophenyl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one (26)
Synthesized from 2,4-dimethoxyacetophenone and 3,4-dichlorobenzaldehyde, yield 67
%.
Molecular weight: 337.20 g/mol
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1H NMR (DMSO-d6) δ: 8.01 (d, J = 2.0 Hz, 1H), 7.73 (dd, J = 8.4, 2.0 Hz, 1H), 7.67
(d, J = 8.4 Hz, 1H), 7.63–7.57 (m, 2H), 7.49 (d, J = 15.9 Hz, 1H), 6.68 (d, J = 2.3
Hz, 1H), 6.64 (dd, J = 8.6, 2.3 Hz, 1H), 3.89 (s, 3H), 3.85 (s,3H).
13C NMR (DMSO-d6) δ: 189.23, 164.32, 160.56, 138.40, 136.02, 132.40, 132.24,
131.90, 131.17, 130.32, 129.27, 128.14, 121.33, 106.22, 98.80, 56.17, 55.78.
Anal. Calcd for C17H14Cl2O3: C, 60.55; H, 4.18. Found: C, 60.72; H, 4.23.
(E)-1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-
one (27)
Synthesized from 2-hydroxy-4,6-dimethoxyacetophenone and 4-methoxybenzaldehyde,
yield 55 %.
Molecular weight: 314.33 g/mol
1H NMR (DMSO-d6) δ: 13.75 (s, 1H), 7.60 (d, J = 8.7 Hz, 2H), 7.14 (d, J = 16.1 Hz,
1H), 6.94 (d, J = 8.8 Hz, 2H), 6.80 (d, J = 16.1 Hz, 1H), 6.31–6.27 (m, 2H), 3.78 (s,
3H), 3.70 (s, 6H).
13C NMR (DMSO-d6) δ: 193.33, 161.93, 161.32, 158.12, 143.76, 130.40, 127.55,
127.06, 127.02, 125.04, 114.58, 111.45, 93.81, 91.26, 90.97, 55.93, 55.57, 55.46.
Anal. Calcd for C18H18O5*0.5 H2O: C, 67.64; H, 6.27. Found: C, 67.47; H, 6.00.
(E)-3-(3,4-Dimethoxyphenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-
1-one (28)
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Synthesized from 2-hydroxy-4,6-dimethoxyacetophenone and 3,4-dimethoxybenzaldehyde,
yield 71 %.
Molecula weight: 344.36 g/mol
1H NMR (DMSO-d6) δ: 13.40 (s, 1H), 7.62 (d, J = 7.4 Hz, 2H), 7.29 (s, 2H), 7.01 (d,
J = 8.7 Hz, 1H), 6.14 (d, J = 2.3 Hz, 1H), 6.11 (d, J = 2.3 Hz, 1H), 3.88 (s, 3H), 3.82
(s, 3H), 3.81 (d, J = 2.1 Hz, 6H).
13C NMR (DMSO-d6) δ: 192.41, 165.39, 165.36, 161.88, 151.28, 149.15, 143.13,
127.77, 125.38, 122.92, 111.97, 111.02, 106.63, 94.06, 91.18, 56.27, 56.17, 55.76, 55.67.
Anal. Calcd for C19H20O6 *0.33 H2O: C, 65.13; H, 5.95. Found: C, 65.00; H, 6.12.
(E)-3-(2-Chlorophenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one
(29)
Synthesized from 2-hydroxy-4,6-dimethoxyacetophenone and 2-chlorobenzaldehyde,
yield 68 %.
Molecular weight: 318.75 g/mol
1H NMR (DMSO-d6) δ: 13.22 (s, 1H), 7.92–7.88 (m, 2H), 7.77 (d, J = 15.7 Hz, 1H),
7.57–7.54 (m, 1H), 7.46–7.42 (m, 2H), 6.15 (d, J = 2.3 Hz, 1H), 6.13 (d, J = 2.3 Hz,
1H), 3.88 (s, 3H), 3.82 (s, 3H).
13C NMR (DMSO-d6) δ: 192.04, 165.94, 165.61, 162.08, 136.79, 134.10, 132.65,
131.79, 130.47, 130.20, 128.36, 128.01, 106.51, 94.06, 91.26, 56.38, 55.83.
Anal. Calcd for C17H15ClO4: C, 64.06; H, 4.74. Found: C, 63.69; H, 4.80.
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(E)-1-(3,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (30)
Synthesized from 3,4-dimethoxyacetophenone and 4-methoxybenzaldehyde, yield 81
%.
Molecular weight: 298.33 g/mol
1H NMR (DMSO-d6) δ: 7.87 (dd, J = 8.4, 1.9 Hz, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.79
(d, J = 15.5 Hz, 1H), 7.67 (d, J = 15.5 Hz, 1H), 7.59 (d, J = 1.9 Hz, 1H), 7.09 (d, J =
8.4 Hz, 1H), 7.01 (d, J = 8.7 Hz, 2H), 3.86 (d, J = 5.6 Hz, 6H), 3.81 (s, 3H).
13C NMR (DMSO-d6) δ: 187.41, 161.34, 153.22, 148.93, 143.15, 130.91, 130.78,
127.62, 123.27, 119.64, 114.51, 111.06, 110.97, 55.91, 55.76, 55.50.
Anal. Calcd for C18H18O4: C, 72.47; H, 6.08. Found: C, 72.12; H, 6.20.
(E)-1,3-Bis(3,4-dimethoxyphenyl)prop-2-en-1-one (31)
Synthesized from 3,4-dimethoxyacetophenone and 3,4-dimethoxybenzaldehyde, yield
81 %.
Molecular weight: 328.36 g/mol
1H NMR (DMSO-d6) δ: 7.80 (d, J = 15.5 Hz, 1H), 7.66–7.63 (m, 1H), 7.51 (d, J =
2.0 Hz, 1H), 7.41 (d, J = 2.0 Hz, 1H), 7.09 (d, J = 8.5 Hz, 1H), 7.04 (d, J = 2.3 Hz,
1H), 7.02 (d, J = 3.5 Hz, 1H), 6.76 (d, J = 1.0 Hz, 1H), 3.86–3.80 (m, 12H).
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13C NMR (DMSO-d6) δ: 197.32, 153.17, 153.09, 149.10, 148.61, 143.59, 130.88,
129.90, 123.59, 123.33, 122.74, 119.73, 111.72, 110.93, 110.43, 55.86, 55.81, 55.57,
55.54.
Anal. Calcd for C19H20O5: C, 69.50; H, 6.14. Found: C, 69.34; H, 6.23.
(E)-3-(2-Chlorophenyl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (32)
Synthesized from 3,4-dimethoxyacetophenone and 2-chlorobenzaldehyde, yield 73 %.
Molecular weight: 302.75 g/mol
1H NMR (DMSO-d6) δ: 7.99 (d, J = 4.4 Hz, 1H), 7.65 (dd, J = 8.5, 2.0 Hz, 1H), 7.52
(dd, J = 7.8, 1.7 Hz, 1H), 7.42 (d, J = 2.0 Hz, 1H), 7.36 (dd, J = 7.9, 1.3 Hz, 1H),
7.25–7.22 (m, 1H), 7.18–7.14 (m, 1H), 7.04 (d, J = 8.5 Hz, 2H), 3.83 (s, 3H), 3.79 (s,
3H).
13C NMR (DMSO-d6) δ: 196.75, 153.22, 148.65, 141.75, 137.78, 133.08, 129.66,
129.41, 128.37, 127.75, 127.29, 124.94, 122.77, 110.98, 110.47, 55.85, 55.61.
Anal. Calcd for C17H15ClO3*0.25 H2O: C, 66.45; H, 5.08. Found: C, 66.67; H, 5.293.
(E)-3-(4-Chlorophenyl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (33)
Synthesized from 3,4-dimethoxyacetophenone and 4-chlorobenzaldehyde, yield 77 %.
Molecular weight: 302.75 g/mol
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1H NMR (DMSO-d6) δ: 7.95 (d, J = 15.6 Hz, 1H), 7.92 (s, 1H), 7.90 (dd, J = 8.5,
2.0 Hz, 2H), 7.68 (d, J = 15.6 Hz, 1H), 7.60 (d, J = 2.0 Hz, 1H), 7.51 (d, J = 8.6 Hz,
2H), 7.10 (d, J = 8.5 Hz, 1H), 3.86 (d, J = 7.8 Hz, 6H).
13C NMR (DMSO-d6) δ: 187.38, 153.50, 148.99, 141.70, 134.99, 133.96, 130.63,
130.63, 130.55, 129.03, 129.03 123.62, 122.90, 111.08, 110.99, 55.95, 55.78.
Anal. Calcd for C17H15ClO3: C, 67.44; H, 4.99. Found: C, 67.19; H, 5.01.
7.1.2.5 General procedure for synthesis of benzochalcones
To a mixture of 5 mmol of a selected acetophenone and 5 mmol of a selected
benzaldehyde in a 50 ml round bottom flask, 20 ml methanol and 35 mmol of LiOH
was added. The reaction mixture was kept in an ultrasonic bath for 1 to 5 hours,
until reaction completion was indicated by TLC. After completion of the reaction
the mixture was poured onto crushed ice and acidified with dilute HCl. Precipitated
product was filtered by suction and washed to neutral. The solid was recrystallized
from dilute ethanol to yield the corresponding benzochalcone
(E)-1-(1-Hydroxynaphthalen-2-yl)-3-phenylprop-2-en-1-one (34)
Synthesized from 2-acetyl-1-hydroxynaphthalene and benzaldehyde, yield 88 %.
Molecular weight: 274.31 g/mol
1H NMR (DMSO-d6) δ: 15.00 (s, 1H), 8.37 (dd, J = 8.3, 0.7 Hz, 1H), 8.30 (d, J =
9.0 Hz, 1H), 8.18 (d, J = 15.5 Hz, 1H), 7.97 (dd, J = 6.2, 3.4 Hz, 2H), 7.93 (d, J =
8.3 Hz, 1H), 7.73 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.60 (ddd, J = 8.2, 6.9, 1.1 Hz, 1H),
7.51–7.48 (m, 3H), 7.46 (d, J = 8.9 Hz, 1H).
13C NMR (DMSO-d6) δ: 193.72, 163.37, 145.42, 137.22, 134.59, 131.19, 130.60,
129.45, 129.08, 127.74, 126.30, 125.17, 124.58, 123.78, 121.18, 118.38, 113.47.
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Anal. Calcd for C19H14O2: C, 83.19; H, 5.14. Found: C, 82.87; H, 5.26.
(E)-1-(1-Hydroxynaphthalen-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (35)
Synthesized from 2-acetyl-1-hydroxynaphthalene and 4-methoxybenzaldehyde, yield
84 %.
Molecular weight: 304.34 g/mol
1H NMR (DMSO-d6) δ: 15.18 (s, 1H), 8.36 (d, J = 8.2 Hz, 1H), 8.29 (d, J = 9.0 Hz,
1H), 8.04 (d, J = 15.4 Hz, 1H), 7.94 (d, J = 9.2 Hz, 3H), 7.92 (d, J = 3.9 Hz, 1H),
7.72 (ddd, J = 8.1, 6.9, 1.3 Hz, 1H), 7.59 (ddd, J = 8.2, 5.0, 1.1 Hz, 1H), 7.45 (d, J =
8.9 Hz, 1H), 7.05 (d, J = 8.8 Hz, 2H), 3.84 (s, 3H).
13C NMR (DMSO-d6) δ: 193.59, 163.26, 161.97, 145.58, 137.11, 131.53, 130.45,
127.71, 127.29, 126.22, 125.13, 123.73, 118.42, 118.25, 114.63, 113.47, 55.57.
Anal. Calcd for C20H16O3*0.25 H2O: C, 77.95; H, 5.58. Found: C,77.83; H, 5.37.
(E)-3-(3,4-Dimethoxyphenyl)-1-(1-hydroxynaphthalen-2-yl)prop-2-en-1-one
(36)
Synthesized from 2-acetyl-1-hydroxynaphthalene and 3,4-dimethoxybenzaldehyde,
yield 79 %.
Molecular weight: 334.37 g/mol
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1H NMR (DMSO-d6) δ: 14.08 (s, 1H), 8.36 (d, J = 8.2 Hz, 1H), 8.25 (d, J = 9.0 Hz,
1H), 8.14 (d, J = 15.4 Hz, 1H), 7.94 (d, J = 9.2 Hz, 3H), 7.92 (d, J = 3.9 Hz, 1H),
7.72 (m, 2H), 7.59 (d, J = 8.2, 1H), 7.47 (d, J = 8.9 Hz, 1H), 3.83 (d, 6H).
13C NMR (DMSO-d6) δ: 193.60, 158.12, 150.2, 149.90, 144.56, 135.26, 130.93, 129.67,
127.68, 127.35, 126.52, 124.99, 123.25, 122.24, 121.93, 121.12, 120.83, 113.57, 110.67,
55.92, 55.57.
Anal. Calcd for C21H18O4: C, 75.43; H, 5.43. Found: C, 75.37; H, 5.51.
(E)-1-(1-Hydroxynaphthalen-2-yl)-3-(3-methoxyphenyl)prop-2-en-1-one (37)
Synthesized from 2-acetyl-1-hydroxynaphthalene and 3-methoxybenzaldehyde, yield
67 %.
Molecular weight: 304.34 g/mol
1H NMR (DMSO-d6) δ: 14.05 (s, 1H), 8.33 (d, J = 8.7 Hz, 2H), 8.18 (d, J = 15.4 Hz,
1H), 7.93 (dd, J = 15.4, 7.3 Hz, 3H), 7.86 (d, J = 8.8 Hz, 1H), 7.72 (dddd, J = 14.0,
8.2, 6.9, 1.3 Hz, 2H), 7.63–7.60 (m, 1H), 7.44–7.41 (m, 1H), 3.85 (s, 3H).
13C NMR (DMSO-d6) δ: 219.48, 193.80, 163.41, 159.87, 147.20, 145.50, 137.26,
136.00, 130.36, 127.78, 126.34, 125.95, 124.60, 124.36, 123.81, 123.71, 121.45, 117.39,
113.88, 55.54.
Anal. Calcd for C20H16O3*0.33 H2O: C, 77.64; H, 5.68. Found: C, 77.59; H, 5.44.
(E)-3-(2-Chlorophenyl)-1-(1-hydroxynaphthalen-2-yl)prop-2-en-1-one (38)
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Synthesized from 2-acetyl-1-hydroxynaphthalene and 2-chlorobenzaldehyde, yield 72
%.
Molecular weight: 308.76 g/mol
1H NMR (DMSO-d6) δ: 14.81 (s, 1H), 8.39–8.35 (m, 1H), 8.32 (dd, J = 7.5, 2.1 Hz,
1H), 8.29 (d, J = 9.0 Hz, 1H), 8.23 (d, J = 3.0 Hz, 2H), 7.93 (d, J = 8.1 Hz, 1H), 7.73
(ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.63–7.57 (m, 2H), 7.51–7.44 (m, 3H).
13C NMR (DMSO-d6) δ: 193.37, 163.51, 139.61, 137.33, 134.79, 132.53, 132.17,
130.78, 130.23, 129.12, 127.85, 127.78, 126.39, 125.17, 124.55, 123.97, 123.87, 118.52,
113.49.
Anal. Calcd for C19H13ClO2: C, 73.91; H, 4.24. Found: C, 74.05; H, 4.19.
(E)-3-(4-Chlorophenyl)-1-(1-hydroxynaphthalen-2-yl)prop-2-en-1-one (39)
Synthesized from 2-acetyl-1-hydroxynaphthalene and 4-chlorobenzaldehyde, yield 76
%.
Molecular weight: 308.76 g/mol
1H NMR (DMSO-d6) δ: 14.95 (s, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 9.0 Hz,
1H), 8.20 (d, J = 15.5 Hz, 1H), 8.02 (d, J = 8.6 Hz, 2H), 7.95 (d, J = 5.2 Hz, 1H),
7.93 (d, J = 1.6 Hz, 1H), 7.74–7.70 (m, 1H), 7.64–7.61 (m, 1H), 7.56 (d, J = 8.5 Hz,
2H), 7.46 (d, J = 8.8 Hz, 1H).
13C NMR (DMSO-d6) δ: 193.63, 163.40, 143.92, 137.25, 135.72, 133.57, 131.14,
130.67, 129.14, 127.76, 126.34, 125.17, 124.55, 123.80, 121.96, 118.43, 113.48.
Anal. Calcd for C19H13ClO2: C, 73.91; H, 4.24. Found: C, 73.85; H, 4.33.
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(E)-3-(3,4-Dichlorophenyl)-1-(1-hydroxynaphthalen-2-yl)prop-2-en-1-one (40)
Synthesized from 2-acetyl-1-hydroxynaphthalene and 3,4-dichlorobenzaldehyde, yield
64 %, mp 161 ºC.
Molecular weight: 343.20 g/mol
1H NMR (DMSO-d6) δ: 14.89 (s, 1H), 8.37 (d, J = 1.9 Hz, 1H), 8.33 (d, J = 9.1 Hz,
1H), 8.27 (d, J = 15.5 Hz, 1H), 7.94 (dd, J = 8.4, 2.3 Hz, 2H), 7.74 (d, J = 8.3 Hz,
2H), 7.71 (ddd, J = 8.2, 5.0, 1.3 Hz, 1H), 7.60 (m, J= 11.3, 8.2, 6.9, 1.2 Hz, 2H), 7.47
(d, J = 8.8 Hz, 1H).
13C NMR (DMSO-d6) δ: 193.57, 163.53, 142.58, 137.36, 135.49, 133.35, 132.09,
131.21, 130.81, 130.63, 129.78, 127.82, 126.43, 125.27, 124.56, 123.87, 123.38, 118.49,
113.54.
Anal. Calcd for C19H12Cl2O2: C, 66.49; H, 3.52. Found: C, 66.23; H, 3.61.
(E)-1-(2-Hydroxynaphthalen-1-yl)-3-phenylprop-2-en-1-one (41)
Synthesized from 1-acetyl-2-hydroxynaphthalene and benzaldehyde, yield 59 %.
Molecular weight: 274.31 g/mol
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1H NMR (DMSO-d6) δ: 8.23 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 15.7 Hz, 1H), 7.58 (d,
J = 7.3 Hz, 2H), 7.45–7.39 (m, 3H), 7.37 (t, J = 7.4 Hz, 2H), 7.33–7.28 (m, 1H), 7.16
(ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 6.94–6.85 (m, 1H), 6.61 (d, J = 9.2 Hz, 1H).
13C NMR (DMSO-d6) δ: 190.38, 175.79, 136.69, 135.95, 134.84, 133.55, 132.31,
129.58, 128.85, 128.66, 127.87, 127.69, 126.22, 124.34, 123.14, 118.88, 116.93.
Anal. Calcd for C19H14O2:C, 83.19; H, 5.14. Found: C, 83.04; H, 5.28.
(E)-1-(2-Hydroxynaphthalen-1-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (42)
Synthesized from 1-acetyl-2-hydroxynaphthalene and 4-methoxybenzaldehyde, yield
62 %.
Molecular weight: 304.34 g/mol
1H NMR (DMSO-d6) δ: 10.15 (s, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.0 Hz,
1H), 7.62 (d, J = 8.8 Hz, 2H), 7.56 (dd, J = 8.4, 0.9 Hz, 1H), 7.41 (ddd, J = 8.4, 6.8,
1.4 Hz, 1H), 7.31 (dt, J = 8.0, 3.9 Hz, 1H), 7.28–7.22 (m, 2H), 7.10 (d, J= 16.1 Hz,
1H), 6.94 (d, J = 8.8 Hz, 2H), 3.78 (s, 3H).
13C NMR (DMSO-d6) δ: 196.35, 161.46, 152.86, 144.30, 131.66, 131.11, 130.57,
128.40, 128.30, 127.79, 127.19, 127.04, 126.70, 123.47, 123.19, 120.40, 118.53, 114.61,
114.08, 55.48.
Anal. Calcd for C20H16O3: C, 78.93; H, 5.30. Found: C, 78.76; H, 5.30.
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(E)-3-(3,4-Dimethoxyphenyl)-1-(2-hydroxynaphthalen-1-yl)prop-2-en-1-one
(43)
Synthesized from 1-acetyl-2-hydroxynaphthalene and 3,4-dimethoxybenzaldehyde,
yield 68 %.
Molecular weight: 334.37 g/mol48
1H NMR (DMSO-d6) δ: 10.12 (s, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.0 Hz,
1H), 7.54 (dd, J = 8.4, 0.9 Hz, 1H), 7.41 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.33–7.30
(m, 1H), 7.29 (d, J = 2.2 Hz, 1H), 7.25 (dd,J= 12.5, 9.5 Hz, 2H), 7.21–7.17 (m, 1H),
7.15 (d, J = 16.0 Hz, 1H), 6.94 (d, J= 8.4 Hz, 1H), 3.77 (d, J = 2.8 Hz, 6H).
13C NMR (DMSO-d6) δ: 196.59, 152.73, 151.32, 149.16, 144.94, 131.69, 130.95,
128.29, 127.77, 127.28, 127.15, 126.94, 123.45, 123.26, 123.16, 120.50, 118.55, 111.76,
110.92, 55.75, 55.72.
Anal. Calcd for C21H18O4: C, 75.43; H, 5.43. Found: C, 75.50; H, 5.35.
(E)-1-(2-Hydroxynaphthalen-1-yl)-3-(3-methoxyphenyl)prop-2-en-1-one (44)
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Synthesized from 1-acetyl-2-hydroxynaphthalene and 3-methoxybenzaldehyde, yield
63 %.
Molecular weight: 304.34g/mol
1H NMR (DMSO-d6) δ: 8.29 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 15.7 Hz, 1H), 7.41 (d,
J= 9.3 Hz, 2H), 7.36 (d, J = 15.7 Hz, 1H), 7.27 (d, J = 7.9 Hz, 1H), 7.16 (dd, J = 6.9,
1.4 Hz, 2H), 7.13–7.11 (m, 1H), 6.92–6.85 (m, 2H), 6.60 (d, J = 9.2 Hz, 1H), 3.77 (s,
3H).
13C NMR (DMSO-d6) δ: 190.67, 159.70, 140.32, 138.24, 137.75, 136.00, 134.67,
133.48, 132.71, 129.84, 128.83, 127.84, 126.24, 124.34, 123.06, 120.13, 116.89, 114.46,
112.75, 55.23.
Anal. Calcd for C20H16O3: C, 78.93; H, 5.30. Found: C, 78.67; H, 5.46.
(E)-3-(2-Chlorophenyl)-1-(2-hydroxynaphthalen-1-yl)prop-2-en-1-one (45)
Synthesized from 1-acetyl-2-hydroxynaphthalene and 2-chlorobenzaldehyde, yield 56
%.
Molecular weight: 308.76 g/mol
1H NMR (DMSO-d6) δ: 8.53 (d, J = 8.6 Hz, 1H), 7.82 (d, J = 15.6 Hz, 1H), 7.76
(dd, J = 7.3, 2.2 Hz, 1H), 7.65 (d, J = 15.6 Hz, 1H), 7.48 (dd, J = 7.0, 2.3 Hz, 1H),
7.40 (d, J = 9.1 Hz, 2H), 7.34–7.30 (m, 2H), 7.15 (ddd, J= 8.5, 6.8, 1.5 Hz, 1H), 6.87
(ddd, J = 7.9, 6.9, 1.2 Hz, 1H), 6.57 (d, J = 9.2 Hz, 1H).
13C NMR (DMSO-d6) δ: 190.19, 176.91, 136.23, 135.64, 134.82, 133.80, 133.20,
129.85, 129.77, 129.73, 128.76, 127.80, 127.67, 127.60, 126.46, 124.33, 122.92, 118.89,
116.50.
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Anal. Calcd for C19H13ClO2: C, 73.91; H, 4.24. Found: C, 73.84; H, 4.31.
(E)-3-(4-Chlorophenyl)-1-(2-hydroxynaphthalen-1-yl)prop-2-en-1-one (46)
Synthesized from 1-acetyl-2-hydroxynaphthalene and 4-chlorobenzaldehyde, yield 68
%.
Molecular weight: 308.76 g/mol
1H NMR (DMSO-d6) δ: 10.00 (s, 1H), 8.16 (d, J = 8.9 Hz, 1H), 7.92 (d, J = 8.6 Hz,
1H), 7.67 (dd, J = 6.5, 5.1 Hz, 3H), 7.62 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H),
7.28 (d, J = 9.0 Hz, 1H), 7.12 (d, J = 9.0 Hz, 1H), 5.83 (dd, J = 13.2, 3.1 Hz, 1H).
13C NMR (DMSO-d6) δ: 192.74, 163.20, 137.79, 134.31, 133.31, 130.95, 129.68,
129.04, 129.00, 128.83, 128.74, 128.65, 128.13, 125.12, 124.92, 119.11, 112.01.
Anal. Calcd for C19H13ClO2: C, 73.91; H, 4.24. Found: C, 73.68; H, 4.26.
(E)-3-(3,4-Dichlorophenyl)-1-(2-hydroxynaphthalen-1-yl)prop-2-en-1-one (47)
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Synthesized from 1-acetyl-2-hydroxynaphthalene and 4-chlorobenzaldehyde, yield 71
%.
Molecular weight: 343.20 g/mol
1H NMR (DMSO-d6) δ: 8.42 (d, J = 8.5 Hz, 1H), 7.82 (dd, J = 12.2, 8.7 Hz, 2H),
7.59 (dd, J = 11.2, 5.1 Hz, 2H), 7.41 (dd, J = 5.3, 4.1 Hz, 2H), 7.31 (d, J = 15.7 Hz,
1H), 7.15 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H), 6.92–6.86 (m, 1H), 6.60 (d, J = 9.2 Hz, 1H).
13C NMR (DMSO-d6) δ: 190.07, 176.41, 138.00, 136.07, 134.86, 133.78, 131.60,
131.40, 130.92, 130.44, 129.58, 129.13, 127.83, 127.54, 126.43, 124.40, 122.99, 119.00,
116.65.
Anal. Calcd for C19H12Cl2O2: C, 66.49; H, 3.52. Found: C, 66.60; H, 3.42.
(E)-3-(4-Fluoro-3-methoxyphenyl)-1-(1-hydroxynaphthalen-2-yl)prop-2-en-
1-one (48)
Synthesized from 2-acetyl-1-hydroxynaphthalene and 4-fluoro-3-methoxybenzaldehyde,
yield 69 %.
Molecular weight: 322.33 g/mol
1H NMR (DMSO-d6) δ: 15.08 (s, 1H), 8.36 (d, J = 8.4 Hz, 1H), 8.30 (d, J = 8.9 Hz,
1H), 8.10 (d, J = 15.4 Hz, 1H), 8.03 (dd, J = 12.8, 1.7 Hz, 1H), 7.96 – 7.84 (m, 2H),
7.71 (t, J = 7.0 Hz, 2H), 7.59 (t, J = 7.2 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 7.30 –
7.21 (m, 1H), 3.92 (s, 3H).
13C NMR (DMSO-d6) δ: 193.34, 152.77, 150.82, 149.80, 149.72, 137.24, 130.50,
128.00, 127.95, 127.71, 126.19, 125.30, 123.84, 115.59, 115.45, 113.97, 113.57, 56.39.
Anal. Calcd for C20H15FO3: C, 74.52; H, 4.69. Found: C, 74.25; H, 4.74.
117
Chapter 7 Experimental work
7.1.2.6 General procedure for synthesis of 7,8- and 5,6-benzoflavones
An appropriate benzochalcone (2 mmol) and I2 (0.14 g) were dissolved in DMSO
(10 ml). The resulting solution was refluxed for 7-8 h. After completion of the
reaction as indicated by TLC, the solution was cooled to room temperature and
poured onto crushed ice. 1 N HCl solution (50 ml) was added and stirred for 15 min.
This solution was extracted with ethyl acetate. The organic phase was washed 3
times with brine and evaporated under reduced pressure to get crude product. It
was further purified by column chromatography using silica gel as solid phase and
dichloromethane: methanol (9.5:0.5) as eluent to yield pure benzoflavones.
2-Phenyl-4H -benzo[h ]chromen-4-one (49)
Synthesized from (E )-1-(1-hydroxynaphthalen-2-yl)-3-phenylprop-2-en-1-one, yield
68 %.
Molecular weight: 272.30 g/mol
1H NMR (DMSO-d6) δ: 8.63 – 8.57 (m, 1H), 8.21 – 8.15 (m, 2H), 8.07 – 8.02 (m,
1H), 7.95 (d, J = 8.7 Hz, 1H), 7.87 (d, J = 8.6 Hz, 1H), 7.78 – 7.74 (m, 2H), 7.63 –
7.58 (m, 3H), 7.13 (s, 1H).
13C NMR (DMSO-d6) δ: 176.92, 162.00, 152.86, 135.55, 131.82, 131.34, 129.63,
129.35, 128.34, 127.78, 126.46, 125.47, 123.60, 122.36, 120.08, 119.74, 108.25.
Anal. Calcd for C19H12O2: C, 83.81; H, 4.44. Found: C, 83.72; H, 4.52.
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2-(4-Methoxyphenyl)-4H -benzo[h ]chromen-4-one (50)
Synthesized from (E )-1-(1-hydroxynaphthalen-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-
one, yield 72 %.
Molecular weight: 302.32 g/mol
1H NMR (DMSO-d6) δ: 8.70 – 8.66 (m, 1H), 8.22 – 8.18 (m, 2H), 8.13 – 8.09 (m,
1H), 8.00 (d, J = 8.7 Hz, 1H), 7.93 (d, J = 8.6 Hz, 1H), 7.84 – 7.80 (m, 2H), 7.18 –
7.15 (m, 2H), 7.09 (s, 1H), 3.88 (s, 3H).
13C NMR (DMSO-d6) δ: 176.83, 162.22, 152.78, 135.54, 129.60, 128.38, 128.35,
127.80, 125.37, 123.63, 123.52, 122.37, 120.17, 119.68, 114.83, 106.80, 55.65.
Anal. Calcd for C20H14O3: C, 79.46; H, 4.67. Found: C, 79.33; H, 4.73.
2-(3,4-Dimethoxyphenyl)-4H -benzo[h ]chromen-4-one (51)
Synthesized from (E )-3-(3,4-dimethoxyphenyl)-1-(1-hydroxynaphthalen-2-yl)prop-2-
en-1-one, yield 64 %.
Molecular weight: 332.35 g/mol
1H NMR (DMSO-d6) δ: 8.66 – 8.62 (m, 1H), 8.12 – 8.08 (m, 1H), 7.99 (d, J = 8.6
Hz, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.85 (dd, J = 8.5, 2.2 Hz, 1H), 7.83 – 7.79 (m,
2H), 7.66 (d, J = 2.2 Hz, 1H), 7.18 (s, 2H), 3.93 (s, 3H), 3.87 (s, 3H).
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13C NMR (DMSO-d6) δ: 176.89, 162.22, 152.79, 152.06, 149.27, 135.55, 129.58,
128.39, 127.84, 125.35, 123.63, 122.31, 120.16, 119.98, 119.67, 112.01, 109.58, 107.16,
56.00, 55.86.
Anal. Calcd for C21H16O4: C, 75.89; H, 4.85. Found: C, 75.56; H, 5.02.
2-(4-Fluoro-3-methoxyphenyl)-4H -benzo[h ]chromen-4-one (52)
Synthesized from (E )-3-(4-fluoro-3-methoxyphenyl)-1-(1-hydroxynaphthalen-2-yl)prop-
2-en-1-one, yield 76 % .
Molecular weight: 320.32 g/mol
1H NMR (DMSO-d6) δ: 8.70 – 8.64 (m, 1H), 8.12 – 8.04 (m, 3H), 7.98 (d, J = 8.7
Hz, 1H), 7.94 – 7.89 (m, 1H), 7.83 – 7.78 (m, 2H), 7.40 – 7.33 (m, 1H), 7.15 (s, 1H),
3.95 (s, 3H).
13C NMR (DMSO-d6) δ: 176.83, 160.98, 152.80, 152.71, 150.76, 135.57, 129.67,
128.36, 127.84, 125.51, 123.99, 123.74, 123.57, 122.53, 120.10, 119.69, 114.33, 113.98,
107.63, 56.47.
Anal. Calcd for C20H13FO3: C, 74.99; H, 4.09. Found: C, 74.68; H, 4.25.
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3-Phenyl-1H -benzo[f ]chromen-1-one (53)
Synthesized from (E )-1-(2-hydroxynaphthalen-1-yl)-3-phenylprop-2-en-1-one, yield
59 %.
Molecular weight: 272.30 g/mol
1H NMR (DMSO-d6) δ: 9.98 – 9.90 (m, 1H), 8.35 (d, J = 9.0 Hz, 1H), 8.16 – 8.12
(m, 2H), 8.11 – 8.07 (m, 1H), 7.87 (d, J = 9.0 Hz, 1H), 7.77 (ddd, J = 8.5, 6.9, 1.5
Hz, 1H), 7.67 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.63 – 7.58 (m, 3H), 7.18 (s, 1H).
13C NMR (DMSO-d6) δ: 179.32, 160.38, 157.15, 135.90, 131.78, 130.88, 130.51,
129.81, 129.29, 129.17, 128.71, 126.72, 126.31, 126.21, 118.28, 116.37, 109.90.
Anal. Calcd for C19H12O2: C, 83.81; H, 4.44. Found: C, 83.72; H, 4.52.
3-(4-Methoxyphenyl)-1H -benzo[f ]chromen-1-one (54)
Synthesized from (E )-1-(2-hydroxynaphthalen-1-yl)-3-(4-methoxyphenyl)prop-2-en-1-
one, yield 65 %.
Molecular weight: 302.32 g/mol
1H NMR (DMSO-d6) δ: 9.99 – 9.95 (m, 1H), 8.35 (d, J = 9.0 Hz, 1H), 8.12 (d, J =
9.0 Hz, 2H), 8.11 – 8.08 (m, 1H), 7.88 (d, J = 9.0 Hz, 1H), 7.77 (ddd, J = 8.5, 6.9,
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1.5 Hz, 1H), 7.67 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.14 (d, J = 9.0 Hz, 2H), 7.09 (s,
1H), 3.87 (s, 3H).
13C NMR (DMSO-d6) δ: 179.24, 162.17, 160.52, 157.01, 135.67, 130.49, 129.87,
129.07, 128.67, 128.15, 126.62, 126.23, 123.01, 118.27, 116.24, 114.76, 108.45, 55.67.
Anal. Calcd for C20H14O3: C, 79.46; H, 4.67. Found: C, 79.51; H, 4.59
3-(3,4-Dimethoxyphenyl)-1H -benzo[f ]chromen-1-one (55)
Synthesized from (E )-3-(3,4-dimethoxyphenyl)-1-(2-hydroxynaphthalen-1-yl)prop-2-
en-1-one, yield 77 %.
Molecular weight: 332.35 g/mol
1H NMR (DMSO-d6) δ: 9.98 – 9.94 (m, 1H), 8.33 (d, J = 9.0 Hz, 1H), 8.07 (dd, J
= 8.3, 1.0 Hz, 1H), 7.88 (d, J = 9.0 Hz, 1H), 7.78 – 7.72 (m, 2H), 7.69 – 7.62 (m,
2H), 7.16 (s, 1H), 7.13 (d, J = 8.6 Hz, 1H), 3.91 (s, 3H), 3.85 (s, 3H).
13C NMR (DMSO-d6) δ: 179.30, 160.51, 157.01, 151.97, 149.26, 135.60, 130.48,
129.89, 129.04, 128.66, 126.60, 126.26, 123.10, 119.78, 118.33, 116.23, 111.94, 109.46,
108.72, 56.03, 55.86.
Anal. Calcd for C21H16O4: C, 75.89; H, 4.85. Found: C, 76.03; H, 4.67.
7.1.2.7 General procedure for synthesis of 3-hydroxy flavones and
benzoflavones
An appropriate chalcone or benzochalcone (5 mmol) was dissolved in EtOH (25 ml).
NaOH 25% (10 ml) and H2O2 25% (10 ml) were added in small portions to the
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solution. This solution was stirred overnight at room temperature. After completion
of reaction as indicated by TLC, the reaction mixture was poured onto crushed
ice and was acidified with dilute HCl. Yellow-brown precipitate was filtered under
suction, washed with water. The crude product was recrystallized from ethanol to
give 3-hydroxy flavones or benzoflavones.
3-Hydroxy-2-phenyl-4H -chromen-4-one (56)
Synthesized from (E )-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one, yield 59 %.
Molecular weight: 238.24 g/mol
1H NMR (DMSO-d6) δ: 11.86 (s, 0H), 8.30 – 8.21 (m, 2H), 7.69 (ddd, J = 1.6, 7.1,
8.6, 1H), 7.58 (d, J = 8.5, 1H), 7.53 (dd, J = 4.7, 10.3, 2H), 7.49 – 7.43 (m, 1H),
7.40 (t, J = 7.5, 1H), 7.07 (dd, J = 2.8, 5.9, 1H).
13C NMR (DMSO-d6) δ: 173.49, 155.44, 144.98, 138.46, 133.64, 131.07, 130.20,
128.60, 128.31, 127.77, 126.30, 125.47, 124.53, 120.66, 118.28.
Anal. Calcd for C15H10O3*H2O: C, 70.31; H, 4.72. Found: C, 70.22; H, 4.83.
3-Hydroxy-2-(4-methoxyphenyl)-4H -chromen-4-one (57)
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Synthesized from (E )-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one, yield
61 %.
Molecular weight: 268.26 g/mol
1H NMR (DMSO-d6) δ: 9.39 (s, 1H), 8.20 (d, J = 9.2 Hz, 2H), 7.91 – 7.86 (m, 1H),
7.82 – 7.69 (m, 2H), 7.45 (ddd, J = 8.0, 6.8, 1.3 Hz, 1H), 7.12 (d, J = 9.2 Hz, 2H),
3.84 (s, 3H).
13C NMR (DMSO-d6) δ: 172.77, 160.60, 154.59, 145.74, 138.28, 133.61, 131.45,
129.54, 124.87, 123.73, 121.50, 118.44, 114.19, 55.50.
Anal. Calcd for C16H12O4: C, 71.64; H, 4.51. Found: C, 71.53; H, 4.64.
2-(3,4-dimethoxyphenyl)-3-hydroxy-4H -chromen-4-one (58)
Synthesized from (E )-3-(3,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one,
yield 66 %.
Molecular weight: 298.29 g/mol
1H NMR (DMSO-d6) δ: 12.58 (s, 1H), 7.90 – 7.86 (m, 2H), 7.69 (d, J = 8.7 Hz, 1H),
7.02 – 6.99 (m, 2H), 6.48 (dt, J = 5.9, 2.4 Hz, 2H), 3.81 (s, 3H), 3.78 (s, 3H).
13C NMR (DMSO-d6) δ: 171.97, 167.12, 165.28, 163.56, 162.98, 131.76, 131.47,
123.13, 113.95, 107.17, 105.78, 100.86, 55.69, 55.57.
Anal. Calcd for C17H14O5: C, 68.45; H, 4.73. Found: C, 68.19; H, 4.91.
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2-(3,4-Dimethoxyphenyl)-3-hydroxy-7-methoxy-4H -chromen-4-one (59)
Synthesized from (E )-3-(3,4-dimethoxyphenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-
2-en-1-one, yield 62 %.
Molecular weight: 328.32 g/mol
1H NMR (DMSO-d6) δ: 9.27 (s, 1H), 7.98 (d, J = 8.9, 1H), 7.85 (dd, J = 2.1, 8.6
Hz, 1H), 7.79 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 2.3 Hz, 1H), 7.13 (d, J = 8.7, 1H),
7.03 (dd, J = 2.4, 8.9 Hz, 1H), 3.92 (s, 3H), 3.84 (d, J = 3.1 Hz, 6H).
13C NMR (DMSO-d6) δ: 172.18, 163.66, 156.47, 150.32, 148.59, 144.94, 138.06,
126.20, 123.94, 121.41, 115.29, 114.64, 111.70, 111.10, 100.49, 56.22, 55.90, 55.76.
Anal. Calcd for C18H16O6*0.5 H2O: C, 64.09; H, 5.08. Found: C, 63.94; H, 5.17.
3-Hydroxy-5,7-dimethoxy-2-(4-methoxyphenyl)-4H -chromen-4-one (60)
Synthesized from (E )-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphenyl)prop-
2-en-1-one, yield 70 %.
Molecular weight: 328.32 g/mol
1H NMR (DMSO-d6) δ: 9.12 (d, J = 1.7 Hz, 1H), 7.66 (d, J = 8.9 Hz, 2H), 6.90 (d,
J = 8.9 Hz, 2H), 6.35 (s, 2H), 3.75 (s, 6 H), 3.69 (s, 3H).
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13C NMR (DMSO-d6) δ: 191.14, 162.18, 159.23, 158.24, 148.88, 131.44, 127.52,
116.02, 114.13, 108.89, 91.27, 55.99, 55.62, 55.29.
Anal. Calcd for C18H16O6: C, 65.85; H, 4.91. Found: C, 65.67; H, 5.11.
3-Hydroxy-2-phenyl-4H -benzo[h ]chromen-4-one (61)
Synthesized from (E )-1-(1-hydroxynaphthalen-2-yl)-3-phenylprop-2-en-1-one, yield
57 %.
Molecular weight: 288.30 g/mol
1H NMR (DMSO-d6) δ: 9.78 (s, 1H), 8.66 (dd, J = 6.1, 3.4 Hz, 1H), 8.34 (dd, J =
8.5, 1.2 Hz, 2H), 8.10 (dd, J = 6.0, 3.3 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 7.89 (d, J
= 8.7 Hz, 1H), 7.84 – 7.79 (m, 2H), 7.74 (d, J = 8.7 Hz, 1H), 7.64 – 7.60 (m, 2H).
13C NMR (DMSO-d6) δ: 172.80, 151.96, 144.74, 140.52, 135.24, 131.61, 129.92,
129.73, 128.87, 128.48, 127.90, 127.68, 125.04, 124.89, 123.76, 123.21, 122.46, 120.28,
117.66.
Anal. Calcd for C19H12O3: C, 79.16; H, 4.20. Found: C, 79.28; H, 4.15.
3-Hydroxy-2-(4-methoxyphenyl)-4H -benzo[h ]chromen-4-one (62)
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Synthesized from (E )-1-(1-hydroxynaphthalen-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-
one, yield 59 %.
Molecular weight: 318.32 g/mol
1H NMR (DMSO-d6) δ: 9.60 (s, 1H), 8.68 – 8.62 (m, 1H), 8.32 (d, J = 8.9 Hz, 2H),
8.14 – 8.07 (m, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.89 (d, J = 8.7 Hz, 1H), 7.81 (dd, J
= 6.0, 3.3 Hz, 2H), 7.18 (d, J = 9.0 Hz, 2H), 3.87 (s, 3H).
13C NMR (DMSO-d6) δ: 172.46, 160.52, 151.70, 145.18, 139.53, 135.14, 129.58,
129.39, 128.46, 127.83, 124.75, 123.91, 123.73, 122.37, 120.30, 117.64, 114.38, 55.50.
Anal. Calcd for C20H14O4: C, 75.46; H, 4.43. Found: 75.37; H, 4.54.
2-(3,4-Dimethoxyphenyl)-3-hydroxy-4H -benzo[h ]chromen-4-one (63)
Synthesized from (E )-3-(3,4-dimethoxyphenyl)-1-(1-hydroxynaphthalen-2-yl)prop-2-
en-1-one, yield 61 %.
Molecular weight: 348.35 g/mol
1H NMR (DMSO-d6) δ: 9.61 (s, 1H), 8.61 (s, 1H), 8.10 (d, J = 9.1, 1H), 8.04 (d, J
= 8.7, 1H), 7.95 (d, J = 8.5, 1H), 7.91 (d, J = 2.0, 1H), 7.89 (d, J = 8.8, 1H), 7.83
– 7.79 (m, 2H), 7.20 (d, J = 8.6, 1H), 3.88 (d, J = 12.2, 6H).
13C NMR (DMSO-d6) δ: 172.44, 151.70, 150.44, 148.68, 145.14, 139.66, 135.17,
129.60, 128.49, 127.92, 124.00, 123.72, 117.63, 111.96, 111.19, 55.83, 55.80.
Anal. Calcd for C21H16O5*0.5 H2O: C, 72.41; H, 4.63. Found: C, 72.35; H, 4.71.
127
Chapter 7 Experimental work
2-(4-Fluoro-3-methoxyphenyl)-3-hydroxy-4H -benzo[h ]chromen-4-one (64)
Synthesized from (E )-3-(4-fluoro-3-methoxyphenyl)-1-(1-hydroxynaphthalen-2-yl)prop-
2-en-1-one, yield 54 %.
Molecular weight: 336.31 g/mol
1H NMR (DMSO-d6) δ: 9.85 (s, 1H), 8.72 – 8.63 (m, 1H), 8.22 – 8.08 (m, 3H), 8.04
(d, J = 8.7 Hz, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.86 – 7.77 (m, 2H), 7.41 (t, J = 8.9
Hz, 1H), 3.95 (s, 3H).
13C NMR (DMSO-d6) δ: 172.56, 151.77, 150.32, 148.47, 144.01, 143.78, 140.07,
135.22, 129.70, 128.46, 127.90, 124.90, 124.64, 124.29, 123.68, 122.52, 120.26, 117.67,
115.10, 114.13, 56.36.
Anal. Calcd for C20H13FO4: C, 71.43; H, 3.90. Found: C, 71.54; H, 3.78.
2-Hydroxy-3-phenyl-1H -benzo[f ]chromen-1-one (65)
Synthesized from (E )-1-(2-hydroxynaphthalen-1-yl)-3-phenylprop-2-en-1-one, yield
63 %.
Molecular weight: 288.30 g/mol
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1H NMR (DMSO-d6) δ: 8.49 (d, J = 8.5 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 7.86 –
7.82 (m, 2H), 7.78 (d, J = 9.0 Hz, 1H), 7.71 (td, J = 7.5, 1.4 Hz, 1H), 7.65 (d, J =
9.0 Hz, 1H), 7.61 (dt, J = 13.4, 4.6 Hz, 1H), 7.55 – 7.48 (m, 2H), 7.35 (ddd, J =
8.0, 6.8, 1.1 Hz, 1H), 7.16 (d, J = 8.9 Hz, 1H).
13C NMR (DMSO-d6) δ: 172.28, 165.73, 159.67, 156.12, 142.48, 135.82, 134.73,
134.56, 129.88, 128.77, 127.98, 127.94, 124.59, 123.33, 119.04, 113.08.
Anal. Calcd for C19H12O3* H2O: C, 74.50; H, 4.61. Found: C, 74.57; H, 4.88.
2-Hydroxy-3-(4-methoxyphenyl)-1H -benzo[f ]chromen-1-one (66)
Synthesized from (E )-1-(2-hydroxynaphthalen-1-yl)-3-(4-methoxyphenyl)prop-2-en-1-
one, yield 57 %.
Molecular weight: 318.32 g/mol
1H NMR (DMSO-d6) δ: 9.33 (s, 1H), 8.67 (dd, J = 7.2, 1.7 Hz, 1H), 7.79 – 7.71 (m,
2H), 7.54 (d, J = 7.5 Hz, 1H), 7.49 (d, J = 7.5 Hz, 2H), 7.42 (dtd, J = 19.9, 7.4,
1.6 Hz, 2H), 6.97 (d, J = 7.5 Hz, 2H), 3.81 (s, 3H).
13C NMR (DMSO-d6) δ: 172.28, 167.89, 161.06, 159.95, 143.82, 134.65, 131.57,
131.44, 130.02, 128.79, 128.03, 127.00, 126.96, 124.54, 123.41, 118.94, 116.64, 114.47,
55.42.
Anal. Calcd for C20H14O4: C, 75.46; H, 4.43. Found: C, 75.27; H, 4.67.
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3-(3,4-Dimethoxyphenyl)-2-hydroxy-1H -benzo[f ]chromen-1-one (67)
Synthesized from (E )-3-(3,4-dimethoxyphenyl)-1-(2-hydroxynaphthalen-1-yl)prop-2-
en-1-one, yield 66 %.
Molecular weight: 348.10 g/mol
1H NMR (DMSO-d6) δ: 9.83 (s, 1H), 7.55 (dd, J = 8.4, 2.0 Hz, 2H), 7.43 (d, J =
2.0 Hz, 2H), 7.29 (d, J = 2.0 Hz, 1H), 7.18 (ddd, J = 14.2, 7.5, 4.5 Hz, 1H), 7.03 (d,
J = 8.5 Hz, 2H), 6.42 (d, J = 15.9 Hz, 1H), 3.81 (s, 3H), 3.79 (s, 3H).
13C NMR (DMSO-d6) δ: 167.98, 167.22, 152.78, 150.95, 149.15, 148.47, 127.22,
123.32, 123.12, 122.74, 116.86, 112.11, 111.74, 111.47, 111.17, 110.55, 55.80, 55.62.
Anal. Calcd for C21H16O5: C, 72.41; H, 4.63. Found: C, 72.18; H, 4.92.
7.1.2.8 General procedure for synthesis of 3-methoxy flavones and
benzoflavones
To a solution of 3-hydroxyflavone or 3-hydroxybenzoflavone (2 mmol) in acetone
(25 ml), K2CO3 (2 mmol) and methyl iodide (3 mmol) were added. The resulting
mixture was refluxed for 24 h. After completion of the reaction acetone and methyl
iodide were removed under reduced pressure. To the resulting solid water was added,
the precipitated product was filtered and washed with water to remove traces of
K2CO3. The product was dried at room temperature and recrystallized from ethanol
to yield corresponding 3-methoxy flavones and benzoflavones.
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3-Methoxy-2-phenyl-4H -chromen-4-one (68)
Synthesized from 3-hydroxy-2-phenyl-4H-chromen-4-one, yield 74 %.
Molecular weight: 252.26 g/mol
1H NMR (CDCl3) δ: 8.26 (dd, J = 8.0, 1.7 Hz, 1H), 8.12 – 8.06 (m, 2H), 7.66 (ddd,
J = 8.5, 7.1, 1.7 Hz, 1H), 7.55 – 7.48 (m, 4H), 7.39 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H),
3.89 (s, 3H).
13C NMR (CDCl3) δ: 175.14, 155.60, 155.28, 141.53, 133.45, 130.72, 128.53, 128.50,
125.83, 124.66, 117.98, 60.13.
Anal. Calcd for C16H12O3: C, 76.18; H, 4.79. Found: C, 75.92; H, 4.96.
3-Methoxy-2-(4-methoxyphenyl)-4H -chromen-4-one (69)
Synthesized from 3-hydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one, yield 64 %.
Molecular weight: 282.29 g/mol
1H NMR (DMSO-d6) δ: 8.09 (d, J = 1.3 Hz, 1H), 8.08 – 8.06 (m, 1H), 8.06 – 8.04
(m, 1H), 7.80 (ddd, J = 8.6, 7.0, 1.7 Hz, 1H), 7.75 – 7.71 (m, 1H), 7.47 (ddd, J =
8.0, 7.0, 1.1 Hz, 1H), 7.16 – 7.11 (m, 2H), 3.85 (s, 3H), 3.80 (s, 3H).
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13C NMR (DMSO-d6) δ: 173.80, 161.38, 155.10, 154.76, 140.22, 134.01, 130.20,
125.08, 125.01, 123.68, 122.75, 118.47, 114.35, 59.61, 55.58.
Anal. Calcd for C17H14O4: C, 72.33; H, 5.00: C, 72.47; H, 5.38.
2-(3,4-Dimethoxyphenyl)-3-methoxy-4H -chromen-4-one (70)
Synthesized from 2-(3,4-dimethoxyphenyl)-3-hydroxy-4H-chromen-4-one, yield 73 %.
Molecular weight: 312.32 g/mol
1H NMR (DMSO-d6) δ: 8.08 (dd, J = 7.9, 1.6 Hz, 1H), 7.81 (ddd, J = 8.5, 6.9, 1.6
Hz, 1H), 7.78 – 7.75 (m, 1H), 7.72 (dd, J = 8.5, 2.1 Hz, 1H), 7.68 (d, J = 2.1 Hz,
1H), 7.48 (ddd, J = 8.0, 6.9, 1.2 Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 3.86 (d, J = 1.8
Hz, 6H), 3.82 (s, 3H).
13C NMR (DMSO-d6) δ: 173.81, 155.07, 154.75, 151.26, 148.62, 140.35, 134.00,
125.10, 125.00, 123.65, 122.76, 122.14, 118.57, 111.78, 111.68, 59.64, 55.82.
Anal. Calcd for C18H16O5: C, 69.22; H, 5.16. Found: C, 69.28; H, 5.13.
2-(3,4-Dimethoxyphenyl)-3,7-dimethoxy-4H -chromen-4-one (71)
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Synthesized from 2-(3,4-dimethoxyphenyl)-3-hydroxy-7-methoxy-4H-chromen-4-one,
yield 71 %.
Molecular weight: 342.34 g/mol
1H NMR (DMSO-d6) δ: 7.96 (d, J = 8.9 Hz, 1H), 7.71 (dd, J = 8.5, 2.1 Hz, 1H),
7.66 (d, J = 2.1 Hz, 1H), 7.27 (d, J = 2.3 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.05
(dd, J = 8.9, 2.4 Hz, 1H), 3.91 (s, 3H), 3.86 (s, 6H), 3.81 (s, 3H).
13C NMR (DMSO-d6) δ: 173.21, 163.86, 156.57, 154.50, 151.11, 148.60, 140.10,
126.36, 122.83, 121.93, 117.44, 114.71, 111.73, 111.56, 100.73, 59.62, 56.26, 55.84,
55.80.
Anal. Calcd for C19H18O6: C, 66.66; H, 5.30. Found: C, 66.38; H, 5.64.
3-Methoxy-2-phenyl-4H -benzo[h ]chromen-4-one (72)
Synthesized from 3-hydroxy-2-phenyl-4H-benzo[h]chromen-4-one, yield 62 %.
Molecular weight: 302.32 g/mol
1H NMR (DMSO-d6) δ: 8.59 (dd, J = 6.1, 3.4 Hz, 1H), 8.21 – 8.18 (m, 2H), 8.14 –
8.10 (m, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.94 (d, J = 8.7 Hz, 1H), 7.85 – 7.79 (m,
2H), 7.68 – 7.61 (m, 3H), 3.90 (s, 3H).
13C NMR (DMSO-d6) δ: 173.83, 154.36, 152.10, 142.14, 135.39, 130.99, 130.70,
129.82, 129.02, 128.44, 128.40, 127.97, 125.34, 123.56, 122.40, 120.22, 120.05, 59.82.
Anal. Calcd for C20H14O3: C, 79.46; H, 4.67. Found: C, 79.29; H, 4.81.
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3-Methoxy-2-(4-methoxyphenyl)-4H -benzo[h ]chromen-4-one (73)
Synthesized from 3-hydroxy-2-(4-methoxyphenyl)-4H-benzo[h]chromen-4-one, yield
59 %.
Molecular weight: 332.35 g/mol
1H NMR (DMSO-d6) δ: 8.59 – 8.54 (m, 1H), 8.20 – 8.16 (m, 2H), 8.11 – 8.07 (m,
1H), 8.01 (d, J = 8.7 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.80 (ddd, J = 4.7, 2.2, 0.8
Hz, 2H), 7.19 (d, J = 9.1 Hz, 2H), 3.88 (s, 6H).
13C NMR (DMSO-d6) δ: 173.58, 161.33, 154.37, 151.85, 141.34, 135.31, 130.13,
129.67, 128.41, 127.87, 125.16, 123.53, 122.87, 122.31, 120.23, 119.96, 114.52, 59.58,
55.56.
Anal. Calcd for C21H16O4: C, 75.89; H, 4.85. Found: C, 75.58; H, 5.04.
2-(3,4-Dimethoxyphenyl)-3-methoxy-4H -benzo[h ]chromen-4-one (74)
Synthesized from 2-(3,4-dimethoxyphenyl)-3-hydroxy-4H-benzo[h]chromen-4-one, yield
69 %.
Molecular weight: 362.38 g/mol
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1H NMR (DMSO-d6) δ: 8.58 (dd, J = 3.5,6.2 Hz, 1H), 8.12 (dd, J= 3.1,6.2 Hz, 1H),
8.03 (d, J = 8,7 Hz, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.84 (d, J = 2.1 Hz, 1H), 7.83-7.82
(m, 1H), 7.81 (d, J = 3.3 Hz, 1H), 7.77 (d, J = 2.1 Hz, 1H), 7.22 (d, J = 8.6 Hz, 1H),
3.92 (d, J = 11.4 Hz, 6H), 3.76 (s, 3H).
13C NMR (DMSO-d6) δ: 173.61, 154.45, 151.90, 151.22,148.72, 135.37, 129.72, 128.47,
128.00, 125.24, 123.57, 122.89, 122.33, 121.99, 120.27, 119.99, 111.98, 111.62, 59.67,
55.85, 55.81.
Anal. Calcd for C22H18O5: C, 72.92; H, 5.01. Found: C, 72.68; H, 5.25.
2-(4-Fluoro-3-methoxyphenyl)-3-methoxy-4H -benzo[h ]chromen-4-one (75)
Synthesized from 2-(4-fluoro-3-methoxyphenyl)-3-hydroxy-4H-benzo[h]chromen-4-one,
yield 74 %.
Molecular weight: 350.34 g/mol
1H NMR (DMSO-d6) δ: 8.41 (dd, J = 7.5, 1.6 Hz, 1H), 7.75 (dt, J = 8.1, 1.4 Hz,
2H), 7.61 (d, J = 7.1 Hz, 1H), 7.44 (dtd, J = 25.6, 7.2, 1.5 Hz, 2H), 6.88 – 6.81 (m,
3H), 3.61 (s, 3H), 3.55 (s, 3H).
13C NMR (DMSO-d6) δ: 173.68, 158.40, 155.41, 154.67, 151.95, 151.02, 150.80,
136.86, 134.25, 129.19, 129.16, 128.22, 128.27, 127.72, 125.19, 124.54, 124.15, 123.62,
123.57, 123.22, 121.35, 115.26, 115.04, 114.78, 114.72, 61.45, 59.80, 57.76.
Anal. Calcd for C21H15FO4: C, 71.99; H, 4.32. Found: C, 72.18; H, 4.24.
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2-Methoxy-3-phenyl-1H -benzo[f ]chromen-1-one (76)
Synthesized from 2-hydroxy-3-phenyl-1H-benzo[f]chromen-1-one, yield 54 %.
Molecular weight: 302.32 g/mol
1H NMR (DMSO-d6) δ: 8.78 (dd, J = 7.5, 1.6 Hz, 1H), 7.82 – 7.76 (m, 2H), 7.58 –
7.54 (m, 1H), 7.49 (td, J = 7.5, 1.5 Hz, 1H), 7.42 (td, J = 7.5, 1.5 Hz, 1H), 7.32 (dd,
J = 7.5, 1.3 Hz, 2H), 7.24 (t, J = 7.3 Hz, 2H), 7.21 – 7.15 (m, 1H), 3.49 (s, 3H).
13C NMR (DMSO-d6) δ: 172.01, 156.52, 152.44, 136.05, 133.83, 131.19, 130.92,
130.85, 130.59, 128.69, 128.47, 128.01, 127.98, 126.47, 125.09, 119.04, 116.89, 59.51.
Anal. Calcd for C20H14O3: C, 79.46; H, 4.67. Found: C, 79.14; H, 4.88.
2-Methoxy-3-(4-methoxyphenyl)-1H -benzo[f ]chromen-1-one (77)
Synthesized from 2-hydroxy-3-(4-methoxyphenyl)-1H-benzo[f]chromen-1-one, yield
63 %.
Molecular weight: 332.35 g/mol
1H NMR (DMSO-d6) δ: 8.75 (dd, J = 7.5, 1.7 Hz, 1H), 7.81 – 7.75 (m, 2H), 7.66 –
7.58 (m, 1H), 7.51 (dtd, J = 25.1, 7.3, 1.7 Hz, 2H), 7.32 (d, J = 7.5 Hz, 2H), 6.89 (d,
J = 7.5 Hz, 2H), 3.77 (s, 3H), 3.59 (s, 3H).
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13C NMR (DMSO-d6) δ: 173.14, 160.42, 155.62, 152.44, 138.05, 133.73, 130.92,
130.85, 129.87, 128.01, 127.98, 126.47, 125.09, 123.08, 119.04, 114.85, 113.56, 59.97,
58.03.
Anal. Calcd for C21H16O4: C, 75.89; H, 4.85. Found: C, 75.68; H, 5.03.
3-(3,4-Dimethoxyphenyl)-2-methoxy-1H -benzo[f ]chromen-1-one (78)
Synthesized from 3-(3,4-dimethoxyphenyl)-2-hydroxy-1H-benzo[f]chromen-1-one, yield
68 %.
Molecular weight: 362.38 g/mol
1H NMR (DMSO-d6) δ: 8.79 (dd, J = 7.4, 1.6 Hz, 1H), 7.85 – 7.78 (m, 2H), 7.68 –
7.62 (m, 1H), 7.45 (dtd, J = 25.1, 7.4, 1.5 Hz, 2H), 7.08 – 6.91 (m, 2H), 6.79 (d, J =
7.8 Hz, 1H), 3.59 (s, 6H), 3.51 (s, 3H).
13C NMR (DMSO-d6) δ: 176.04, 155.52, 153.59, 152.27, 149.41, 137.83, 133.83,
130.92, 130.85, 128.01, 127.98, 126.47, 125.09, 123.58, 122.40, 119.04, 114.85, 112.34,
111.89, 61.45, 56.78.
Anal. Calcd for C22H18O5: C, 72.92; H, 5.01. Found: C, 73.05; H, 5.12.
7.1.2.9 General procedure for synthesis of pentamethyl ethers of quercetin
and morin
To a solution of quercetin hydrate or morin (10 mmol) in acetone (50 ml), K2CO3
(30 mmol) and methyl iodide (70 mmol, excess) were added. The resulting mixture
was refluxed for 24 h. After completion of the reaction acetone and methyl iodide
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were removed under reduced pressure. To the resulting solid water was added, the
precipitated product was filtered and washed with water to remove traces of K2CO3.
The product was dried at room temperature and recrystallized from ethanol to yield
pentamethylquercetine or pentamethylmorin.
2-(3,4-Dimethoxyphenyl)-3,5,7-trimethoxy-4H -chromen-4-one (79)
Synthesized from quercetin, yield 82 %.
Molecular weight: 372.37 g/mol
1H NMR (DMSO-d6) δ: 7.69 (s, 1H), 7.67 (d, J = 2.1 Hz, 1H), 6.96 (d, J = 8.3 Hz,
1H), 6.48 (d, J = 2.3 Hz, 1H), 6.33 (d, J = 2.3 Hz, 1H), 3.94 (s, 9H), 3.88 (s, 3H),
3.86 (s, 3H).
13C NMR (DMSO-d6) δ: 174.00, 163.87, 161.02, 158.78, 152.52, 150.79, 148.65,
141.18, 123.41, 121.60, 111.26, 110.76, 109.49, 95.72, 92.42, 59.93, 56.39, 56.05, 55.95,
55.75.
Anal. Calcd for C20H20O7: C, 64.51; H, 5.41. Found: C, 64.34; H, 5.62.
2-(2,4-Dimethoxyphenyl)-3,5,7-trimethoxy-4H -chromen-4-one (80)
138
7.1 Chemistry
Synthesized from morin, yield 76 %.
Molecular weight: 372.37 g/mol
1H NMR (DMSO-d6) δ: 7.34 (d, J = 8.4 Hz, 1H), 6.69 (d, J = 2.3 Hz, 1H), 6.64
(dd, J = 8.5, 2.3 Hz, 1H), 6.61 (d, J = 2.3 Hz, 1H), 6.47 (d, J = 2.3 Hz, 1H), 3.83
(d, J = 2.1 Hz, 9H), 3.79 (s, 3H), 3.60 (s, 3H).
13C NMR (DMSO-d6) δ: 172.12, 163.71, 162.44, 160.64, 158.85, 158.38, 152.86,
141.48, 131.46, 114.37, 112.26, 109.11, 105.34, 98.78, 96.01, 93.05, 59.57, 56.30, 56.10,
55.91, 55.63.
Anal. Calcd for C20H20O7: C, 64.51; H, 5.41. Found: C, 64.67; H, 5.34.
7.1.2.10 General procedure for synthesis of tetramethyl ethers of quercetin
and morin
Quercetin hydrate or morin (10 mmol) was added to a mixture of acetone (150 ml)
and water (75 ml). To the resulting solution, 30% aqueous KOH (6 ml) was added
and refluxed for 10 minutes. Dimethyl sulfate (2.4 ml) was added and refluxed for
20 min. More amount of KOH (3 ml) was added producing a dark brown solution.
To this solution an additional amount of dimethyl sulfate (2.4 ml) was added and
refluxed for additional 20 min. After this KOH (3.0 ml) and dimethyl sulfate (3.5 ml)
were added again and the solution was refluxed further for 1.5 h and allowed to cool
to room temperature. Evaporation of acetone gave a dark yellow to brown residue.
This residue was purified by column chromatography using hexan:ethylacetate (1:3)
as mobile phase. The first two fractions were combined and evaporated to give pure
tetramethylquercetin or tetramethylmorin.
2-(3,4-Dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy-4H -chromen-4-one (81)
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Synthesized from quercetin, yield 51 %.
Molecular weight: 358.34 g/mol
1H NMR (DMSO-d6) δ: 12.61 (s, 1H), 7.71 (dd, J = 8.6, 2.1 Hz, 1H), 7.65 (d, J =
2.1 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 6.77 (d, J = 2.1 Hz, 1H), 6.37 (d, J = 2.2 Hz,
1H), 3.87 – 3.84 (m, 9H), 3.82 (s, 3H).
13C NMR (DMSO-d6) δ: 178.20, 165.34, 160.81, 156.51, 155.59, 151.52, 148.67,
138.51, 122.25, 122.22, 111.79, 111.52, 105.39, 97.95, 92.70, 59.94, 56.27, 55.85.
Anal. Calcd for C19H18O7*0.5 H2O: C, 62.12; H, 5.21. Found: C, 62.27; H, 5.32.
2-(2,4-Dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy-4H -chromen-4-one (82)
Synthesized from morin, yield 48 %.
Molecular weight: 358.34 g/mol
1H NMR (DMSO-d6) δ: 12.62 (s, 1H), 7.39 (d, J = 8.5 Hz, 1H), 6.72 (d, J = 2.3 Hz,
1H), 6.66 (dd, J = 8.5, 2.3 Hz, 1H), 6.61 (d, J = 2.2 Hz, 1H), 6.38 (d, J = 2.2 Hz,
1H), 3.84 (d, J = 7.2 Hz, 6H), 3.81 (s, 3H), 3.69 (s, 3H).
13C NMR (DMSO-d6) δ: 178.24, 165.31, 162.85, 161.27, 158.56, 157.10, 156.82,
139.54, 131.58, 111.72, 105.77, 105.53, 98.80, 97.98, 92.48, 60.12, 56.24, 55.99, 55.67.
Anal. Calcd for C19H18O7*0.5 H2O: C, 62.12; H, 5.21. Found: C, 61.99; H, 5.36.
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7.1.2.11 General procedure for synthesis of substituted quinazolin-4(3H)-ones
Method A: To a stirred mixture of anthranilamide (20 mmol) and a selected
substituted benzaldehyde (20 mmol) in 20 ml DMF, iodine (3.17 g, 25 mmol) and
anhydrous potassium carbonate (2.76 g, 20 mmol) were added. Then the mixture
was heated at 70-90 °C for 4-5 hours. The mixture was poured on to crushed ice
and the precipitate formed was filtered. The product was washed with 100 ml 20 %
solution of sodiumthiosulfate to remove traces of iodine, followed by washing with
water. The product was recrystallized from ethanol to yield pale yellow to dark
yellow crystals.
Method B: A mixture of 2-aminobenzoic acid (anthranilic acid) or 2-amino-4,5-
dimethoxybenzoic acid (20 mmol) and formamide (20 mmol) was heated at 150 ºC
for 10-18 hours. To the resulting mixture 50 ml water was added, which resulted in
precipitation of a lot of solid. The reaction mixture was stirred for another 30-45
minutes and the resulting precipitate was filtered and washed with a lot of water.
The product was recrystallized from ethanol to yield white to pale yellow crystals.
2-Phenylquinazoline-4(3H)-one (83)
Synthesized from anthranilamide and benzaldehyde using method A, yield 79 %.
Molecular weight: 222.24 g/mol
1H NMR (DMSO-d6) δ: 11.56 (s, 1H), 8.23 (d, J = 7.6 Hz, 1H), 7.98 (dd, J =7.9 Hz,
1H), 7.79 (dd, J = 8.1, 4.2 Hz, 2H), 7.68-7.52 (m, 2H), 7.46-7.38 (m, 3H), 7.22 (t, J
= 8.2 Hz, 1H).
13C NMR (DMSO-d6) δ: 164.23, 157.08, 143.68, 138.92, 131.47, 129.01, 127.22,
126.91, 125.12, 124.37, 123.06, 119.56.
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2-(3,4-Dimethoxyphenyl)quinazolin-4(3H)-one (84)
Synthesized from anthranilamide and 3,4-dimethoxybenzaldehyde using method A,
yield 86 %
Molecular weight: 282.29 g/mol
1H NMR (DMSO-d6) δ: 12.37 (s, 1H), 8.14 – 8.10 (m, 1H), 7.89 – 7.84 (m, 1H), 7.82
– 7.80 (m, 1H), 7.79 – 7.77 (m, 1H), 7.70 (dd, J = 8.2, 0.5 Hz, 1H), 7.46 (ddd, J =
8.1, 7.1, 1.2 Hz, 1H), 7.09 (dd, J = 10.0, 5.7 Hz, 1H), 3.85 (dd, J = 16.6, 7.6 Hz, 6H).
13C NMR (DMSO-d6) δ: 162.76, 152.27, 151.72, 149.04, 148.71, 134.57, 127.32,
126.16, 125.97, 125.14, 121.30, 120.84, 111.55, 110.93, 55.85, 55.84.
Quinazolin-4(3H)-one (85)
Synthesized from anthranilic acid and formamide as descreibed in method B, yield
85 %.
Molecular weight: 146.15 g/mol
1H NMR (DMSO-d6) δ: 12.20 (s, 1H), 8.11 (ddd, J = 7.9, 1.6, 0.5 Hz, 1H), 8.07 (s,
1H), 7.80 (ddd, J = 8.2, 7.1, 1.6 Hz, 1H), 7.65 (ddd, J = 8.2, 1.0, 0.4 Hz, 1H), 7.51
(ddd, J = 8.1, 7.2, 1.2 Hz, 1H).
13C NMR (DMSO-d6) δ: 160.86, 148.84, 145.51, 134.40, 127.28, 126.83, 125.93,
122.75.
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6,7-Dimethoxyquinazolin-4(3H)-one (86)
Synthesized from 2-Amino-4,5-dimethoxybenzoic acid and formamide as described in
method B, yield 89%.
Molecular weight: 206.20 g/mol
1H NMR (DMSO-d6) δ: 12.02 (s, 1H), 7.96 (s, 1H), 7.43 (s, 1H), 7.12 (s, 1H), 3.87
(d, J = 17.4 Hz, 6H).
13C NMR (DMSO-d6) δ: 160.16, 154.60, 148.70, 145.01, 143.94, 115.75, 108.17,
105.10, 56.05, 55.83.
7.1.2.12 General procedure for synthesis of substituted 4-chloroquinazolines
To phosphorus oxychloride (30 ml), the selected quinazolin-4(3H )-one (10 mmol)
was added at 0°C and stirred for 10 minutes. The resulting mixture was refluxed
for 9 hours. After removal of the excess solvent, the residue was dissolved in ice-
water (50 mL) and the solution was neutralized with ammonium hydroxide. The
solution was extracted 3 times with dichloromethane (50 mL). The organic layer was
washed with brine (100 mL), dried over MgSO4, and the solvent was removed under
reduced pressure. The formed solid was recrystallized from ethanol. For further use
compounds were confirmed by NMR analysis.
4-Chloro-2-phenylquinazoline (87)
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Synthesized from 2-phenylquinazoline-4(3H)-one, yield 87%.
Molecular weight: 240.69 g/mol
1H NMR (DMSO-d6) δ: 8.41-8.36 (m, 2H), 8.01 (ddd, J = 8.0, 1.43, 0.62 Hz, 1H),
7.78 (ddd, J = 8.2, 1.71, 0.52 Hz, 1H), 7.59 (m, 1H), 7.48 (m, 1H), 7.39-7.31 (m, 3H).
13C NMR (DMSO-d6) δ: 164.2, 159.8, 153.5, 137.3, 135.6, 132.3, 130.2, 129.8, 128.1,
127.3, 123.9, 120.8.
4-Chloro-2-(3,4-dimethoxyphenyl)quinazoline (88)
Synthesized from 2-(3,4-dimethoxyphenyl)quinazolin-4(3H)-one, yield 78 %.
Molecular weight: 300.74 g/mol
1H NMR (DMSO-d6) δ: 8.19 – 8.15 (m, 1H), 8.12 (d, J = 8.0 Hz, 1H), 7.96 – 7.89
(m, 1H), 7.89 – 7.82 (m, 2H), 7.60 (ddd, J = 8.1, 7.3, 1.1 Hz, 1H), 7.20 (d, J = 8.5
Hz, 1H), 3.90 (d, J = 19.6 Hz, 6H).
13C NMR (DMSO-d6) δ: 161.20, 154.77, 153.24, 148.66, 135.55, 127.59, 126.44,
123.40, 123.21, 120.00, 112.16, 111.63, 56.09, 56.06.
4-Chloroquinazoline (89)
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Synthesized from quinazolin-4(3H)-one, yield 82 %.
Molecular weight: 164.59 g/mol
1H NMR (DMSO-d6) δ: 8.31 (s, 1H), 8.01 (dd, 1H, J = 7.6, 1.2 Hz), 7.79 (t, 1H, J
= 8.0 Hz), 7.69 (d, 1H, J = 7.9 Hz), 7.51 (t, 1H, J = 7.2 Hz).
13C NMR (DMSO-d6) δ: 161.07, 146.01, 144.71, 133.85, 126.92, 125.31, 124.05,
118.21.
4-Chloro-6,7-dimethoxyquinazoline (90)
Synthesized from 6,7-dimethoxyquinazolin-4(3H)-one, yield 71 %.
Molecular weight: 224.64 g/mol
1H NMR (DMSO-d6) δ: 8.51 (s, 1H), 7.45 (s, 1H), 7.23 (s, 1H), 3.91 (s, 3H), 3.88 (s,
3H).
13C NMR (DMSO-d6) δ: 159.26, 155.08, 149.32, 148.72, 115.11, 107.00, 105.54,
105.18, 56.31, 56.27, 56.04.
7.1.2.13 General procedure for synthesis of N-phenylpiperazines
In an atmosphere of dry nitrogen, a mixture of substituted aniline (5 mmol), bis(2-
chloroethyl)amine hydrochloride (5 mmol) and diethylene glycol monomethylether
(0.75 ml) was heated at 150 ºC for 6-12 hours. After cooling to room temperature,
the mixture was dissolved in MeOH (4-5 mL) followed by addition of diethyl ether
(150 ml). The precipitate was filtered off and washed with diethyl ether to provide
the HCl salt. The HCl salt was further converted to the free amine by treatment
with Na2CO3 solution and extracted with ethylacetat 2 times. The combined organic
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layers were dried over MgSO4, and concentrated in vacuum to provide the free amine.
The product was used without further purification and its structure was confirmed
by NMR spectroscopy before use.
1-Phenylpiperazine (91)
Synthesized from aniline and bis(2-chloroethyl)amine hydrochloride, oily compound,
yield 59 %.
Molecular weight: 162.23 g/mol
1H NMR (DMSO-d6) δ: 8.34 (s, 1H), 7.12 (t, J = 7.34 Hz, 2H), 6.82 – 6.77 (m, 3H),
3.48 (m, 2H), 3.29 (m, 2H), 2.79 – 2.71 (m, 4H),
13C NMR (DMSO-d6) δ: 151.22, 130.45, 119.97, 116.45, 50.01, 45.70.
1-(3-Bromophenyl)piperazine (92)
Synthesized from 3-bromoaniline and bis(2-chloroethyl)amine hydrochloride, oily
compound, yield: 63 %
Molecular weight: 241.13 g/mol
1H NMR (DMSO-d6) δ: 8.02 (s, 1H), 7.09 – 7.05 (m, 1H), 7.02 – 6.98 (m, 1H), 6.93
(ddd, J = 7.8, 1.8, 0.8 Hz, 1H), 6.79 (ddd, J = 8.4, 2.4, 0.7 Hz, 1H), 3.11 (dd, J =
6.1, 3.9 Hz, 4H), 2.99 (dd, J = 6.1, 3.9 Hz, 4H).
13C NMR (DMSO-d6) δ: 152.86, 130.24, 123.16, 122.22, 118.68, 114.39, 49.71, 45.80.
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1-(3-Chlorophenyl)piperazine (93)
Synthesized from 3-chloroaniline and bis(2-chloroethyl)amine hydrochloride, oily
compound, yield 68 %
Molecular weight: 196.68 g/mol
1H NMR (CDCl3) δ: 8.07 (s, 1H), 7.13 (t, J = 8.1 Hz, 1H), 6.84 (t, J = 2.2 Hz, 1H),
6.77 (dddd, J = 17.5, 8.4, 2.2, 0.8 Hz, 2H), 3.14 (dd, J = 6.2, 3.9 Hz, 4H), 3.02 (dd,
J = 6.2, 3.9 Hz, 4H).
13C NMR (CDCl3) δ: 152.58, 134.89, 129.98, 119.44, 115.86, 115.78, 113.99, 113.79,
77.25, 77.00, 76.74.
1-(3-Chloro-4-fluorophenyl)piperazine (94)
Synthesized from 3-chloro-4-fluoroaniline and bis(2-chloroethyl)amine hydrochloride,
oily compound, yield 54 %
Molecular weight: 214.67 g/mol
1H NMR (DMSO-d6) δ: 8.21 (s, 1H), 6.89 (t, J = 8.1 Hz, 1H), 6.69 (dd, J = 5.9,
1.8 Hz, 1H), 6.58-6.47 (m, 1H), 3.37 (dd, J = 5.9, 3.4 Hz, 4H), 3.02 (dd, J = 6.3, 3.7
Hz, 4H).
13C NMR (DMSO-d6) δ: 153.14, 151.23, 148.76, 118.00, 116.41, 115.84, 77.25, 76.99,
76.74.
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1-(3-Methoxyphenyl)piperazine (95)
Synthesized from 3-methoxyaniline and bis(2-chloroethyl)amine hydrochloride, oily
compound, yield 61 %
Molecular weight: 192.26 g/mol
1H NMR (DMSO-d6) δ: 8,75 (s, 1H), 6.76 (t, J = 2.7 Hz, 1H), 6.68 (dd, J = 48.7,
16.5 Hz, 4H), 6.61 – 6.54 (m, 1H), 3.83 – 3.79 (m, 3H), 3.71 – 3.66 (m, 2H), 3.50 –
3.45 (m, 2H), 2.86 – 2.79 (m, 4H).
13C NMR (DMSO-d6) δ: 160.34, 158.23, 129.69, 129.59, 108.16, 104.25, 101.58, 54.98,
49.04, 45.39.
1-(3-Nitrophenyl)piperazine (96)
Synthesized from 3-nitroaniline and bis(2-chloroethyl)amine hydrochloride, oily com-
pound, yield 68 %
Molecular weight: 207.23 g/mol
1H NMR (DMSO-d6) δ: 8.15 (s, 1 H), 7.61 (t, J = 2.3 Hz, 1H), 7.55 (ddd, J = 8.0,
2.2, 0.9 Hz, 1H), 7.45 (t, J = 8.2 Hz, 1H), 7.37 (ddd, J = 8.4, 2.6, 0.8 Hz, 1H), 3.22
– 3.18 (m, 4H), 2.91 – 2.85 (m, 4H).
13C NMR (DMSO-d6) δ: 152.09, 149.01, 130.23, 121.36, 112.71, 108.40, 48.19, 45.06.
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1-(4-Nitrophenyl)piperazine (97)
Synthesized from 4-nitroaniline and bis(2-chloroethyl)amine hydrochloride, oily com-
pound, yield 59 %
Molecular weight: 207.23 g/mol
1H NMR (DMSO-d6) δ: 8.14 (s, 1H), 8.08 – 8.01 (m, 2H), 7.03 – 6.97 (m, 2H), 3.44
– 3.39 (m, 4H), 2.91 – 2.83 (m, 4H).
13C NMR (DMSO-d6) δ: 155.01, 136.96, 125.83, 112.68, 46.93, 44.85.
7.1.2.14 General procedure for synthesis of 4-anilinoquinazolines
4-Chloroquinazolines (1 mmol) were dissolved in refluxing 2-propanol (20 ml) and
the substituted aniline was added drop wise. The reaction mixture was refluxed for
3-4 hours, until the reaction was complete as indicated by TLC. The precipitate
formed was filtered off and washed with 2-propanol (10 ml) and the ehter (10 ml). If
no precipitate was formed, the solvent was removed under reduced pressure to yield
solid product. The product was recrystallized from 75 % ethanol.
N ,2-Diphenylquinazolin-4-amine (98)
Synthesized from aniline and 4-chloro-2-phenylquinazoline, yield 70%
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Molecular weight: 297.35 g/mol
1H NMR (DMSO-d6) δ: 11.49 (s, 1H), 8.90 (d, J = 8.3 Hz, 1H), 8.39 – 8.34 (m, 2H),
8.31 (d, J = 8.4 Hz, 1H), 8.07 (t, J = 7.3 Hz, 1H), 7.88 – 7.84 (m, 2H), 7.80 (t, J =
7.4 Hz, 1H), 7.68 (t, J = 7.3 Hz, 1H), 7.62 (t, J = 7.5 Hz, 2H), 7.56 – 7.50 (m, 2H),
7.34 (t, J = 7.4 Hz, 1H).
13C NMR (DMSO-d6) δ: 159.10, 157.52, 137.23, 135.81, 133.18, 129.23, 129.08,
128.84, 128.07, 126.38, 124.60, 124.52, 112.96.
Anal. Calcd for C20H15N3: C, 80.78; H, 5.08; N, 14.13. Found: C, 80.45; H, 5.23; N,
13.87.
N -(2-Bromophenyl)-2-phenylquinazolin-4-amine (99)
Synthesized from 2-bromoaniline and 4-chloro-2-phenylquinazoline, yield 81 %.
Molecular weight: 376.25 g/mol
1H NMR (DMSO-d6) δ: 11.49 (s, 1H), 8.90 (d, J = 8.3 Hz, 1H), 8.39 – 8.34 (m, 2H),
8.31 (d, J = 8.4 Hz, 1H), 8.07 (t, J = 7.3 Hz, 1H), 7.88 – 7.84 (m, 2H), 7.80 (t, J =
7.4 Hz, 1H), 7.68 (t, J = 7.3 Hz, 1H), 7.62 (t, J = 7.5 Hz, 2H), 7.56 – 7.50 (m, 2H),
7.34 (t, J = 7.4 Hz, 1H).
13C NMR (DMSO-d6) δ: 159.10, 157.52, 137.23, 135.81, 133.18, 129.23, 129.08,
128.84, 128.07, 126.38, 124.60, 124.52, 112.96.
Anal. Calcd for C20H14BrN3: C, 63.84; H, 3.75; N, 11.17. Found: C, 63.54; H, 4.15;
N, 10.75.
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N -(3-Bromophenyl)-2-phenylquinazolin-4-amine (100)
Synthesized from 3-bromoaniline and 4-chloro-2-phenylquinazoline, yield 78 %.
Molecular weight: 376.25 g/mol
1H NMR (DMSO-d6) δ: 11.59 (s, 1H), 8.94 (d, J = 8.1 Hz, 1H), 8.44 – 8.38 (m, 2H),
8.33 (d, J = 8.3 Hz, 1H), 8.25 (s, 1H), 8.07 (t, J = 7.6 Hz, 1H), 7.94 – 7.86 (m, 1H),
7.81 (t, J = 7.5 Hz, 1H), 7.69 (t, J = 7.3 Hz, 1H), 7.62 (t, J = 7.5 Hz, 2H), 7.54 –
7.44 (m, 2H).
13C NMR (DMSO-d6) δ: 159.09, 157.50, 149.08, 139.01, 135.88, 133.18, 130.70,
129.21, 129.07, 128.64, 128.10, 126.92, 124.63, 123.07, 121.21, 113.06.
Anal. Calcd for C20H14BrN3: C, 63.84; H, 3.75; N, 11.17. Found: C, 63.61; H, 4.05;
N, 11.27.
N -(4-Bromophenyl)-2-phenylquinazolin-4-amine (101)
Synthesized from 4-bromoaniline and 4-chloro-2-phenylquinazoline, yield 82 %.
Molecular weight: 376.25 g/mol
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1H NMR (DMSO-d6) δ: 11.57 (s, 1H), 8.93 (d, J = 8.2 Hz, 1H), 8.41 – 8.37 (m, 2H),
8.33 (d, J = 8.1 Hz, 1H), 8.07 (t, J = 7.4 Hz, 1H), 7.89 – 7.84 (m, 2H), 7.81 (t, J =
7.5 Hz, 1H), 7.74 – 7.70 (m, 2H), 7.68 (d, J = 7.3 Hz, 1H), 7.63 (t, J = 7.5 Hz, 2H).
13C NMR (DMSO-d6) δ: 159.03, 157.58, 150.03, 136.75, 135.86, 133.16, 131.69,
129.28, 129.12, 128.10, 126.38, 124.65, 118.42, 113.06.
Anal. Calcd for C20H14BrN3: C, 63.84; H, 3.75; N, 11.17. Found: C, 63.67; H, 4.01;
N, 10.94.
N -(3-Chlorophenyl)-2-phenylquinazolin-4-amine (102)
Synthesized from 3-chloroaniline and 4-chloro-2-phenylquinazoline, yield 69 %.
Molecular weight: 331.80 g/mol
1H NMR (DMSO-d6) δ: 11.56 (s, 1H), 8.93 (d, J = 8.1 Hz, 1H), 8.46 – 8.36 (m, 2H),
8.32 (d, J = 8.1 Hz, 1H), 8.11 – 8.02 (m, 2H), 7.87 (dd, J = 8.1, 1.2 Hz, 1H), 7.81 (t,
J = 7.6 Hz, 1H), 7.69 (t, J = 7.3 Hz, 1H), 7.63 (t, J = 7.5 Hz, 2H), 7.55 (t, J = 8.1
Hz, 1H), 7.38 (dd, J = 7.9, 1.3 Hz, 1H).
13C NMR (DMSO-d6) δ: 159.12, 157.58, 138.94, 136.21, 135.85, 133.13, 132.94,
130.42, 129.17, 129.07, 128.08, 125.73, 124.61, 124.01, 122.70, 113.08.
Anal. Calcd for C20H14ClN3: C, 72.40; H, 4.25; N, 12.66. Found: C, 72.29; H, 4.75;
N, 12.37.
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N -(3-Chloro-4-fluorophenyl)-2-phenylquinazolin-4-amine(103)
Synthesized from 3-chloro-4-fluoroaniline and 4-chloro-2-phenylquinazoline, yield 73
%.
Molecular weight: 349.79 g/mol
1H NMR (DMSO-d6) δ: 11.69 (s, 1H), 8.95 (d, J = 8.0 Hz, 1H), 8.38 (d, J = 7.3 Hz,
2H), 8.33 (d, J = 8.0 Hz, 1H), 8.20 (dd, J = 6.8, 2.4 Hz, 1H), 8.07 (t, J = 7.6 Hz,
1H), 7.89 (ddd, J = 8.9, 4.2, 2.6 Hz, 1H), 7.80 (t, J = 7.7 Hz, 1H), 7.69 (t, J = 7.2
Hz, 1H), 7.61 (dd, J = 13.9, 6.6 Hz, 2H), 7.57 (d, J = 9.0 Hz, 1H).
13C NMR (DMSO-d6) δ: 159.15, 157.54, 156.00, 154.05, 135.90, 134.57, 133.18,
129.19, 129.08, 128.12, 126.34, 124.98, 124.65, 119.30, 119.15, 117.06, 116.89, 112.96.
Anal. Calcd for C20H13ClFN3 : C, 68.67; H, 3.75; N, 12.01. Found: C, 68.52; H, 3.92;
N, 11.89.
N -(2-Methoxyphenyl)-2-phenylquinazolin-4-amine(104)
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Synthesized from 2-methoxyaniline and 4-chloro-2-phenylquinazoline, yield 68 %.
Molecular weight: 327.38 g/mol
1H NMR (DMSO-d6) δ: 11.39 (s, 1H), 8.82 (d, J = 7.9 Hz, 1H), 8.42 (d, J = 8.2 Hz,
1H), 8.27 (d, J = 7.6 Hz, 2H), 8.08 (t, J = 7.7 Hz, 1H), 7.81 (t, J = 7.6 Hz, 1H),
7.65 (t, J = 7.3 Hz, 1H), 7.61 – 7.51 (m, 3H), 7.43 (t, J = 7.6 Hz, 1H), 7.25 (d, J =
8.2 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 3.81 (s, 3H).
13C NMR (DMSO-d6) δ: 159.81, 157.21, 154.04, 150.05, 145.43, 135.93, 133.28,
129.17, 128.98, 128.93, 128.22, 127.83, 125.15, 124.47, 120.45, 112.47, 112.33, 55.92
Anal. Calcd for C21H17N3O: C, 77.04; H, 5.23; N, 12.84. Found: C, 77.34; H, 5.14;
N, 12.98.
N -(3-Methoxyphenyl)-2-phenylquinazolin-4-amine (105)
Synthesized from 3-methoxyaniline and 4-chloro-2-phenylquinazoline, yield 77 %.
Molecular weight: 327.38 g/mol
1H NMR (DMSO-d6) δ: 11.06 (s, 1H), 8.85 (d, J = 8.2 Hz, 1H), 8.42 (d, J = 7.0 Hz,
2H), 8.23 (d, J = 8.2 Hz, 1H), 8.02 (t, J = 7.5 Hz, 1H), 7.76 (t, J = 7.4 Hz, 1H),
7.64 (d, J = 7.1 Hz, 1H), 7.61 (d, J = 8.0 Hz, 2H), 7.50 (dd, J = 8.0, 1.0 Hz, 1H),
7.41 (t, J = 8.1 Hz, 1H), 6.87 (dd, J = 8.2, 2.0 Hz, 1H), 6.79 (dd, J = 6.0, 2.8 Hz,
1H), 3.82 (s, 3H).
13C NMR (DMSO-d6) δ: 160.11, 159.54, 158.80, 157.87, 154.93, 138.99, 135.23,
132.55, 130.57, 129.51, 128.93, 127.60, 124.28, 116.01, 113.65, 113.28, 111.61, 109.34,
107.39, 55.39.
Anal. Calcd for C21H17N3O: C, 77.04; H, 5.23; N, 12.84. Found: C, 76.82; H, 5.06;
N, 12.78.
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N -(4-Methoxyphenyl)-2-phenylquinazolin-4-amine (106)
Synthesized from 4-methoxyaniline and 4-chloro-2-phenylquinazoline, yield 62 %.
Molecular weight: 327.38 g/mol
1H NMR (DMSO-d6) δ: 11.55 (s, 1H), 8.89 (d, J = 8.2 Hz, 1H), 8.43 – 8.26 (m, 3H),
8.06 (t, J = 7.4 Hz, 1H), 7.84 – 7.73 (m, 3H), 7.69 (t, J = 7.3 Hz, 1H), 7.62 (t, J =
7.6 Hz, 2H), 7.12 – 7.05 (m, 2H), 3.82 (s, 3H).
13C NMR (DMSO-d6) δ: 158.82, 157.65, 157.35, 135.78, 133.29, 129.82, 129.26,
129.08, 128.06, 125.98, 124.57, 114.01, 112.80, 55.50.
Anal. Calcd for C21H17N3O: C, 77.04; H, 5.23; N, 12.84. Found: C, 76.91; H, 5.17;
N, 12.81.
N -(3,4-Dimethoxyphenyl)-2-phenylquinazolin-4-amine(107)
Synthesized from 3,4-dimethoxyaniline and 4-chloro-2-phenylquinazoline, yield 79 %.
Molecular weight: 357.41 g/mol
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1H NMR (DMSO-d6) δ: 11.10 (s, 1H), 8.81 (d, J = 7.9 Hz, 1H), 8.44 – 8.37 (m, 2H),
8.21 (d, J = 7.2 Hz, 1H), 8.02 (t, J = 7.6 Hz, 1H), 7.76 (t, J = 7.6 Hz, 1H), 7.64 (qd,
J = 14.5, 7.0 Hz, 4H), 7.40 (dd, J = 8.6, 2.3 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 3.81
(d, J = 5.0 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.51, 157.72, 148.49, 146.98, 135.27, 132.77, 130.71,
128.97, 127.70, 124.21, 116.09, 113.11, 111.72, 108.78, 55.88, 55.75.
Anal. Calcd for C22H19N3O2: C, 73.93; H, 5.36; N, 11.76. Found: C, 73.74; H, 5.50;
N, 11.82.
N -(2-Nitrophenyl)-2-phenylquinazolin-4-amine (108)
Synthesized from 2-nitroaniline and 4-chloro-2-phenylquinazoline, yield 83 %.
Molecular weight: 342.35 g/mol
1H NMR (DMSO-d6) δ: 11.82 (s, 1H), 8.54 – 8.47 (m, 1H), 7.94 (ddd, J = 5.2, 4.3,
1.4 Hz, 2H), 7.59 – 7.51 (m, 2H), 7.44 – 7.30 (m, 5H), 7.03 – 6.97 (m, 2H), 6.60 (ddd,
J = 8.4, 6.8, 1.3 Hz, 2H).
13C NMR (DMSO-d6) δ: 165.96, 159.13, 151.40, 146.31, 137.68, 135.80, 134.26,
130.85, 130.47, 128.70, 128.11, 127.75, 127.09, 125.48, 123.44, 119.30, 115.59, 115.01.
Anal. Calcd for C20H14N4O2: C, 70.17; H, 4.12; N, 16.37. Found: C, 70.01; H, 3.98;
N, 16.41.
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N -(3-Nitrophenyl)-2-phenylquinazolin-4-amine (109)
Synthesized from 3-nitroaniline and 4-chloro-2-phenylquinazoline, yield 89 %.
Molecular weight: 342.35 g/mol
1H NMR (DMSO-d6) δ: 11.43 (s, 1H), 9.12 (s, 1H), 8.90 (d, J = 8.3 Hz, 1H), 8.46
(d, J = 7.2 Hz, 2H), 8.35 (dd, J = 8.1, 1.3 Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 8.12
(dd, J = 8.2, 1.7 Hz, 1H), 8.07 (t, J = 7.8 Hz, 1H), 7.86 – 7.77 (m, 2H), 7.67 (t, J =
7.2 Hz, 1H), 7.61 (t, J = 7.4 Hz, 2H).
13C NMR (DMSO-d6) δ: 158.96, 157.93, 147.97, 146.81, 139.17, 135.60, 132.74,
130.14, 129.49, 129.03, 127.90, 124.34, 119.88, 117.99, 113.34.
Anal. Calcd for C20H14N4O2: C, 70.17; H, 4.12; N, 16.37. Found: C, 69.87; H, 4.32;
N, 16.73.
N -(4-Nitrophenyl)-2-phenylquinazolin-4-amine (110)
Synthesized from 4-nitroaniline and 4-chloro-2-phenylquinazoline, yield 80 %.
Molecular weight: 342.35 g/mol
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1H NMR (DMSO-d6) δ: 11.21 (s, 1H), 8.84 (d, J = 8.1 Hz, 1H), 8.51 – 8.35 (m, 4H),
8.28 (d, J = 8.7 Hz, 2H), 8.17 (d, J = 7.8 Hz, 1H), 8.05 (t, J = 7.8 Hz, 1H), 7.79 (t,
J = 7.4 Hz, 1H), 7.62 (d, J = 7.5 Hz, 3H).
13C NMR (DMSO-d6) δ: 158.89, 157.14, 148.13, 146.57, 140.35, 135.73, 132.16,
132.05, 130.85, 129.22, 128.78, 127.22, 126.19, 124.32, 120.78, 119.47, 112.39.
Anal. Calcd for C20H14N4O2: C, 70.17; H, 4.12; N, 16.37. Found: C, 70.25; H, 4.23;
N, 16.43.
N -(4-Fluoro-3-nitrophenyl)-2-phenylquinazolin-4-amine (111)
Synthesized from 4-fluoro,3-nitroaniline and 4-chloro-2-phenylquinazoline, yield 65
%.
Molecular weight: 360.34 g/mol
1H NMR (DMSO-d6) δ: 11.39 (s, 1H), 9.01 (d, J = 4.6 Hz, 1H), 8.85 (d, J = 8.1 Hz,
1H), 8.45 (d, J = 7.4 Hz, 2H), 8.37 – 8.27 (m, 1H), 8.20 (d, J = 7.3 Hz, 1H), 8.06 (t,
J = 7.7 Hz, 1H), 7.86 – 7.70 (m, 2H), 7.64 (dt, J = 15.0, 7.3 Hz, 3H).
13C NMR (DMSO-d6) δ: 158.80, 157.98, 150.68, 136.45, 135.46, 133.67, 132.60,
130.94, 128.98, 127.81, 124.21, 120.50, 118.91, 118.74, 113.26.
Anal. Calcd for C20H13FN4O2: C, 66.66; H, 3.64; N, 15.55. Found: C, 66.61; H, 3.58;
N, 15.60.
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3-((2-Phenylquinazolin-4-yl)amino)benzonitrile (112)
Synthesized from 3-aminobenzonitrile and 4-chloro-2-phenylquinazoline, yield 91 %.
Molecular weight: 322.36 g/mol
1H NMR (DMSO-d6) δ: 11.73 (s, 1H), 8.97 (d, J = 8.3 Hz, 1H), 8.43 – 8.36 (m, 3H),
8.32 (d, J = 8.3 Hz, 1H), 8.27 – 8.19 (m, 1H), 8.08 (t, J = 7.4 Hz, 1H), 7.88 – 7.66
(m, 4H), 7.61 (dd, J = 10.4, 4.7 Hz, 2H).
13C NMR (DMSO-d6) δ: 159.22, 157.65, 138.46, 135.93, 133.12, 130.23, 129.39,
129.16, 129.07, 128.98, 128.13, 127.52, 124.66, 118.57, 113.08, 111.60.
Anal. Calcd for C21H14N4: C, 78.24; H, 4.38; N, 17.38. Found: C, 78.12; H, 4.46; N,
16.98.
2-Phenyl-N -(3-(trifluoromethyl)phenyl)quinazolin-4-amine (113)
Synthesized from 3-(trifluoromethyl)aniline and 4-chloro-2-phenylquinazoline, yield
69 %.
Molecular weight: 365.35 g/mol
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1H NMR (DMSO-d6) δ: 11.66 (s, 1H), 8.96 (d, J = 8.3 Hz, 1H), 8.48 (s, 1H), 8.41
(dd, J = 14.1, 6.9 Hz, 2H), 8.32 (d, J = 8.0 Hz, 1H), 8.16 (d, J = 8.3 Hz, 1H), 8.08
(t, J = 7.5 Hz, 1H), 7.82 (t, J = 7.7 Hz, 1H), 7.76 (t, J = 7.9 Hz, 1H), 7.68 (dd, J =
14.3, 7.2 Hz, 2H), 7.60 (t, J = 7.6 Hz, 2H).
13C NMR (DMSO-d6) δ: 159.14, 157.61, 138.40, 135.84, 133.10, 130.02, 129.52,
129.27, 129.12, 128.99, 128.08, 127.70, 125.33, 124.59, 123.16, 122.18, 120.80, 113.14.
Anal. Calcd for C21H14F3N3: C, 69.04; H, 3.86; N, 11.50. Found: C, 68.74; H, 4.02;
N, 11.70.
2-Phenyl-N -(4-(trifluoromethyl)phenyl)quinazolin-4-amine (114)
Synthesized from 4-(trifluoromethyl)aniline and 4-chloro-2-phenylquinazoline, yield
73 %.
Molecular weight: 365.35 g/mol
1H NMR (DMSO-d6) δ: 11.59 (s, 1H), 8.97 (d, J = 8.2 Hz, 1H), 8.46 – 8.39 (m, 2H),
8.32 (d, J = 8.3 Hz, 1H), 8.17 (t, J = 9.6 Hz, 2H), 8.08 (t, J = 7.4 Hz, 1H), 7.93 –
7.86 (m, 2H), 7.81 (dd, J = 17.0, 9.6 Hz, 1H), 7.73 – 7.59 (m, 3H).
13C NMR (DMSO-d6) δ: 159.16, 157.80, 141.35, 135.82, 132.97, 129.24, 129.10,
128.04, 125.97, 125.94, 125.47, 124.65, 124.17, 123.30, 113.23.
Anal. Calcd for C21H14F3N3: C, 69.04; H, 3.86; N, 11.50. Found: C, 69.15; H, 3.93;
N, 11.45.
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3-((2-Phenylquinazolin-4-yl)amino)phenol (115)
Synthesized from 3-aminophenol and 4-chloro-2-phenylquinazoline, yield 59 %.
Molecular weight: 357.41 g/mol
1H NMR (DMSO-d6) δ: 10.51 (s, 1H), 8.32 (s, 1H), 8.18 (dd, J = 7.4, 1.6 Hz, 1H),
7.75 (dd, J = 7.7, 1.8 Hz, 1H), 7.67 (td, J = 7.3, 1.7 Hz, 1H), 7.49 (td, J = 7.8, 1.3
Hz, 1H), 7.39 – 7.25 (m, 5H), 6.88 – 6.81 (m, 3H), 6.79 (dt, J = 7.5, 1.8 Hz, 1H).
13C NMR (DMSO-d6) δ: 161.59, 156.34, 154.82, 147.33, 142.26, 137.06, 131.26,
131.05, 130.57, 128.98, 126.24, 124.22, 122.59, 120.61, 119.35, 116.25, 115.03, 111.50.
Anal. Calcd for C20H15N3O: C, 76.66; H, 4.82; N, 13.41. Found: C, 76.59; H, 5.03;
N, 13.55.
2-(3,4-Dimethoxyphenyl)-N -phenylquinazolin-4-amine (116)
Synthesized from aniline and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline, yield 62
%.
Molecular weight: 357.41 g/mol
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1H NMR (DMSO-d6) δ: 11.23 (s, 1H), 7.97 (dd, J = 7.7, 16 Hz, 1H), 7.70 (dd, J =
7.5, 1.3 Hz, 1H), 7.68 (td, J = 7.2, 1.6 Hz, 1H), 7.47 (td, J = 7.7, 1.3 Hz, 1H), 7.30
– 7.22 (m, 2H), 7.09 (t, J = 7.8 Hz, 2H), 6.87 (d, J = 7.2 Hz, 1H), 6.75 – 6.67 (m,
3H), 3.80 (d, J = 11.4 Hz, 6H).
13C NMR (DMSO-d6) δ: 161.82, 159.14, 152.81, 150.83, 148.62, 140.60, 135.32,
131.96, 131.05, 129.18, 126.22, 124.90, 123.72, 123.18, 119.55, 114.07, 113.26, 107.91,
56.12, 55.95.
Anal. Calcd for C22H19N3O2: C, 73.93; H, 5.36; N, 11.76. Found: C, 73.84; H, 5.53;
N, 11.81.
N -(3-Bromophenyl)-2-(3,4-dimethoxyphenyl)quinazolin-4-amine (117)
Synthesized from 3-bromoaniline and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline,
yield 86 %.
Molecular weight: 436.30 g/mol
1H NMR (DMSO-d6) δ: 11.54 (s, 1H), 8.86 (d, J = 8.2 Hz, 1H), 8.43 (d, J = 8.2 Hz,
1H), 8.17 (t, J = 1.8 Hz, 1H), 8.12 (dd, J = 8.6, 2.2 Hz, 1H), 8.10 – 8.00 (m, 2H),
7.87 (ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 7.77 (dd, J = 11.4, 4.1 Hz, 1H), 7.56 – 7.43 (m,
2H), 7.18 (d, J = 8.7 Hz, 1H), 3.88 (d, J = 3.0 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.83, 156.74, 153.55, 148.92, 138.89, 135.93, 130.66,
128.88, 127.86, 127.07, 124.58, 123.59, 123.42, 121.21, 112.66, 112.08, 111.74, 56.07,
56.02.
Anal. Calcd for C22H18BrN3O2: C, 60.56; H, 4.16; N, 9.63. Found: C, 60.71; H, 3.89;
N, 9.47.
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N ,2-Bis(3,4-dimethoxyphenyl)quinazolin-4-amine (118)
Synthesized from 3,4-dimethoxyaniline and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline,
yield 53 %.
Molecular weight: 417.46 g/mol
1H NMR (DMSO-d6) δ: 11.43 (s, 1H), 8.81 (d, J = 8.1 Hz, 1H), 8.45 (d, J = 8.2 Hz,
1H), 8.15 – 8.08 (m, 2H), 8.07 – 8.01 (m, 1H), 7.77 (t, J = 7.5 Hz, 1H), 7.48 (d, J =
2.4 Hz, 1H), 7.38 (dd, J = 8.6, 2.4 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 7.09 (d, J =
8.7 Hz, 1H), 3.87 (d, J = 4.3 Hz, 6H), 3.80 (d, J = 11.7 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.47, 156.48, 153.61, 148.88, 148.57, 147.49, 135.78,
130.03, 127.81, 124.43, 123.70, 117.02, 112.51, 112.31, 111.78, 111.59, 109.47, 56.06,
56.03, 55.91, 55.89.
Anal. Calcd for C24H23N3O4: C, 69.05; H, 5.55; N, 10.07. Found: C, 69.42; H, 5.68;
N, 10.14.
2-(3,4-Dimethoxyphenyl)-N -(2-nitrophenyl)quinazolin-4-amine (119)
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Synthesized from 2-nitroaniline and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline,
yield 57 %.
Molecular weight: 402.40 g/mol
1H NMR (DMSO-d6) δ: 11.15 (s, 1H), 8.14 – 8.09 (m, 1H), 8.06 (dd, J = 14.6, 2.0
Hz, 1H), 7.98 – 7.92 (m, 1H), 7.91 – 7.88 (m, 1H), 7.57 (ddd, J = 8.1, 6.0, 2.2 Hz,
1H), 7.38 (ddd, J = 10.0, 6.1, 2.7 Hz, 2H), 7.11 (d, J = 8.5 Hz, 1H), 7.00 (dd, J =
8.6, 1.3 Hz, 1H), 6.63 – 6.53 (m, 1H), 5.76 – 5.67 (m, 1H), 3.88 (s, 3H), 3.85 (s, 3H).
13C NMR (DMSO-d6) δ: 165.69, 158.99, 151.49, 148.80, 146.31, 135.80, 134.14,
130.30, 127.53, 126.58, 125.48, 123.41, 121.63, 119.30, 115.59, 114.73, 111.60, 111.13,
55.76, 55.63.
Anal. Calcd for C22H18N4O4: C, 65.66; H, 4.51; N, 13.92. Found: C, 65.39; H, 4.72;
N, 14.11.
2-(3,4-Dimethoxyphenyl)-N -(3-nitrophenyl)quinazolin-4-amine (120)
Synthesized from 3-nitroaniline and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline,
yield 72 %.
Molecular weight: 402.40 g/mol
1H NMR (DMSO-d6) δ: 11.60 (s, 1H), 8.93 (s, 1H), 8.86 (d, J = 8.2 Hz, 1H), 8.47 –
8.29 (m, 2H), 8.11 (dt, J = 31.4, 9.8 Hz, 3H), 7.80 (q, J = 7.8 Hz, 2H), 7.17 (d, J =
8.6 Hz, 1H), 3.86 (d, J = 15.9 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.86, 157.03, 148.92, 147.91, 138.78, 135.86, 130.12,
127.80, 124.48, 123.62, 120.35, 118.53, 112.84, 112.01, 111.74, 56.04, 55.88.
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Anal. Calcd for C22H18N4O4: C, 65.66; H, 4.51; N, 13.92. Found: C, 65.48; H, 4.62;
N, 13.69.
2-(3,4-Dimethoxyphenyl)-N -(4-nitrophenyl)quinazolin-4-amine (121)
Synthesized from 4-nitroaniline and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline,
yield 68 %.
Molecular weight: 402.40 g/mol
1H NMR (DMSO-d6) δ: 11.54 (s, 1H), 8.86 (d, J = 8.2 Hz, 1H), 8.45 – 8.31 (m, 3H),
8.29 – 8.17 (m, 2H), 8.12 (dd, J = 6.8, 2.1 Hz, 2H), 8.06 (t, J = 7.7 Hz, 1H), 7.78 (t,
J = 7.7 Hz, 1H), 7.20 (d, J = 9.2 Hz, 1H), 3.89 (d, J = 12.0 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.70, 157.07, 153.30, 148.90, 144.03, 135.85, 127.74,
124.53, 124.46, 123.90, 123.57, 113.09, 112.00, 111.87, 56.00, 55.92.
Anal. Calcd for C22H18N4O4: C, 65.66; H, 4.51; N, 13.92. Found: C, 65.71; H, 4.32;
N, 13.75.
2-(3,4-Dimethoxyphenyl)-N -(3-(trifluoromethyl)phenyl)quinazolin-4-amine
(122)
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Synthesized from 3-(trifluoromethyl)aniline and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline,
yield 74 %.
Molecular weight: 425.40 g/mol
1H NMR (DMSO-d6) δ: 11.62 (s, 1H), 8.87 (d, J = 8.2 Hz, 1H), 8.43 (d, J = 7.9 Hz,
1H), 8.31 (s, 1H), 8.18 (d, J = 8.2 Hz, 1H), 8.10 – 8.04 (m, 3H), 7.82 – 7.74 (m, 2H),
7.68 (d, J = 7.7 Hz, 1H), 7.16 (d, J = 8.3 Hz, 1H), 3.87 (d, J = 9.8 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.99, 156.90, 153.56, 148.95, 138.23, 135.97, 130.02,
129.64, 129.39, 128.25, 127.89, 124.56, 123.65, 122.56, 120.99, 112.76, 112.19, 111.70,
56.07, 55.97.
Anal. Calcd for C23H18F3N3O2: C, 64.94; H, 4.26; N, 9.88. Found: C, 64.72; H, 4.51;
N, 9.69.
3-((2-(3,4-Dimethoxyphenyl)quinazolin-4-yl)amino)benzonitrile (123)
Synthesized from 3-aminobenzonitrile and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline,
yield 89 %.
Molecular weight: 382.41 g/mol
1H NMR (DMSO-d6) δ: 11.07 (s, 1H), 8.32 (dd, J = 7.1, 1.7 Hz, 1H), 7.75 (dd, J =
7.3, 1.5 Hz, 1H), 7.69 (td, J = 7.7, 1.6 Hz, 1H), 7.54 (td, J = 7.7, 1.3 Hz, 1H), 7.31
(t, J = 7.0 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.23 – 7.16 (m, 2H), 7.01 (dt, J = 7.6, 1.5
Hz, 1H), 6.89 (d, J = 7.4 Hz, 1H), 3.77 (d, J = 2.4 Hz, 6H).
13C NMR (DMSO-d6) δ: 159.99, 155.94, 152.18, 150.83, 147.62, 140.37, 133.29,
131.10, 131.00, 129.77, 127.38, 125.93, 125.11, 124.72, 122.81, 122.86, 118.39, 113.27,
112.31, 111.02, 108.65, 56.33, 55.61.
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Anal. Calcd for C23H18N4O2: C, 72.24; H, 4.74; N, 14.65. Found: C, 71.88; H, 4.83;
N, 14.71.
2-((2-(3,4-Dimethoxyphenyl)quinazolin-4-yl)amino)phenol (124)
Synthesized from 2-aminophenol and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline,
yield 57 %.
Molecular weight: 373.40 g/mol
1H NMR (DMSO-d6) δ: 10.15 (s, 1H), 8.34 (s, 1H), 7.94 (dd, J = 6.9, 1.8 Hz, 1H),
7.73 (dd, J = 7.2, 1.3 Hz, 1H), 7.69 – 7.63 (m, 1H), 7.39 (t, J = 7.2 Hz, 1H), 6.90
(d, J = 7.1 Hz, 2H), 6.88 (d, J = 7.6 Hz, 1H), 6.70 – 6.56 (m, 4H), 3.59 (d, J = 3.1
Hz, 6H).
13C NMR (DMSO-d6) δ: 161.54, 156.08, 152.65, 150.87, 148.01, 145.92, 132.74,
131.90, 130.49, 126.22, 125.34, 123.88, 123.10, 121.98, 121.00, 113.77, 111.24, 107.38,
56.29, 55.90.
Anal. Calcd for C22H19N3O3: C, 70.76; H, 5.13; N, 11.25. Found: C, 70.61; H, 5.34;
N, 11.43.
3-((2-(3,4-Dimethoxyphenyl)quinazolin-4-yl)amino)phenol (125)
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Synthesized from 3-aminophenol and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline,
yield 60 %.
Molecular weight: 373.40 g/mol
1H NMR (DMSO-d6) δ: 11.32 (s, 1H), 9.75 (s, 1H), 8.81 (d, J = 8.3 Hz, 1H), 8.41
(d, J = 8.2 Hz, 1H), 8.16 (dd, J = 8.6, 2.2 Hz, 1H), 8.08 (d, J = 2.2 Hz, 1H), 8.07 –
8.01 (m, 1H), 7.77 (t, J = 7.3 Hz, 1H), 7.35 – 7.23 (m, 3H), 7.20 (d, J = 8.7 Hz,
1H), 6.76 (ddd, J = 8.0, 2.3, 1.1 Hz, 1H), 3.87 (d, J = 2.8 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.65, 157.79, 156.52, 153.54, 148.89, 138.02, 135.82,
129.37, 127.80, 124.53, 123.55, 115.26, 113.62, 112.58, 112.23, 111.75, 56.07, 55.85.
Anal. Calcd for C22H19N3O3: C, 70.76; H, 5.13; N, 11.25. Found: C, 70.56; H, 5.28;
N, 11.35.
4-((2-(3,4-Dimethoxyphenyl)quinazolin-4-yl)amino)phenol (126)
Synthesized from 4-aminophenol and 4-chloro-2-(3,4-dimethoxyphenyl)quinazoline,
yield 57 %.
Molecular weight: 373.40 g/mol
1H NMR (DMSO-d6) δ: 11.37 (s, 1H), 9.72 (s, 1H), 8.76 (d, J = 8.2 Hz, 1H), 8.38 (d,
J = 8.3 Hz, 1H), 8.11 – 7.97 (m, 3H), 7.75 (t, J = 7.4 Hz, 1H), 7.59 (d, J = 8.8 Hz,
2H), 7.20 (d, J = 8.6 Hz, 1H), 6.91 (d, J = 8.8 Hz, 2H), 3.87 (d, J = 4.3 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.35, 156.39, 156.17, 153.53, 148.84, 135.71, 128.16,
127.76, 126.23, 124.38, 123.48, 115.21, 112.44, 112.19, 111.79, 56.05, 55.92.
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Anal. Calcd for C22H19N3O3: C, 70.76; H, 5.13; N, 11.25. Found: C, 70.82; H, 5.21;
N, 11.49.
N -(3-Bromophenyl)quinazolin-4-amine (127)
Synthesized from 3-bromoaniline and 4-chloroquinazoline, yield 68 %.
Molecular weight: 300.15 g/mol
1H NMR (DMSO-d6) δ: 11.89 (s, 1H), 9.03 (dd, J = 8.4, 0.7 Hz, 1H), 8.98 (s, 1H),
8.11 (ddd, J = 8.4, 7.1, 1.2 Hz, 1H), 8.07 (t, J = 1.9 Hz, 1H), 8.02 (dd, J = 8.4, 0.8
Hz, 1H), 7.86 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.80 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H),
7.52 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H).
13C NMR (DMSO-d6) δ: 160.08, 151.21, 139.09, 138.52, 136.41, 130.74, 129.32,
128.77, 127.40, 125.17, 123.82, 121.26, 120.05, 113.74.
Anal. Calcd for C14H10BrN3: C, 56.02; H, 3.36; N, 14.00. Found: C, 55.88; H, 3.50;
N, 13.75.
3-(Quinazolin-4-ylamino)benzonitrile (128)
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Synthesized from 3-aminobenzonitrile and 4-chloroquinazoline, yield 71 %.
Molecular weight: 246.27 g/mol
1H NMR (DMSO-d6) δ: 12.07 (s, 1H), 9.07 (d, J = 7.8 Hz, 1H), 9.00 (s, 1H), 8.31 (t,
J = 1.8 Hz, 1H), 8.16 – 8.09 (m, 2H), 8.03 (dd, J = 8.4, 0.8 Hz, 1H), 7.88 (ddd, J =
8.3, 7.1, 1.1 Hz, 1H), 7.78 (dt, J = 7.7, 1.3 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H).
13C NMR (DMSO-d6) δ: 160.19, 151.30, 139.32, 137.94, 136.52, 130.28, 130.03,
129.58, 128.85, 128.08, 125.20, 120.23, 118.47, 113.78, 111.65.
Anal. Calcd for C15H10N4: C, 73.16; H, 4.09; N, 22.75. Found: C, 73.30; H, 4.28; N,
22.51.
N -(3-Nitrophenyl)quinazolin-4-amine (129)
Synthesized from 3-nitroaniline and 4-chloroquinazoline, yield 79 %.
Molecular weight: 266.25 g/mol
1H NMR (DMSO-d6) δ: 12.08 (s, 1H), 9.07 (dd, J = 8.4, 0.7 Hz, 1H), 9.03 (s, 1H),
8.77 (t, J = 2.1 Hz, 1H), 8.31 (ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 8.18 – 8.11 (m, 2H),
8.04 (dd, J = 8.4, 0.8 Hz, 1H), 7.89 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.78 (t, J = 8.2
Hz, 1H).
13C NMR (DMSO-d6) δ: 160.20, 151.35, 147.92, 139.51, 138.31, 136.50, 130.86,
130.22, 128.85, 125.19, 120.93, 120.37, 119.21, 113.90.
Anal. Calcd for C14H10N4O2: C, 63.15; H, 3.79; N, 21.04. Found: C, 62.83; H, 3.91;
N, 21.02.
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N -(3-(Trifluoromethyl)phenyl)quinazolin-4-amine (130)
Synthesized from 3-(trifluoromethyl)aniline and 4-chloroquinazoline, yield 85 %.
Molecular weight: 289.26 g/mol
1H NMR (DMSO-d6) δ: 10.00 (s, 1H), 8.67 (s, 1H), 8.57 (d, J = 8.0 Hz, 1H), 8.34 (s,
1H), 8.25 (d, J = 8.2 Hz, 1H), 7.88 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.82 (d, J = 7.5
Hz, 1H), 7.71 – 7.60 (m, 2H), 7.45 (d, J = 7.7 Hz, 1H).
13C NMR (DMSO-d6) δ: 157.73, 154.33, 149.86, 140.34, 133.37, 129.75, 129.52,
129.27, 128.05, 126.64, 125.63, 123.09, 119.80, 119.77, 118.17, 118.13, 115.30.
Anal. Calcd for C15H10F3N3: C, 62.28; H, 3.48; N, 14.53. Found: C, 62.00; H, 3.61;
N, 14.38.
N -(3,4-Dimethoxyphenyl)quinazolin-4-amine (131)
Synthesized from 3,4-dimethoxyaniline and 4-chloroquinazoline, yield 91 %.
Molecular weight: 281.31 g/mol
1H NMR (DMSO-d6) δ: 11.70 (s, 1H), 8.95 (d, J = 8.3 Hz, 1H), 8.88 (s, 1H), 8.12 –
8.04 (m, 1H), 7.98 (d, J = 8.4 Hz, 1H), 7.83 (dd, J = 11.4, 4.2 Hz, 1H), 7.39 (d, J =
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2.4 Hz, 1H), 7.30 (dd, J = 8.6, 2.4 Hz, 1H), 7.05 (d, J = 8.7 Hz, 1H), 3.78 (d, J =
13.4 Hz, 6H).
13C NMR (DMSO-d6) δ: 159.71, 148.66, 147.72, 138.50, 136.20, 129.68, 128.63,
124.98, 119.67, 117.34, 113.54, 111.73, 109.68, 55.90, 55.86.
Anal. Calcd for C16H15N3O2: C, 68.31; H, 5.37; N, 14.94. Found: C, 68.52; H, 5.20;
N, 15.27.
N -(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine (132)
Synthesized from 3-bromoaniline and 4-chloro-6,7-dimethoxyquinazoline, yield 84 %.
Molecular weight: 360.21 g/mol
1H NMR (DMSO-d6) δ: 11.32 (s, 1H), 8.86 (s, 1H), 8.30 (s, 1H), 8.02 (t, J = 1.9 Hz,
1H), 7.77 (ddd, J = 7.9, 2.0, 1.1 Hz, 1H), 7.49 (ddd, J = 8.0, 1.9, 1.1 Hz, 1H), 7.44
(t, J = 8.0 Hz, 1H), 7.34 (s, 1H), 4.01 (d, J = 12.1 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.18, 156.52, 150.40, 138.91, 130.72, 128.79, 127.10,
123.50, 121.28, 107.62, 104.00, 100.38, 57.07, 56.61.
Anal. Calcd for C16H14BrN3O2: C, 53.35; H, 3.92; N, 11.67. Found: C, 53.07; H,
4.16; N, 11.49.
6,7-Dimethoxy-N -(3-(trifluoromethyl)phenyl)quinazolin-4-amine (133)
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Synthesized from 3-(trifluoromethyl)aniline and 4-chloro-6,7-dimethoxyquinazoline,
yield 90 %.
Molecular weight: 349.31 g/mol
1H NMR (DMSO-d6) δ: 11.74 (s, 1H), 8.87 (s, 1H), 8.46 (s, 1H), 8.17 (s, 1H), 8.11
(d, J = 8.1 Hz, 1H), 7.70 (t, J = 7.9 Hz, 1H), 7.66 – 7.61 (m, 1H), 7.39 (s, 1H), 4.01
(d, J = 23.6 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.35, 156.59, 150.43, 138.15, 136.11, 129.94, 129.60,
129.34, 128.55, 122.48, 121.16, 121.13, 107.65, 104.39, 100.00, 57.25, 56.60.
Anal. Calcd for C17H14F3N3O2: C, 58.45; H, 4.04; N, 12.03. Found: C, 58.39; H,
4.33; N, 12.19.
3-((6,7-Dimethoxyquinazolin-4-yl)amino)benzonitrile (134)
Synthesized from 3-aminobenzonitrile and 4-chloro-6,7-dimethoxyquinazoline, yield
83 %.
Molecular weight: 306.32 g/mol
1H NMR (DMSO-d6) δ: 11.39 (s, 1H), 8.87 (s, 1H), 8.29 (s, 1H), 8.27 (t, J = 1.8 Hz,
1H), 8.07 (ddd, J = 8.1, 2.2, 1.2 Hz, 1H), 7.75 (dt, J = 7.7, 1.3 Hz, 1H), 7.69 (dd, J
= 11.8, 4.1 Hz, 1H), 7.33 (s, 1H), 4.01 (d, J = 10.9 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.22, 157.87, 156.63, 150.48, 138.33, 130.29, 129.50,
129.22, 127.76, 118.54, 111.68, 107.70, 103.89, 57.09, 56.65.
Anal. Calcd for C17H14N4O2: C, 66.66; H, 4.61; N, 18.29. Found: C, 66.40; H, 4.93;
N, 18.40.
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6,7-Dimethoxy-N -(2-nitrophenyl)quinazolin-4-amine (135)
Synthesized from 2-nitroaniline and 4-chloro-6,7-dimethoxyquinazoline, yield 68 %.
Molecular weight: 326.31 g/mol
1H NMR (DMSO-d6) δ: 8.59 (s, 1H), 7.94 (dd, J = 8.7, 1.5 Hz, 1H), 7.41 – 7.32 (m,
4H), 7.28 (d, J = 8.9 Hz, 2H), 7.00 (dd, J = 8.5, 1.3 Hz, 1H), 6.60 (ddd, J = 8.2,
6.8, 1.3 Hz, 1H), 3.92 (d, J = 16.1 Hz, 6H).
13C NMR (DMSO-d6) δ: 164.58, 155.62, 149.97, 148.50, 146.65, 136.14, 130.82,
125.82, 119.64, 115.93, 110.57, 107.22, 101.24, 69.89, 56.46, 56.26.
Anal. Calcd for C16H14N4O4: C, 58.89; H, 4.32; N, 17.17. Found: C, 58.62; H, 4.52;
N, 17.05.
6,7-Dimethoxy-N -(3-nitrophenyl)quinazolin-4-amine (136)
Synthesized from 3-nitroaniline and 4-chloro-6,7-dimethoxyquinazoline, yield 94 %.
Molecular weight: 326.31 g/mol
1H NMR (DMSO-d6) δ: 11.13 (s, 1H), 8.87 (s, 1H), 8.70 (t, J = 2.2 Hz, 1H), 8.27
(ddd, J = 8.1, 2.1, 0.9 Hz, 1H), 8.19 (s, 1H), 8.11 (dd, J = 8.2, 2.2 Hz, 1H), 7.77 (t,
J = 8.2 Hz, 1H), 7.31 (s, 1H), 4.01 (d, J = 12.2 Hz, 6H).
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13C NMR (DMSO-d6) δ:
Anal. Calcd for C16H14N4O4: C, 58.89; H, 4.32; N, 17.17. Found: C, 59.00; H, 4.51;
N, 17.26.
6,7-Dimethoxy-N -(4-nitrophenyl)quinazolin-4-amine (137)
Synthesized from 4-nitroaniline and 4-chloro-6,7-dimethoxyquinazoline, yield 83 %.
Molecular weight: 326.31 g/mol
1H NMR (DMSO-d6) δ: 10.94 (s, 1H), 8.58 (s, 1H), 8.06 (d, J = 7.5 Hz, 2H), 7.68
(s, 1H), 7.30 (s, 1H), 7.09 (d, J = 7.5 Hz, 2H), 3.72 (s, 3H), 3.59 (s, 3H).
13C NMR (DMSO-d6) δ: 158.72, 153.70, 152.39, 148.90, 147.76, 146.88, 141.27,
126.05, 119.22, 111.20, 107.53, 103.70, 56.23, 55.99.
Anal. Calcd for C16H14N4O4: C, 58.89; H, 4.32; N, 17.17. Found: C, 59.09; H, 4.41;
N, 17.00.
N -(3,4-Dimethoxyphenyl)-6,7-dimethoxyquinazolin-4-amine (138)
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Synthesized from 3,4-dimethoxyaniline and 4-chloro-6,7-dimethoxyquinazoline, yield
76 %.
Molecular weight: 341.36 g/mol
1H NMR (DMSO-d6) δ: 11.08 (s, 1H), 8.75 (s, 1H), 8.18 (s, 1H), 7.29 (dd, J = 8.7,
5.1 Hz, 2H), 7.19 (dd, J = 8.6, 2.4 Hz, 1H), 7.05 (d, J = 8.7 Hz, 1H), 3.99 (d, J =
5.0 Hz, 6H), 3.79 (d, J = 10.7 Hz, 6H).
13C NMR (DMSO-d6) δ: 156.26, 150.24, 148.75, 147.48, 129.93, 117.35, 111.82,
109.74, 107.25, 103.85, 56.93, 56.56, 55.89.
Anal. Calcd for C18H19N3O4: C, 63.33; H, 5.61; N, 12.31. Found: C, 63.20; H, 5.72;
N, 12.29.
7.1.2.15 General procedure for synthesis of 4-N-piperazinylquinazolines
To a solution of 4-chloro-2-phenylquinazoline (240 mg, 1 mmol) and K2CO3 (280 mg,
2 mmol) in refluxing 2-propanol (20 ml), the substituted N-phenyl-piperazine was
added dropwise. The reaction mixture was refluxed for 10-12 hours, until the reaction
was complete as indicated by TLC. The solvent was removed under reduced pressure
and water was added to resulting solid and filtered under suction and washed with
water. The resulting solid was recrystallized from 50 % ethanol.
2-Phenyl-4-(4-phenylpiperazin-1-yl)quinazoline (139)
Synthesized from 1-phenylpiperazine and 4-chloro-2-phenylquinazoline, yield 51 %.
Molecular weight: 366.46 g/mol
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1H NMR (DMSO-d6) δ: 8.57 – 8.44 (m, 2H), 8.09 (d, J = 8.2 Hz, 1H), 7.94 – 7.79
(m, 2H), 7.53 (dd, J = 15.3, 7.1 Hz, 4H), 7.25 (t, J = 7.9 Hz, 2H), 7.00 (d, J = 8.1
Hz, 2H), 6.81 (t, J = 7.2 Hz, 1H), 3.98 (m, 4H), 3.42 (m, 4H).
13C NMR (DMSO-d6) δ: 164.21, 158.28, 152.27, 150.94, 138.21, 133.08, 130.46,
129.15, 128.53, 128.09, 125.54, 125.46, 119.20, 115.58, 114.89, 49.19, 48.17.
Anal. Calcd for C24H22N4: C, 78.66; H, 6.05; N, 15.29. Found: C, 78.40; H, 6.23; N,
15.18.
4-(4-(3-Bromophenyl)piperazin-1-yl)-2-phenylquinazoline (140)
Synthesized from 1-(3-bromophenyl)piperazine and 4-chloro-2-phenylquinazoline,
yield 54 %.
Molecular weight: 445.35 g/mol
1H NMR (DMSO-d6) δ: 8.50 (dd, J = 7.7, 1.9 Hz, 2H), 8.08 (d, J = 7.7 Hz, 1H),
7.90 (dd, J = 8.4, 0.9 Hz, 1H), 7.83 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.57 – 7.46 (m,
4H), 7.22 – 7.15 (m, 1H), 7.13 (t, J = 2.1 Hz, 1H), 6.99 (dd, J = 8.3, 2.1 Hz, 1H),
6.94 (dd, J = 7.8, 1.1 Hz, 1H), 4.03 – 3.90 (m, 4H), 3.53 – 3.41 (m, 4H).
13C NMR (DMSO-d6) δ: 164.10, 158.26, 152.26, 138.19, 133.08, 130.93, 130.45,
128.52, 128.08, 125.52, 125.44, 122.71, 121.23, 117.42, 114.85, 114.10, 48.91, 47.47.
Anal. Calcd for C24H21BrN4: C, 64.73; H, 4.75; N, 12.58. Found: C, 64.57; H, 4.69;
N, 12.37.
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4-(4-(3-Chlorophenyl)piperazin-1-yl)-2-phenylquinazoline (141)
Synthesized from 1-(3-chlorophenyl)piperazine and 4-chloro-2-phenylquinazoline,
yield 48 %.
Molecular weight: 400.90 g/mol
1H NMR (DMSO-d6) δ: 8.53 – 8.48 (m, 2H), 8.09 (dd, J = 8.3, 0.8 Hz, 1H), 7.90
(dd, J = 8.4, 1.0 Hz, 1H), 7.83 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.56 – 7.49 (m, 4H),
7.27 – 7.22 (m, 1H), 7.00 (t, J = 2.2 Hz, 1H), 6.97 – 6.93 (m, 1H), 6.81 (ddd, J =
7.9, 1.9, 0.7 Hz, 1H), 4.01 – 3.95 (m, 4H), 3.51 – 3.44 (m, 4H).
13C NMR (DMSO-d6) δ: 164.12, 158.26, 152.27, 152.10, 138.19, 134.03, 133.09,
130.63, 130.46, 128.53, 128.09, 125.53, 125.45, 118.30, 114.86, 114.58, 113.69, 48.91,
47.47
Anal. Calcd for C24H21ClN4: C, 71.90; H, 5.28; N, 13.98. Found: C, 72.06; H, 5.13;
N, 13.82.
4-(4-(3-Chloro-4-fluorophenyl)piperazin-1-yl)-2-phenylquinazoline (142)
Synthesized from 1-(3-choloro,4-fluorophenyl)piperazine and 4-chloro-2-phenylquinazoline,
yield 61 %.
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Molecular weight: 418.89 g/mol
1H NMR (DMSO-d6) δ: 8.55 – 8.45 (m, 2H), 8.07 (d, J = 8.2 Hz, 1H), 7.90 (d, J =
8.3 Hz, 1H), 7.83 (t, J = 7.5 Hz, 1H), 7.53 (dd, J = 14.9, 7.3 Hz, 4H), 7.27 (t, J = 9.1
Hz, 1H), 7.16 – 7.10 (m, 1H), 6.99 (d, J = 9.0 Hz, 1H), 3.96 (m, 4H), 3.41 (m, 4H).
13C NMR (DMSO-d6) δ: 164.17, 158.27, 152.26, 151.96, 150.07, 148.44, 138.18,
133.10, 130.47, 128.56, 128.53, 128.09, 125.57, 125.40, 117.10, 116.93, 116.80, 115.74,
115.69, 114.87, 48.99, 48.29.
Anal. Calcd for C24H20ClFN4: C, 68.81; H, 4.81; N, 13.37. Found: C, 68.68; H, 5.04;
N, 13.42.
4-(4-(3-Methoxyphenyl)piperazin-1-yl)-2-phenylquinazoline (143)
Synthesized from 1-(3-methoxyphenyl)piperazine and 4-chloro-2-phenylquinazoline,
yield 57 %.
Molecular weight: 396.48 g/mol
1H NMR (DMSO-d6) δ: 8.22 (s, 1H), 7.99 (s, 1H), 7.81 (s, 1H), 7.69 – 7.52 (m, 2H),
7.44 (s, 1H), 7.39 – 7.31 (m, 2H), 7.26 (s, 1H), 7.07 (s, 1H), 6.48 (s, 1H), 6.37 (d, J
= 30.4 Hz, 2H), 3.92 (s, 3H), 3.77 – 3.62 (m, 4H), 3.50 – 3.39 (m, 4H).
13C NMR (DMSO-d6) δ: 163.24, 160.28, 160.03, 154.59, 152.83, 136.73, 132.37,
131.86, 130.85, 130.16, 129.11, 128.80, 126.95, 126.00, 118.32, 109.86, 105.33, 101.11,
61.04, 48.98, 47.34.
Anal. Calcd for C25H24N4O: C, 75.73; H, 6.10; N, 14.13. Found: C, 75.77; H, 6.23;
N, 14.29.
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4-(4-(3-Nitrophenyl)piperazin-1-yl)-2-phenylquinazoline (144)
Synthesized from 1-(3-nitrophenyl)piperazine and 4-chloro-2-phenylquinazoline, yield
69 %.
Molecular weight: 411.46 g/mol
1H NMR (DMSO-d6) δ: 8.55 – 8.47 (m, 2H), 8.11 (d, J = 7.6 Hz, 1H), 7.91 (dd, J =
8.4, 1.2 Hz, 1H), 7.84 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.71 (t, J = 2.3 Hz, 1H), 7.63 –
7.59 (m, 1H), 7.57 – 7.48 (m, 5H), 7.45 (dd, J = 8.0, 2.2 Hz, 1H), 4.08 – 3.95 (m,
4H), 3.64 – 3.53 (m, 4H).
13C NMR (DMSO-d6) δ: 164.08, 158.26, 152.27, 151.43, 149.04, 138.18, 133.11,
130.47, 130.37, 128.53, 128.09, 125.55, 125.47, 121.22, 114.85, 112.85, 108.32, 48.77,
47.21.
Anal. Calcd for C24H21N5O2: C, 70.06; H, 5.14; N, 17.02. Found: C, 70.27; H, 5.18;
N, 17.11 .
4-(4-(4-Nitrophenyl)piperazin-1-yl)-2-phenylquinazoline (145)
Synthesized from 1-(4-nitrophenyl)piperazine and 4-chloro-2-phenylquinazoline, yield
64 %.
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Molecular weight: 411.46 g/mol
1H NMR (DMSO-d6) δ: 8.51 (d, J = 5.7 Hz, 2H), 8.10 (d, J = 8.3 Hz, 3H), 7.97 –
7.76 (m, 2H), 7.52 (dd, J = 12.4, 6.3 Hz, 4H), 7.01 (d, J = 9.0 Hz, 2H), 4.18 – 3.98
(m, 4H), 3.78 (m, 4H).
13C NMR (DMSO-d6) δ: 163.66, 158.20, 154.45, 152.30, 138.22, 137.01, 133.03,
130.45, 128.50, 128.09, 125.92, 125.56, 125.37, 114.73, 112.23, 48.20, 45.69.
Anal. Calcd for C24H21N5O2: C, 70.06; H, 5.14; N, 17.02 Found: C, 70.14; H, 5.19;
N, 16.89.
7.1.2.16 General procedure for synthesis of N2,N4-disubsubstituted
quinazolines
2,4-dichloro-6,7-dimethoxyquinazoline (1 mmol) was dissolved in refluxing 2-propanol
(20 ml) and the substituted aniline (2.5 mmol) was added drop wise. The reaction
mixture was refluxed for 12-24 hours, until the reaction was complete as indicated
by TLC. The precipitate formed was filtered off and washed with 2-propanol (10 ml)
and ether (10 ml). The product was recrystallized from 75 % ethanol.
N 2,N 4-Bis(3-bromophenyl)-6,7-dimethoxyquinazoline-2,4-diamine (146)
Synthesized from 3-bromoaniline and 2,4-dichloro-6,7-dimethoxyquinazoline, yield 58
%.
Molecular weight: 530.21 g/mol
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1H NMR (DMSO-d6) δ: 12.05 (s, 1H), 10.17 (s, 1H), 7.64 (s, 1H), 7.38 (s, 1H), 7.30
(d, J = 1.3 Hz, 1H), 7.19 (ddt, J = 9.8, 4.4, 2.7 Hz, 5H), 6.88 – 6.73 (m, 1H), 6.65
(dt, J = 7.1, 1.5 Hz, 1H), 3.65 (s, 3H), 3.58 (s, 3H).
13C NMR (DMSO-d6) δ: 156.97, 155.67, 154.79, 150.42, 145.92, 145.53, 145.00,
130.05, 129.68, 125.54, 125.34, 124.03, 124.03, 122.90, 122.68, 120.78, 120.77, 111.61,
105.76, 101.76, 57.01, 55.39.
Anal. Calcd for C22H18Br2N4O2: C, 49.84; H, 3.42; N, 10.57. Found: C, 49.79; H,
3.60; N, 10.39.
6,7-Dimethoxy-N 2,N 4-bis(3-(trifluoromethyl)phenyl)quinazoline-2,4-diamine
(147)
Synthesized from 3-(trifluoromethyl)aniline and 2,4-dichloro-6,7-dimethoxyquinazoline,
yield 54 %.
Molecular weight: 508.42 g/mol
1H NMR (DMSO-d6) δ: 11.95 (s, 1H), 8.73 (s, 1H), 7.46 (s, 1H), 7.32 (s, 1H), 7.27
(d, J = 1.4 Hz, 1H), 7.12 – 6.97 (m, 3H), 6.82 (dd, J = 3.2, 2.5 Hz, 2H), 6.71 – 6.66
(m, 1H), 6.54 (ddd, J = 5.9, 3.3, 1.7 Hz, 1H), 3.54 (d, J = 6.0 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.95, 156.07, 154.32, 149.26, 144.98, 143.04, 141.70,
134.50, 130.31, 128.82, 126.39, 126.07, 124.83, 123.92, 119.25, 118.78, 115.07, 110.54,
106.29, 103.88, 55.72, 54.89.
Anal. Calcd for C24H18F6N4O2: C, 56.70; H, 3.57; N, 11.02. Found: C, 56.57; H,
3.70; N, 11.29
182
7.1 Chemistry
3,3’-((6,7-Dimethoxyquinazoline-2,4-diyl)bis(azanediyl))dibenzonitrile (148)
Synthesized from 3-aminobenzonitrile and 2,4-dichloro-6,7-dimethoxyquinazoline,
yield 73 %.
Molecular weight: 422.44 g/mol
1H NMR (DMSO-d6) δ: 12.04 (s, 1H), 9.01 (s, 1H), 7.48 (s, 1H), 7.32 (s, 1H), 7.28
(ddd, J = 6.9, 6.5, 4.3 Hz, 3H), 7.09 (t, J = 1.7 Hz, 1H), 7.01 (ddd, J = 7.3, 2.5, 1.3
Hz, 2H), 6.71 (dt, J = 7.1, 1.3 Hz, 1H), 6.55 (dt, J = 7.3, 1.7 Hz, 1H), 3.68 (d, J =
5.9 Hz, 6H).
13C NMR (DMSO-d6) δ: 158.38, 156.40, 153.12, 150.61, 147.82, 141.30, 141.21,
133.50, 131.17, 130.06, 127.99, 125.31, 123.08, 121.47, 118.62, 116.57, 115.05, 110.33,
106.19, 101.22, 56.07, 55.31.
Anal. Calcd for C24H18N6O2: C, 68.24; H, 4.29; N, 19.89. Found: C, 68.33; H, 4.10;
N, 20.05.
6,7-Dimethoxy-N 2,N 4-bis(3-nitrophenyl)quinazoline-2,4-diamine (149)
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Synthesized from 3-nitroaniline and 2,4-dichloro-6,7-dimethoxyquinazoline, yield 67
%.
Molecular weight: 462.41 g/mol
1H NMR (DMSO-d6) δ: 12.08 (s, 1H), 8.93 (s, 1H), 7.85 – 7.78 (m, 4H), 7.34 – 7.28
(m, 2H), 7.10 (ddd, J = 7.7, 4.9, 3.1 Hz, 3H), 6.57 (s, 1H), 3.81 (d, J = 4.9 Hz, 6H).
13C NMR (DMSO-d6) δ: 159.07, 157.48, 155.40, 152.32, 149.02, 148.67, 145.05,
144.69, 143.91, 130.67, 128.38, 124.27, 123.11, 115.24, 114.30, 112.74, 110.61, 105.03,
103.22, 56.31, 55.82.
Anal. Calcd for C22H18N6O6: C, 57.14; H, 3.92; N, 18.17. Found: C, 56.80; H, 4.11;
N, 18.24.
N 2,N 4-Bis(3,4-dimethoxyphenyl)-6,7-dimethoxyquinazoline-2,4-diamine (150)
Synthesized from 3,4-dimethoxyaniline and 2,4-dichloro-6,7-dimethoxyquinazoline,
yield 59 %.
Molecular weight: 492.52 g/mol
1H NMR (CDCl3) δ: 12.82 (s, 1H), 9.72 (s, 1H), 9.10 (s, 1H), 7.66 (s, 1H), 7.53 (d, J
= 2.2 Hz, 1H), 7.46 (dd, J = 8.6, 2.3 Hz, 1H), 6.82 (dd, J = 8.6, 2.4 Hz, 1H), 6.56
(d, J = 2.4 Hz, 1H), 6.40 (dd, J = 8.7, 1.9 Hz, 2H), 6.29 (s, 1H), 4.07 (s, 3H), 3.82
(d, J = 16.9 Hz, 6H), 3.65 (d, J = 4.5 Hz, 6H), 3.58 (s, 3H).
13C NMR (CDCl3) δ: 157.08, 156.12, 150.47, 148.94, 148.81, 147.36, 146.89, 146.85,
134.75, 130.54, 129.15, 115.07, 114.97, 110.72, 110.61, 107.19, 104.20, 102.60, 97.71,
56.81, 56.13, 56.05, 56.03, 56.00, 55.92.
Anal. Calcd for C26H28N4O6: C, 63.40; H, 5.73; N, 11.38. Found: C, 63.21; H, 5.99;
N, 11.50.
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7.2 Biological testing
7.2.1 Materials
7.2.1.1 Chemicals
Chemicals Manufacturer Article number
Calcein-AM Sigma 17783
Calcium chloride dihydrate Merck P 4901
Cyclosporin A Sigma C 3662
D-glucosemonohydrate Merck 1040740500
Dimethylsulfoxid (DMSO) Acros AC19773
Disodium phosphate Applichem A4732
Doxorubicin Fluka 44583
Geniticin (G418) Sigma G 9516
HEPES (free acid) Applichem A 3707
Hoechst 33342 Sigma B 2261
Hydrochloric acid (0.5 M) Gru¨ssing 23204
Ko143 Tocris 3241
Magnesium sulfate heptahydrate Applichem A4101
Melsept SF Braun 18907
Methanol Merck 107018
Mitoxanthron Sigma M 6545
Pheophorbide A Fontier Scientific Inc. 15664296
Potassium chloride Merck 104936
Potassium phosphate Applichem A 3095
SN-38 TCI Europe N.V. E0748
Sodium bicarbonate Merck 106329
Sodium chloride Merck 106404
Sodium hydroxide solution (1 M) Gru¨ssing 22195
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7.2.1.2 Materials for cell culture and assays
Materials Manufacturer Article number
1.0-5.0 ml Bulk, Natural pipette
tips
Starlab I1009-5000
1.5 ml Amber microtubes with
attached pp cap
Sarstedt 72690004
1.5 ml Neutral microtubes with
attached pp cap
Sarstedt 72690001
2.0 ml MaxyClear microtubes Axygen scientific MCT-200-C
96 Well, clear PS microplate, flat
bottom
Greiner bio-one 655098
96 Well, clear PS microplate,
U-shape bottom
Greiner bio-one 650101
96F untreated black microwell SH
plate
Nunc 237108
96-Well tissue culture plate , flat
bottom with lid, sterile
Sarstedt 831835
CASYton solution Scha¨rfe System 43001
Conical test tube PP 15 ml,
sterile
Nerbeplus GmbH 25027001
Conical test tube PP 50 ml,
sterile
Nerbeplus GmbH 25707001
Cryos PP with screw cap, sterile Greiner bio-one 123263
FACSClean Becton Dickinson 340345
FACSFlow Becton Dickinson 342003
FACSRinse Becton Dickinson 340346
FACS-testtubes Sarstedt 551579
Fetal bovine serum Sigma F 7524
Glass pasteur pipettes (230 mm) VWR international 612-1702
Growth medium D-MEM 5671 Sigma M 5650
Growth medium RPMI-1640 PAN Biotech GmbH P0416500
L-Glutamine 200 mmol/l Sigma G 7513
Membrane filter 0.2 µm, sterile Whatman 10462200
Norm-Ject 10 ml syringe Henke Sass Wolf 4100-000V0
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Materials Manufacturer Article number
Norm-Ject 20 ml syringe Henke Sass Wolf 4200-000V0
Penicillin-Streptomycin solution Sigma P0781
Serological pipette 10 ml, sterile Sarstedt 86.1254.001
Serological pipette 25 ml, sterile Sarstedt 86.1685.001
TipOne 0.1-10.0 µl natural
pipette tips
Starlab S1111-3000
TipOne 101-1000 µl natural
pipette tips
Starlab S1111-2020
TipOne 1-200 µl yellow pipette
tips
Starlab S1111-0006
Tissue culture flasks, 175 cm²,
sterile, filter cap
Greiner bio-one 660175
Tissue culture flasks, 25 cm²,
sterile, filter cap
Greiner bio-one 690175
Tissue culture flasks, 75 cm²,
sterile, filter cap
Greiner bio-one 658175
Trypsin-EDTA solution PAN Biotech GmbH P100231SP
7.2.1.3 Instruments
Instruments Manufacturer Serial number
Accu-Jet suction pump Brand 441938
Avanti centrifuge J-25 Beckman JHY97G35
Axiovert 25 microscope Zeiss 660197
CASY1 model TT Schaerfe System SC1 TT
CO2 cell MMM Group -
CO2 water jacket incubator Forma Scientific -
FACSCalibur Becton Dickinson E3231
FLUOstar Optima fluorescence
plate reader
BMG Lab Technologies 4131164, 4132279
Laminar flow cabinet (model:
Antares 48)
Steril S.p.A. 10155/1996
pH-Meter 744 Metrohm 20506
Pipette 0.1-2.5 µl Eppendorf 3638475
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Instruments Manufacturer Serial number
Pipette 100-1000 µl Eppendorf 4741196
Pipette 20-200 µl Eppendorf 3534296
Pipette 2-20 µl Eppendorf 3407866
Pipette 500-5000 µl Eppendorf 3615095
POLARstar Galaxy fluorescence
plate reader
BMG Lab Technologies 4030639
RH basic magnetic stirrer IKA Labortechnik 3061661
Vacuum pump BVC21 Brand 08E12592
Vortex stirrer Minishaker Vacuubrand 2.88069E+13
Waterbath type 1083 GFL 11530203
7.2.1.4 Buffers used for preparing cells for biological assays
1. Krebs-HEPES buffer (KHB)
In the current study, most of the cell based assays were performed using Krebs-HEPES
buffer (KHB). KHB was prepared as described in Table 7.1. All the constituents
were weighed so as to get 5X concentrated buffer solution.
Table 7.1: Preparation of Krebs-HEPES buffer (KHB)
Chemical Molecular
formula
Molecular
weight
(g/mol)
Conc. (mM)
for 5X
concentrated
solution
Amount (g)
required for 5X
concentrated
solution (500 ml)
Sodium chloride NaCl 58.44 593 17.330
Potassium chloride KCl 74.55 5.64 0.876
Potassium
phosphate
KH2PO4 136.09 6.00 0.408
Sodium
bicarbonate
NaHCO3 84.01 21 0.882
D-glucose-
monohydrate
C6H12O6*H2O 198.17 58.5 5.796
HEPES (free acid) C8H18N2O4S 238.31 50 5.958
All substances were transferred to a 500 ml volumetric flask and dissolved in 450
ml of distilled water. The pH value of the solution was adjusted to 7.4 using 1.0 M
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sodium hydroxide solution. After adjusting the pH, the volume of the solution was
made up to 500 ml using distilled water. From this stock solution 100 ml aliquots
were made and stored at -20°C.
To make a buffer solution for use in the assays, 100 ml of 5X concentrated buffer
solution was transferred to a 500 ml volumetric flask and 650 µl of 1 M calcium
chloride solution was added to give 2.50 mM concentration. To the resulting solution
approximately 350 ml of distilled water was added, mixed well and 600 µl of 1M
magnesium sulfate heptahydrate solution was added to give 1.20 mM final concen-
tration. The volume of the solution was made up to 500 ml and mixed well. The
solution was filtered using a membrane filter (pore size: 0.2 µm) and aliquots were
prepared as required and stored at -20°C.
2. Phosphate buffered saline (PBS)
Before passaging the cells, the medium was removed and cells were washed once with
phosphate buffered saline (PBS). PBS is suitable for washing cells being isotonic and
nontoxic to cells. The buffer solution was prepared as described in Table 7.2.
Table 7.2: Preparation of phosphate buffered saline (PBS)
Chemicals Molecular
formula
Molecular
weight
(g/mol)
Concentration
mmol/l
Amount (g)
for 100 ml
solution
Sodium chloride NaCl 58.4 137 8.01
Potassium chloride KCl 74.6 2.7 0.20
Monopotassium
phosphate
KH2PO4 136.1 2.0 0.27
Disodium
phosphate
Na2HPO4 141.9 10 1.44
All substances were transferred to a 1000 ml volumetric flask in the mentioned
quantities and dissolved in 800 ml distilled water. The pH value was adjusted to 7.4
using 0.1 M sodium hydroxide solution and the volume was made up to 1000 ml with
distilled water. The prepared buffer solution was sterilized before use in an autoclave
at 121 °C and 2 bar pressure for 20 minutes. It was stored at 4 °C for further use.
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7.2.2 Cell culture
7.2.2.1 Cell lines
Several different wild-type, resistant or transfected tumor cell lines were used for
biological studies of the synthesized compounds.
1. MCF-7 and MCF-7 MX cell line:
The human breast cancer cell line MCF-7 MX was kindly provided by Dr. E.
Schneider (Wadsworth Center, Albany, NY, USA). The cell line MCF-7 wt was
originally selected from the mammary epithelial tissue of a Caucasian woman with
adenocarcinoma. Cells were grown in RPMI-1640 medium supplemented with 20 %
fetal bovine serum (FBS), 50 µg/ml streptomycin, 50 U/ml penicillin G and 2 mM
L-glutamine. To maintain the resistance in the BCRP expressing MCF-7 MX cell
line, cells were intermittently incubated with 100 nM mitoxantrone for one passage.
2. MDCK wild type and MDCK BCRP cells:
The cell line MDCK wt and MDCK BCRP were received as a generous gift from
Dr. A. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands).
MDCK BCRP cells were generated by transfection of the canine kidney epithelial cell
line MDCKII with the human wild-type cDNA C-terminally linked to the cDNA of
the green fluorescent protein (GFP). These cells were cultured in Dulbecco’s modified
eagle medium (DMEM) with 10 % fetal bovine serum (FBS), 50 µg/ml streptomycin,
50 U/ml penicillin G and 2 mM L-glutamine.
3. A2780 and P-gp over-expressing A2780 adr cells:
Human ovarian carcinoma cell lines A2780 and the corresponding MDR1 over-
expressing doxorubicin resistant A2780 adr cell line were purchased from ECACC
(Nos. 93112519 and 93112520). The cell lines were grown in RPMI-1640 medium
supplemented with 10 % FBS, 50 µg/ml streptomycin, 50 U/ml penicillin G, and
300 mg/l L-glutamine. To maintain the P-gp overexpression in the A2780 adr cell
line, intermittently cells were incubated with 1µM doxorubicin for one passage.
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4. 2008 wild type and overexpressing 2008 MRP1 cells:
The human ovarian cancer cell line 2008 MRP1 stably expressing MRP1 was a gift
from Prof. Dr. Piet Borst (The Netherlands Cancer Institute, Amsterdam, The
Netherlands). The cell line 2008 MRP1 was grown in the same medium as described
for A2780 cells with addition of 400 µg/ml G-418 (Geneticin) for maintaining ABCC1
overexpression.
7.2.2.2 Growing and subculturing of cells
All the cell lines used for biological testing of the synthesized compounds were
cultivated in standard culture flasks of different capacities. Tissue cuture flasks T25
(25 cm2), T75 (75 cm2) and T175 (175 cm2) were used depending on the number of
cells needed to perform assays. Cells were cultivated in an incubator maintained at
37 °C and 5 % CO2. The culture medium was changed every 2-3 days depending on
cell confluence. In general the medium was changed when the phenyl red indicator
present changed its color from pink to orange. In general for T25 flask 10 ml, for
T75 flask 15-20 ml and for T175 flask 25-30 ml culture medium was used.
Subculturing of cells was done after a confluence of 80-90% was attained. For
subculturing, first, the old medium was removed by aspiration and cells were washed
with 3 ml of PBS buffer to remove floating dead cells and traces from culture medium.
After this, 3 ml of trypsin-EDTA solution was added and incubated at 37 °C for
5-15 minutes depending on the cell line. The separation of cells from the surface
of culture flasks was confirmed under the microscope. After incubation, 7 ml of
culture medium was added and mixed well. The cell suspension was transferred to a
50 ml centrifugation tube and centrifuged at 1200 x g for 4 minutes at 4 °C. The
trypsin containing medium was gently removed by aspiration and 10 ml fresh culture
medium was added. Cells were re-suspended and depending on cell line and cell
density, one to three ml of cell suspension was transferred into a new culture flask
containing sufficient fresh growth medium. The rest of the cell suspension was used
for performing assays.
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7.2.2.3 Cryopreservation and defrosting of cells
For performing assays, most of the cell lines were used until a maximum passage
number of 30. Hence it was necessary to have cell backups with lower passage
numbers. To generate backups, cells were grown in T175 flasks and were harvested
as described above. After centrifugation and removal of trypsin containing culture
medium, cells were re-suspended in growth medium containing 10 % DMSO. After
mixing well, cells were transferred into 1 ml cryovials. Cryovials were stored in -80
°C as fast as possible, to avoid toxic effect of DMSO. These cryovials were stored for
one week at -80 °C and then transferred into liquid nitrogen tank ( -190 °C) where
longer storage of cells is possible.
For using cells with lower passage number, they were taken out of the nitrogen tank
and defrosted at 37 °C in a water bath. Cells were transferred as fast as possible to
T25 or T75 flasks filled with an adequate amount of fresh culture medium pre-warmed
at 37 °C. Flasks were placed into the incubator. On the next day, old culture medium
containing slight amount of DMSO was aspired along with floating cells and replaced
with fresh culture medium. Cells were cultured for 1-2 more passages before used in
assays.
7.2.2.4 Cell counting using CASY1 model TT
For performing different cell based assays, the cell number was important. For this,
20 µl of cell suspension was pipetted into 10 ml of sterile filtered Casy ton solution
and analyzed with the CASY1 model TT cell counter using a 150 µm capillary.
The instrument measures the cell count along with the cell diameter. From this
information and graphical presentation the status of the cells can be checked. For
the measurement of cell count a cell size range of 8 µm to 40 µm was defined.
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7.2.3 Assays
For the investigation of the synthesized compounds different cell based assays were
applied. 10 mM stock solutions of the tested compounds were prepared in DMSO.
Different dilutions of compounds were prepared in sterile filtered KHB. For some
compounds with low solubility methanol was used for preparing 1 mM concentrations.
The amount of methanol was chosen so that it did not exceed 5 % in the highest
concentration used in the assay. The highest concentration of DMSO present in
dilutions used for the assays was not more than 0.5 %.
7.2.3.1 Hoechst 33342 accumulation assay
Figure 7.1: General principle of the Hoechst 33342 assay [58]
Hoechst 33342 is a fluorescent bisbenzimidazole derivative, which is primarily used
as a cell permeable nucleic acid stain [225–227]. Hoechst 33342 has been found to
bind to the minor groove of double-stranded DNA with more preference for adenine
and thymine rich sequences which enhance fluorescence intensity [228, 229]. Hoechst
33342 shows fluorescence with an excitation maximum of 340 nm and an emission
maximum of 450 nm [228] when bound to nucleotides. Unbound Hoechst 33342 shows
fluorescence with an emission maximum 510–540 nm in very high concentrations.
Hoechst 33342 has been found to be transported by the ABC transporters BCRP
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and P-gp [230, 231]. Because of this, it shows less fluorescence in BCRP and P-gp
overexpressing cells as compared to wild type cells. When BCRP or P-gp are inhibited
by a modulator, the transport of Hoechst 33342 decreases leading to an increase in
its total fluorescence. This increase in fluorescence can be used as a parameter to
determine the extent of BCRP inhibition. In this study the Hoechst 33342 assay was
used to investigate BCRP inhibition of all synthesized compounds.
Procedure: To investigate the inhibitory effect of synthesized compounds on BCRP,
a Hoechst 33342 accumulation assay was performed as described earlier with small
modifications [125, 232]. MDCK (BCRP) or MCF-7 (MX) cells were harvested after
reaching a confluence of 80-90 % as described above (see section 7.2.2.2). The cell
density was determined using a CASY1 model TT cell counter device. In general 3
million cells were needed per 96 well microplate. The required amount of cells from
a 50 ml centrifugation tube was transfered to 2 ml microtubes and centrifuged at
7840 x g for 10-15 seconds. Cells were washed three times with Krebs-Hepes buffer
(KHB) and seeded into black 96 well microplates at a density of approximately 20,000
cells per well in a volume of 90 µl. To this, 10 µl of the test compound in different
concentrations was added to achieve a total volume of 100 µl. The general scheme
used for pippeting compounds and different cells is shown in Figure 7.2.
Figure 7.2: Arrangement of 96 well microplate for the Hoechst 33342 assay
The prepared 96 well plate was kept under 5 % CO2 and 37 °C for 30 min. After
this preincubation period, 20 µl of a 6 µM Hoechst 33342 solution (protected from
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light) was added to each well yielding a final concentration of Hoechst 33342 of 1 µM .
Fluorescence was measured immediately in constant intervals (60 s) up to 120 min
at an excitation wavelength of 355 nm and an emission wavelength of 460 nm using
a 37 °C tempered BMG POLARstar OPTIMA or a FLUOstar OPTIMA microplate
reader. Microplate reader parameters used for the assay are listed in Table 7.3.
Table 7.3: Parameters used for performing the Hoechst 33342 assay
Parameter Value
Scanning mode Plate
Incubation temperature 37 °C
Number of cycles 120
Cycle time 60 sec
Number of light flashes 10/sec
Interval between rows 0.5 sec
Measurement direction horizontal
Excitation wavelength 355 nm
Emission wavelength 460 nm
Gain (for FLUOstar) 1700-1800
Gain (for POLARstar) 45-50
Required value 20 %
For the analysis of the data obtained from the assay, first the fluorescence of KHB was
subtracted from the fluorescence reading obtained from MDCK cells. The average of
fluorescence values in the steady state (from 100 min to 109 min) was calculated for
each concentration and from these data concentration-response curves were generated
by nonlinear regression using the four-parameter logistic equation in GraphPad Prism
(v. 5.0, San Diego, CA, USA).
7.2.3.2 Pheophorbide A assay
Pheophorbide A is a chlorophyll-breakdown product and belongs to the chemical
class of porphyrins. Pheophorbide A is present in various plant-derived foods and
food supplements. BCRP plays an important role in transporting pheophorbide
A and limiting its uptake from ingested food [233]. Pheophorbide A is a specific
substrate of BCRP [104] and hence can be effectively used to investigate inhibitors
of BCRP.
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Figure 7.3: Principle of the pheophorbide A assay
Pheophorbide A shows fluorescence with an excitation maximum of 395 nm and
emission maximum of 670 nm. This property makes it suitable for assessment with
flow cytometry where fluorescence of pheophorbide A in individual cells is measured.
Pheophorbide A diffuses easily through cell membranes and is accumulated inside
cells. In case of cells with BCRP overexpression, pheophorbide A is transported
outside the cell leading to a decrease in intracellular fluorescence. When BCRP is
inhibited by modulators, pheophorbide A accumulation is increased which is reflected
in increased intracellular fluorescence. This increase in fluorescence is proportional
to the extent of BCRP inhibition.
Flow cytometry: The pheophorbide A assay was performed by flow cytometry
where the fluorescence of single cells can be measured. For these experiments a
Becton-Dickinson FACSCalibur was used (FACS: fluorescence activated cell sorting).
With use of a very small nozzle and sheath fluid, cells are hydrodynamically brought
in front of a laser light source, where one cell at a time passes the laser light . The
optical system involves an argon laser with excitation wavelength of 488 nm and
detectors for FSC (Forward angle light scatter), SSC (Side scatter) and fluorescence
signals. Fluorescence signals can be detected in three different channels viz. FL1,
FL2 and FL3 which have different wavelengths. For the pheophorbide A assay the
FL3 channel was used which has an filter for 670 nm and longer wavelengths.
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Figure 7.4: Schematic representation of a flow-cytometer [234]
Procedure: The pheophorbide A assay was performed as described earlier with small
modifications [117, 235]. To perform the pheophorbide A assay, cells were prepared
as described for the Hoechst 33342 assay (see section 7.2.3.1). Approximately 45,000
cells per well were seeded into U-shaped clear 96 well microplates in a volume of
160 µl. To this, 20 µl of the test compound in different concentrations was added.
The scheme used for preparing microplates for the pheophorbide A assay is shown in
Figure 7.5.
Figure 7.5: Arrangement of 96 well microplate for the pheophorbide A assay
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The prepared 96 well plate was kept under 5 % CO2 and 37 °C for 30 min. After
this preincubation period, 20 µl of a 5 µM pheophorbide A solution (protected from
light) was added to each well resulting in 0.5 µM end concentration. The 5 µM
pheophorbide A solution was prepared freshly just before its use from a 1 mM stock
solution. For this 15 µl pheophorbide A stock solution was dissolved in 2985 µl
of KHB. After adding pheophorbide A solution into each well, plates were further
incubated for 120 min. Before the measurements cells were again re-suspended
using a multichannel pipette. Fluorescence was measured using a FACSCalibur flow-
cytometer. Concentration-response curves were generated by nonlinear regression
using the four-parameter logistic equation using GraphPad Prism (v. 5.0, San Diego,
CA, USA).
7.2.3.3 Calcein AM accumulation assay
Calcein AM is an acetoxymethyl ester derivative of calcein. Calcein AM is a non-
fluorescent and lipophilic compound which can diffuse through plasma membranes
and can be hydrolyzed by unspecific esterases present in cells to the calcein anion
[236]. In contrast to calcein AM, calcein shows strong green fluorescence. As calcein
is rather hydrophilic, it can leave the cell only by active transport.
Figure 7.6: Principle of the calcein AM assay
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Calcein AM has been found to be transported by the ABC transporter P-gp [237]
as well as MRP1 [236]. This property can be used to asses inhibitors of P-gp and
MRP1. In case of P-gp and MRP1 overexpressing cells, the intracellular fluorescence
of calcein is much lower than in sensitive wild type cells, owing to transport of calcein
AM outside the cell. When P-gp or MRP1 are inhibited by a modulator, this leads
to an increased accumulation of calcein AM being hydrolyzed inside cells and hence
increased fluorescence by calcein. This increase in fluorescence is proportional to the
extent of inhibition of P-gp and MRP1 [157, 238].
In the current study, the calcein AM assay was used to screen all compounds at
10 µM concentration. Compounds showing significant inhibition in comparison to
the standard cyclosporine A, were further investigated with a range of different
concentrations to determine their IC50 values.
Procedure: For checking the selectivity of synthesized compounds towards BCRP,
all compounds were further tested for their P-gp and MRP1 inhibition in the calcein-
AM assay [235]. For this purpose A2780 adr cells for P-gp and 2008 MRP1 cells
for MRP1 were used. After reaching a confluence of 80-90 %, subculturing was
performed by adding 0.05 % trypsin and 0.02 % EDTA. Cells were prepared as
described for the Hoechst 33342 assay (see section 7.2.3.1). Cells were seeded into
colorless 96 well microplates at a density of approximately 30,000 cells in a volume
of 90 µl per well. After this, 10 µl of the test compound was added, resulting in a
final volume of 100 µl per well. The scheme for pippeting compounds and cells is
shown in Figure 7.2. The prepared 96 well plates were preincubated for 30 min at 5
% CO2 and 37 °C. After the preincubation period, 33 µl of a 1.25 µM calcein AM
solution, which was protected from light, was added to each well. The fluorescence
was measured immediately in constant time intervals (60 s) up to 90 min using
an excitation wavelength of 485 nm and an emission filter of 520 nm with a 37 °C
tempered BMG POLARstar OPTIMA or FLUOstar OPTIMA microplate reader.
Microplate reader parameters used for the assay are listed in Table 7.5.
For calculation of inhibitory effects first, the fluorescence from KHB was subtracted
from that of cells. From the obtained data, the first linear part of the generated
fluorescence time curves was used to calculate the slope. The calculated slopes were
plotted against logarithmic concentrations of tested compounds. The concentration-
response curves were fitted with nonlinear regression using the four-parameter logistic
equation in GraphPad Prism (v. 5.0, San Diego, CA, USA).
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Table 7.5: Parameters used for performing the calcein AM assay
Parameter Value
Scanning mode Plate
Incubation temperature 37 °C
Number of cycles 90
Cycle time 60 sec
Number of light flashes 10/sec
Interval between rows 0.2 sec
Measurement direction horizontal
Excitation wavelength 485 nm
Emission wavelength 520 nm
Gain (for FLUOstar) 1700-1800
Gain (for POLARstar) 40-45
Required value 20 %
7.2.3.4 MTT cytotoxicity assay
MTT (Methylthiazolyldiphenyl-tetrazolium bromide) is a yellow tetrazole which
gets reduced in viable cells to formazan which is purple in color. As the formazan
is insoluble in water it forms formazan crystals that can be visualized under the
microscope. After solubilizing with DMSO, formazan color intensity can be quantified
by measuring its absorbance at 544 nm.
Figure 7.7: Reduction of yellow MTT to purple formazan by cellular reductases
In the current study, the MTT assay was used for two purposes:
1. To enable future in vivo studies, it was important that the lead compounds are
not cytotoxic. The most active compounds from each class were investigated for
their cellular toxicity in MTT assays.
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2. To prove the efficiency of lead compounds to sensitize BCRP overexpressing cells
towards toxicity of well known anticancer and cytotoxic compounds. For this purpose
the anticancer drug mitoxantrone and cytotoxic compounds SN-38 (7-Ethyl-10-
hydroxy-camptothecin) and Hoechst 33342 were used. The shift of growth inhibition
curves of these cytotoxic compounds towards lower concentrations (in presence of
lead compounds) was studied by MTT cytotoxicity assay.
Procedure: The MTT assay was performed as described earlier with small modifi-
cations [239]. Cells were harvested as described before for the Hoechst 33342 assay
(see section 7.2.3.1). Cells were seeded into 96-well tissue culture plates at a density
of 2500 cells per well in a volume of 180 µl and were incubated at 5 % CO2 at 37
ºC for 6 h. Attachment of cells was controlled under the microscope and different
concentrations of test compounds prepared in PBS were added to the cells to achieve
the required final concentration in a final volume of 200 µl. Control experiments
were performed with medium containing 1 % (v/v) of DMSO (positive control) and
only PBS (negative control). A General schematic representation of pipetting cells
and tested compounds is shown in Figure 7.8.
Figure 7.8: Preparation of 96 well tissue culture plates for the MTT cytotoxicity
assay
After addition of the compounds, plates were incubated at 37°C and 5 % CO2 for 72 h.
After the incubation period, 20 µl of a 5 mg/ml MTT solution was added to each well.
Plates were further incubated for a period of about 1 h, after which the formation of
purple colored formazan needles could be detected under the microscope. Then the
supernatant was removed and the cells were lysed by addition of 100 µl DMSO per
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well. Color intensity of formed formazan was determined spectrophotometrically by
measuring the absorbance at 544 nm with background correction at 710 nm using
a BMG POLARstar microplate reader. Cell viability was calculated as percentage
of controls treated only with PBS. GI50 values (growth inhibition concentration =
concentration that produced a 50 % reduction of cell viability) were calculated by
nonlinear regression analysis, assuming a sigmoidal concentration-response curve
using GraphPad Prism (v. 5.0, San Diego, CA, USA).
7.2.3.5 IC50 and GI50 calculations using GraphPad Prism
In the current study different accumulation assays (Hoechst 33342, pheophorbide A
and calcein AM) as well cytotoxicity assay (MTT) were performed. For all assays data
are reported as IC50 or GI50 ± S.D. For this purpose the statistics software GraphPad
Prism (version 5.0) was used. For calculating IC50 and GI50 concentration-response
curves were generated using nonlinear regression with the four-parameter logistic
equation (variable slope) and compared to the three-parameter logistic equation
(fixed slope = 1). IC50 is the concentration required to show 50 % inhibitory effect
while GI50 is the concentration which is required to show 50 % inhibition of cell
growth. For the inhibitors where the maximum response was lower than that of
the standard used, top values were fixed to the maximum response of the standard
to generate concentration-response curves. The mathematical model of the logistic
equation used for generating the concentration-response curves is:
Y = Bottom+
Top−Bottom
1 + 10((logIC50−logX)∗Hillslope)
Where, X: concentration of compound, Y: response, increasing or decreasing as
X increases, Bottom: minimum baseline response, Top: maximum response,
Hill-slope: steepness of the curve, IC50: compound concentration to achieve
50 % of the maximum response
All the assays were performed in triplicate and hence data are represented as mean
of values ± S.D. (standard deviation).
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